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ABSTRACT 
Rationale: Streptococcus pneumoniae is a major cause of community- acquired pneumonia and its 
damaging effects on lung tissue can be extensive. The alveolar epithelium consists of alveolar type I 
(ATI) cells, involved in gas exchange, ATII cells, which are progenitor cells which secrete 
surfactant. Cell- specific marker proteins can be used to look at targeted epithelial injury by 
measurement in broncho -alveolar lavage (BAL) fluid, and expression of cell- specific proteins in 
lung tissue can be used to identify changes in cell population and functionality. The initial purpose 
of this thesis was to examine differential alveolar epithelial injury in pneumococcal pneumonia. 
Results: Non -lethal rat models of acute (24 hours), resolving (72 hours) and recovering (3 weeks) 
pneumococcal pneumonia were set up, by way of intratracheal inoculation of wildtype D39 S. 
pneumoniae. Models were characterised by bacterial clearance with an acute inflammatory response 
and damage to the air -blood barrier that was resolving by 72 hours. Lungs were histologically 
normal after 3 weeks. Assessment of ATI cell- specific protein RTI40 demonstrated possible 
regulation in protein expression in both BAL fluid and lung tissue, rendering it inappropriate as a 
marker of injury in this model, and expression differed from that of other ATI cell- specific proteins. 
A new method of quantifying damaged ATII cells, using cell- specific proteins APN /MMC4, 
RTH70 and Pro -SP -C, showed targeted injury to these cells by 24 hours, which was shown to be 
resolving by 72 hours. Differential expression of ATII cell- specific surfactant proteins cytoplasmic 
Pro -SP -C and secreted SP -D was identified. Subsequent study to elucidate the mechanism of this 
differential protein expression compared the initial study with other models of lung infection. To 
determine the effect of pneumococcal toxin pneumolysin, PLN -A pneumolysin- deficient bacteria 
were used. Results showed that changes in expression of RTI40 and SP -D were not dependent on 
pneumolysin production. Further investigation to determine the extent that differential protein 
expression was characteristic of other Gram -positive infections S. aureus, wildtype 8325 -4 strain 
was used. Results demonstrated that differential expression of RTI40 was specific to pneumococcal 
ii 
infection but that expression of SP -D was common to other Gram -positive infections. To further 
explore the mechanism, in vitro bacterial co- culture experiments were carried out using S. 
pneumoniae D39 and the SV40 -T2 alveolar epithelial cell line, to establish if the observation was 
caused by a direct effect by bacteria or bacterial products. These showed that expression of RTI40 
and SP -D were not altered by S. pneumoniae alone. 
Conclusions: Pneumococcal pneumonia induces specific injury to ATII cells and differential 
protein expression in both ATI and ATII cells. Expression of RTI40 is specific to the 
pneumococcus but expression of SP -D is common to other Gram -positive bacteria. Expression of 
neither protein was mediated by pneumolysin or by direct interaction of bacteria or bacterial 
products. These results provide valuable insight into host response to bacterial pathogens. 
iii 
DECLARATION 
All the work presented in this thesis has been carried out by myself, except where acknowledged 
otherwise. 





I acknowledge the financial contribution of the Medical Research Council (MRC), and the 
help and support of the following people: 
Supervisors (current and former): 
John Simpson, Tom Wilkinson, Sarah Howie, Mary McElroy, David Harrison 
Technical assistance: 
Alfred Bernard, Catholic University of Louvain (CC10 analysis), Susan Harvey and Robert Morris 
(tissue processing and cutting), Steve Mitchell (Electron Microscopy), Spike Clay (help with in vivo 
work), Linda Wilson (help with confocal microscopy), Shonna Johnston (help with flow 
cytometry), Scott Bader and Oliver Maddocks (help with bacterial co- culture system) 
Reagents: 
Tim Mitchell, University of Glasgow (S. pneumoniae), Leland Dobbs (RTI40 and RTII70 
antibodies), Michael Beers, University of Pennsylvania (SP -D and Pro -SP -C antibodies), Antoinette 
Wetterwald, University of Berne (E11 antibody), Tim Foster, Trinity College Dublin (S. aureus), 
Mary Williams, Boston University (SV40 -T2 cell line), Erica Crouch, Washington University in 
Saint Louis (recombinant rat SP -D) 
General help and advice: 
Current and former members of the Jules Thorne Research Group (Lesley Farrell, Kallirroi Kefala, 
Olga Lucía Moncayo -Nieto, Andrew Conway- Morris, Key Dhaliwal) 
Current and former members of the Department of Pathology (Helen Caldwell, Louise Treanor, 
Paul Fitch, Linda Franklin, Stuart MacKechnie, Nick Wheelhouse, Susan McIntyre) 
Support and other stuff: 
Ann Tanner, Geraint Bevan, Christina Tyrrell, William Cumming 
v 
CONTENTS 
Abstract... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ii 
Declaration... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... .. ... ... ..iv 
Acllllowledgements ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ..v 
Contents... ... ... ... ... .. ... ... ... ... ... ... ... ... ... ... .. .. ... .. .. ... ... ... ... ... ... ... -.Oa 
Listof Figures ..................................................... .............................xi 
Abbreviations.................................................. ............................... xiii 
CHAPTER 1: INTRODUCTION... ... ...1 
1.1. PNEUMONIA 
1.1.1. Clinical Importance of Pneumonia ........................... ..............................1 
1.1.2. Disease and Aetiology ...................................... ............................... 3 
1.1.3. Pathogenesis... .00 660 666 666 666 000 080 0.8 000 800 000 000 000 0.0 000 000 800 0.0 000 0.0 .00 000 .00 000 600 000 ... 5 
1.1.4. Summary 8 
1.2. THE LUNG 
1.2.1. Structure and Function 
1.2.1. i.O verview ............................................... ............................... 
1.2.1.2.Respiratory Zone (Alveolar Region) 
1.2.1.2.1. Overview... 000 0.0 000 600 000 000 .00 .00 0.0 600 800 SOO 006 00. 000 000 00. 000 000 000 000 0.0 600 0011 
1.2.1.2.2. Surfactant- .00 .00 008 600 40. 6.0 006 666 .00 000 006 000 000 000 000 O.. 000 .00 O.. 006 000 600 000 
1.2.1.2.3 Alveolar Epithelium ............................... .............................15 
1.2.1.2.4. Pulmonary Endothelium and ECM ............ .............................18 
1.2.1.2.5. Alveolar Macrophages ............................ .............................19 
1.3.Summary ................................................... ............................... 20 
1.2.2. Host Defence of the Lung 
1.2.2.1.Introduction to Host Defence... ......21 
1.2.2.2.Innate Immunity ......................................... ............................... 21 
1.2.2.3Adaptive Immunity ...................................... ............................... 24 
1.2.2.4. Summary ..................................................... .............................25 
1.3. INJURY AND REPAIR OF THE LUNG 
1.3.1. Lung Injury and Disease 
1.3.1.1.Acute Injury of the Lung.................................. .............................26 
1.3.1.2Bacterial Infection of the Lung.................. .29 
1.3.1.3.Summary ..................................................... .............................30 
1.3.2. Animal Models of Lung Disease 
i.3.2.1.Overview ...................................................... .............................31 
1 .3.2.2.Techniques .................................................... .............................31 
1.3.2.3.Models of Pneumococcal and Staphylococcal Pneumonia .......................33 




1.4.1. Overview ........................................................ ............................... 37 
1.4.2. ATI Cell- Specific Proteins 
1.4.2.1.RTI40 
1.4.2.1.1. Overview ............................................. .............................38 
1.4.2.1.2. Function .............................................. .............................39 
1.4.2.1.3. ATI Cell Marker ................................... .............................41 
1.4.2.1.4. Injury Marker ...................................... .............................42 
1.4.2.1.5. Summary ............................................ .............................43 
1.4.2.2.Aquaporin 5 .............................................................................. 43 
1. 4. 2. 3. MMC6 ........................................................ .............................44 
1.4.3. ATII Cell- Specific Proteins 
1.4.3.1. SP-C ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... .45 
1.4.3.2.RTII70 ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ....46 
1.4.3.3.SP-D ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... .47 
1.4.3.4.APN/MMC4 ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... 49 
1.4.4. Clara Cell Specific Proteins 
1.4.4.1. CC10 .......................................................... .............................50 
1.4.5. Summary ............................. ............................... ... ... ... ... ... ... ... ......52 
1.5. BACTERIA 
1.5.1. Overview ........................................................ ............................... 53 
1.5.2. Streptococcus pneumoniae 
1.5.2.1.Clinical Importance of Streptococcus pneumoniae ... .............................53 
1.5.2.2.Bacterial Morphology ................................... ............................... 54 
1.5.2.3.Virulence Factors 
1.5.2.3.1. Overview... ....... .56 
1.5.2.3.2. Intracellular Factors 
1.5.2.3.2.1.Pneumolysin .................................... .............................57 
1.5.2.3.2.2.Neuraminidase ................................. .............................59 
1.5.2.3.2.3.Hydrogen Peroxide... 
1.5.2.3.3. Surface Factors 
1.5.2.3.31.Capsule and Cell Wall Components... ......6() 
i .5.2.3.3.2.Autolysin ...................................... ............................... 61 
1.5.2.3.3.3.Other Surface Proteins ....................... .............................61 
1.5.2.4.Summary ..................................................... .............................62 
1.5.3. Staphylococcus aureus 
1.5.3.1.Clinical Importance of Staphylococcus aureus... 000 000 000 000 000 000 00. 000 060 .06. 000.62 
1.5.3.2.Bacterial Morphology ................................... ............................... 63 
1.5.3.3.Virulence Factors- 066 606 600 000 060 006 000 000 000 000 000 000 000 000 00. 000 006 000 000 00. 64 
1.5.3.4.Summary ..................................................... .............................65 
1.6. THESIS OBJECTIVES.. 006 600 000 000 000 000 606 000 600 000 000 060 000 000 000 000 000 000 000 000 000 000 ... 
CHAPTER 2: MATERIALS AND METHODS ..... ............................... 68 
2.1. REAGENTS, ANIMALS AND GMO 
2.1.1. Reagents ........................................................... .............................68 
2.1.2. )11111111111S0.0 .0. 000 0.00 000 000 000 000 060 000 .00 060 60. 600 660 oge eeo eee eoe oee ego 000 600 000 000 000 000 000 0006068 
2.1.3. GMO ............................................................... .............................68 
vii 
2.2. BACTERIA ...............000 000 000 000 000 000 000 000 000 000 00.000 000 
2.2.1. Streptococcus pneumoniae 
000 000 000 000 000 000 000 000 000 000 000 000 0.69 
2.2.1.1. Strains ......................................................... .............................69 
2.2.1.2.Bacterial Culture ......................................... ............................... 69 
2.2.2. Staphylococcus aureus .......................................... .............................70 
2.3. MODELS OF INFECTION 
2.3.1. In vivo Models of Pneumonia 
2.3.1.1.Pneumonia Models... ......... ............ 71 
2.3.1.2.Processing of Animal Tissue 
2.3.1.2.1. Biochemical Analysis .............................. .............................71 
2.3.1.2.2. Morphological Analysis... ... 000 WOO 000 000 000 000 ........73 
23.2. In vitro Models of Bacterial Co- culture 
2.3.2.1.Bacterial Co- culture Model 
2.3.2.1.1. Reagents and Plastics... ... 600 000 a.. 000 000 74 
2.3.2.1.2. Cell Lines ............................................ .............................75 
2.3.2.1.3. Cell Culture.............................. 75 
2.3.2.1.4. Bacterial Co- culture ............................... .............................75 
2.3.2.2.Cell Processing 
2.3.2.2.1. Protein Analysis .................................... .............................75 
2.3.2.2.2. RNA Analysis ....................................... .............................76 
2.4. ANALYSIS 
2.4.1. Protein Assessment 
2.4.1.1.Biochemical Analysis 
2.4.1.1.1. Protein Assay ....................................... .............................78 
2.4.1.1.2. Protein Analysis- 000 000 000 000 000 000 000 000..78 
2.4.1.1.2.1.Dot Blot .......................................... .............................79 
2 .4.1.1.2.2. W esters Blot .................................... .............................80 
2.4.1.1.2.3.ELISA (Enzyme- Linked ImmunoSorbent Assays) ..................81 
Table2. 1 ........................................... .............................82 
2.4.1.1.2.4.Multiplex Bead Array ........................ .............................83 
2.4.1.1.2.5.FACS (Fluorescence- activated cell -sorting) Analysis ...............82 
2.4.1.2Immunohistochemical Analysis 
2.4.1.2.1. Immunofluorescence staining- ...841 
2.4.1.2.2. Antibodies- - 85 
2.4.2. RNA Assessment 
2.4.2.1.RNA Purity Assessment ................................... .............................85 
2.4.2.2.RT -PCR (Reverse Transcription Polymerase Chain Reaction) ................85 
2.4.2.2.1. Reverse Transcription .......................... ............................... 86 
2.4.2.2.2. PCR ................................................... .............................87 
2.5. STATISTICAL ANALYSIS .......................................... .............................89 
3. CHAPTER 3: RESULTS ...... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ..90 
3.1. INTRODUCTION ..................................................... ............................... 90 
3.2. HYPOTHESIS 1 ......................................................... .............................90 
3.3. METHODS- 000 000 000 000 000 000 000 000 SOO 000 WOO 000 000 000 000 00* 000 000 000 000 000 000 WOO 000 000 000 0000090 
viii 
3.4. RESULTS 
3.4.1. Basic Characterisation of S. pneumoniae-induced Pneumonia Model 
3.4.1.1.Aim . ... .0. .0. 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 0000092 
3.4.1.2.Weight Loss... ... ............ 0_0. ... 92 
3.4.1.3.Histology .0.............................................................................92 
3.4.1.4.Bacterial Recovery ems moo 000 000 SOS 000 000 000 COO 000 000 000 000 000 000 000 00G 000 000 000 000 000-93 
3.4.1.5.Airway Inflammation ... .....................................93 
3.4.1.6.Damage to Air-Blood Barrier... ...... 94 
3.4.1.7.Pleural Space............ ......... ... 0.0 ... ... 0.0 ... ......95 
3.4.1.8.Inflammatory Mediators 000 000 000 000 000 000 000 000 COO 000 000 .0. 0.0 000 000 000 000 000 000 COO ...96 
Figures3.1 -3.11 omo 000 oso 000 000 000 000 000 coo coo 000 000 000 000 000 000 000 000 000 000 000 opo 000 000097 
3.4.1.9.Summary ..0 ... .00 .00 .0. 0.0 .0. ... .0. 0.0 .0. 000 000 000 000 000 000000108 
3.4.2. ATI Cell Injury 
00. 0.0 0.. ... ... .0. ... .0. ... ... COO 000 000 000 000 000 000 000 000 000 000 0000109 
3.4.2.2.Assessment of RTE410.0......0 
3.4.2.3.Assessment of PVIMC6 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 COO 000000110 
3.4.2.4.Assessment ofAcplaporin 5.00 00. 000 .00 .00 .0. 0.0 .00 000 000 .00 000 000 000 000 000 001H 
30402050140171)110100Cal Assessment... 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 00112 
Figures 3.12 -3.17 ............... 000 000 000 000 000 000 000 000 000 000 000 oco 000 000 000 000 000 000.113 
3.4.2.6.Summary and Conclusions... 000 000 ......... 000 000 000 000 00 000 000 000 000 000 
3.43. ATII/Clara Cell Injury 
3.4.3.1.Aim... 000 000 COO 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 0000122 
3.4.3.2.1Rtationale... 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 122 
3.4.3.3.Evidence of ATII Cell Injury ...... ......0.. ... 0.000. ... ......122 
3.4.3.4.Quantification of ATII Cell Injury 
3.4.3.4.1. Rationale- ... 000 4.0 000 000 000 000 000 000 000 000 000 000 000 000 000 000123 
3.4.3.4.2. Immunofluorescence Quantification ... ... .0. ......0..... .....123 
Biochemical Quantification." 000 000 000 000 000 000 000 000 000 000 000 000 000 000 0000/24 
3.4.3.4.3.1.Assessment of Pro-SP-C _0124 
3.4.3.4.3.2.Assessment of SP-I)1... 000 000 000 000 000 000 000 000 000 000 000 000 000 0000000125 
3.4.3.4.3.3.Assessment of APN/MMC4... 000 000 000 000 000 000 000 000 000 000 000 000 000000/265 
3.4.3.5.Assessment of Clara Cell Injury 
3.4.3.5.1. Assessment of (21C111111 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 01127 
Figures3.18 -- 3.23 mom 000 000 oco 000 op° 000 000 omm moo oco ooc 000 op° poo 000 000 000 000 000 coo .121 
3.4.3.6.Summary and Conclusions .......... .0.0-0.000 ... 0.. ... 
3.4.4. Overall Conclusions ... 000 000 000 000 000 000 000 COO 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 136 
4. CHAPTER 4: RESULTS 
4.1. INTRODUCTION... 000 000 000 000 000 COO 000 000 000 000 000 000 00o Opp 000 000 000 000 000 000 000 000 000 000 000 0.0 01137 
4.2. PNEUMOLYSIN 
4.2.1. Introduction 000 000 000 000 000 000 000 000 COO 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 131 
4.2.2. Hypothesis 2.1000 COO 000 000 000 000 000 000 000 000 000 000 000 000 000 000 00C 000 000 000 000 000 COO 000 000 000 01131 
4.2.3. Methods 00 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 GOO 000 000 00,0 000 000 000 000 000 000000000108 
4.2.4. Results 
4.2.4.1.Basic Comparison of S. pneumoniae Wildtype and Pneumollysin-DeMent 
Ad[()(141s000 000 000 000 000 000 000 000 000 000 000 000 000 000 00U ... 000 000 000 000 000000000 000 000 000 000 00000140 
4.2.4.2.Differential Protein Expression .0. ... 0.. 0.0 000 000 000 000 000 000 000 COO 000 000 000 000...141 
Figures4.2.1 -- 4.11.13 mmo 000 000 000 coo 000 poo op° °coo pop 000 000 °coo 000 000 coo 000 000 ooc 000 000 mom m][412 
ix 
5. 
4.3. S. aureus 
4.3.1. .^..'^~^^^^.^..^.^....^....~.^^.^^^,...^^..~......^.^.^..^~^^.^..^^..^.^..... 
4.3.2. Hypothesis 2.2._ 0.0.~..0- .................^.. ... ...... ..._. .,- ^.~ ...~..,155 
4.3.3. ...........................,.....,......................155 
4.3.4. Results 
4~3.4L1.BamÜc Comparison of S.aureus and S. pneumoniae ...............856 
Figures 4.3.1 ....~.~......~.......~.,...,~....158 
CHAPTER ~. .~.~.~.~... 000 000 000 000 000 000 000 000 000 000 000 000 000 ... 000 000 000 000 ......... 
5.2 3 .~~.~......... ...~~..~.~...~.....~.,.~~.......172 
5.3. 
RESULTS 
5.4.1. Characterisation of SV40-T2mm......,...,..............,,...........................7B 
5/4.2. Characterisation of&m Vitro Bacterial Co-Culture System ............ .......~...D74 
5.4.3. Differential Protein Expression ...,..,.,,.............. ............... -'..,.,..,......DT4 
5.4.4. Distribution ofRTD40 Expression &m Vivo ..,,.................,........,.'',..,..,,.,.175 
Figures 5.1_,._~.^~~..~......,.......^^-^.^~^^.~^..~.^...^..^^..^,..........,~.,., 
6. CHAPTER 6: .~. 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 ~.~.1188 
6.1. SUMMARY OF 
.~ ~, .~U90 
AppendixI ... .,. ... ... ... ... ... ... ... ... .,. ... ^.. .~. ... ... ... ... ... ... ... ..~ ... ~.. ..... 203 
Bibliography ... ... ... ... ... 000 ... ... ... ... ~.. ~~. .~. ... ..~ ..~ ~.. ... ... .~ .° ~.~ ... ... ... ... ...205 
x 
LIST OF FIGURES 
Figure 1.1 Chest radiograph from patient with bacterial pneumonia._ ............ 0- -.3 
Figure 1.2 Normal and pneumonic lung at the microscopic level_ ..................... .0..0. ....7 
Figure 1.3 Features of Conducting, Intermediate and Respiratory Zones of the lung..........10 
Figure 1.4 Features on a normal 
Figure 1.5 Features of acute alveolar injury and inflammation 27 
Figure 1.6 Features of injury resolution and 
Figure 1.7 Gram-positive stain of S. pneumoniae .0. .0. .00 .0. 0.° .0. .00 .....56 
Table 2.1 Biochemical protein analysis antibody summary.- ......... ............................82 
Table 2.2 Antibodies used in immunofllutorescence staining .............................. .............85 
Figure 3.1 Rat body weight... ... - -00. - ... 0.0 ... 00. 000 ..97 
Figure3.2 H&E of rat lung- ......... 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000..98 
Figure 3.3 CFU recovered from lungs ......... ......... 99 
Figure 3.4 Leukocytes in BAL fluid......... ..................... ....................................... 100 
Figure 3.5 Differential leukocyte count in BAL fluid ....................................... _0_0-101 
Figure 3.6 Protein concentration in BAL 
Figure 3.7 Leukocytes in pleural lavage fluid 0.. 000 000 000 000 000 000 000 000 000 000 000 103 
Figure 3.8 Differential leukocytes count in pleural lavage fEiikJ1 000 ............... 000 000 000 104 
Figure 3.9 Protein concentration in pleural lavage fluid ..................... 000 000 000 000 000 ...105 
Figure 3.10 IL-la, in lung tissue... 00 ..... .0 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 106 
Figure3.11 MCP-1 in lung timue... 0.. 000 noo 000 odo 000 000 ono 000 000 000 opo 000 000 000 000 000 coo 000 000 000 coo 0000.107 
Figure 3.12 RTI40 in BAL fluid and lung tissue ......... ............................................113 
Figure 3.13 MMC6 in BAL fluid and lung tissue................................. ...... 115 
Figure 3.14 Immunofluorescence staining of rat 
Figure 3.15 Immunofluorescence staining of S. pneumoniae-infected rat Rung... 000 000 000 .0.-117 
Figure 3.16 Aquaporin 5 in lung 000 000 000 000 ....118 
Figure 3.17 EM of S. pneumoniae-infected rat lung... ... 000 000 000 000 000 000 000 000 000 000 000 000 000 ..119 
Figure 3.18 EM of S. pneumoniae-infected rat lung ... 0..0.. 128 
Figure 3.19 Quantification of ATII cell sloughing ... .00 ............129 
Figure 3.20 Pro-SP-C in lung 
Figure 3.21 SP-D in BAL fluid and lung -131 
Figure 3.22 APN/MMC4 in BAL fluid and lung tissue 000 000 000 000 000 000 000 000 000 000 000 000 000 000 .....132 
Figure 3.23 CC10 in BAL fluid and 
Figure 4.2.1 Pneumolysin expression in S. pneumoniae .0. ... .0. ..o 000 000 000 000 000 000 000 000 0.. 0.0..142 
Figure 4.2.2 Rat body weight- . . 0- ... 000 000 000 000 000 000 - 000 000 000 000 000143 
Figure 4.2.3 CFU recovered from lungs ..................................................................144 
Figure 4.2.4 Leukocytes in BAL fluid ......... ..................... ............ ..................... ......145 
Figure 4.2.5 Differential leukocyte count in BAL fluid- ... 00. ... 00. 0.0 0.° 0.. 000 000 000 000 000 000...146 
Figure 4.2.6 Protein concentration in BAL fluid_ .................................................147 
Figure 4.2.7 Pleural lavage fluid - GOO 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 .. 000 0..148 
Figure4.2.8 lung tissue... 000 000 000 Do° 000 000 000 000 000 000 no° 000 000 000 poo 000 coo 000 coo ono 000 000 nee 6.6149 
Figure 4.2.9 MCP-1 in lung tigstle... pop 000 000 000 ooc 000 000 000 pc° coo 000 000 000 Goo ooc 000 oco 000 "0E54) 
Figure 4.2.10 RTI40 in BAL fluid and lung 
Figure 4.2.11 MMC6 in B AL fluid and lung tissue-. - 0.0_0-0_ ......... .0. 00.152 
Figure 4.2.12 SP-D in BAL fluid and lung tissue ............... ......... 
xi 
Figure 4.2.13 APN/MMC4 in BAL fluid and lung 
Figure 4.3.1 Rat body weight oo. 000 
Figure 4.3.2 CFU recovered from lungs 0.0.0. o.° oo. 
Figure 4.33 Leukocytes in BAL fluid . 000 000 000 00 000 000 
Figure 4.3.4 Differential leukocyte count in BAL fluid 
Figure 4.3.5 Protein concentration in BAL fluid......... 
Figure 4.3.6 IL-la in lung tissue.,. 
.0. oo. 
000 000 000 
000 
o.° 000 000 000 000 
.....0.0.0.0 000 o.° o.° 000 
000 000 000 000 000 000 000 000 000 
0.0.0.0o. o.. 
000 o.° 







Figure 4.3.7 MCP-1 in lung tissue-0o.- ---00.00.- 0.. o.. .....0.0..........000 o.. ....164 
Figure 4.3.8 RTI40 in BAL fluid and lung tissue-00000000o o.. 00.00.0.000.000.00 -000.000 o..... o. a so.s 165 
Figure 4.3.9 MMC6 in BAL fluid and lung tissue... 00.00o 000 o.° .00 o.° 00.00.0.00.0.00.0000. o.. o.. ......166 
Figure 4.3.10 Aquaporin 5 in lung tissue-000o 
Figure 4.3.11 SP-D in BAL fluid and lung tissue.......0o00.00. o.. 0.0.00 oo.... 0- .168 
Figure 4.3.12 APN/MMC4 in BAL fluid and lung tissue... 000 000 000 000 000 000 000000o-169 
Figure 5.1 Expression of IL-la and MCP-1 in SV40-T2 cens...00-0o_ 0.0 000 °o. °o.- 176 
Figure 5.2 Expression of RTI40 in SV40-T2 cells 
Figure 5.3 Expression of SP-D in SV40-T2 o.......0 o.. ....00.0.0.......178 
Figure 5.4 CFU recovered from S. pneumoniae-infected ií cullture -0.0.179 
Figure5.5 IL-la expression 0.0 0.000.000 0.00.0 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 0..180 
Figure5.6 MCP-1 expression-0000 066 000 000 000 000 00o 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 no. 181 
Figure5.7 RTI40 expression ......00. 000 0. 0.0000000 00000°0o. 00.0.00.. o.. oo°00.000 000 000 000 000 .00.182 
Figure5.8 SP-D oo............................00.00.......0.0.000.00.0 °o. .000_183 
Figure 5.9 In vitro summary _00_184 
Figure 5.10 Immunofluorescence staining of rat lung................00.0.00.0.0.0.... °o. 0..185 
Figure 6.1 Possible mechanisms of S. pneumoniae mediation............ 000 000 000 000 000 000 000 000 060 198 
xii 
ABBREVIATIONS 
8325 -4 = wildtype strain of S. aureus 
A. fumigatus = Aspergillus fumigatus 
AM = Alveolar macrophage 
APC = Antigen presenting cell 
APN = Aminopeptidase N 
AQP = Aquaporin 
ARDS = Acute respiratory distress syndrome 
ATI = Alveolar type I 
ATII = Alveolar type II 
BAB = Blood agar base 
BAL = Broncho- alveolar lavage 
BSA = Bovine serum albumin 
Can = Collagen -binding adhesin 
CAP = Community acquired pneumonia 
CbpA = Choline binding protein A 
CC10(16) = Clara cell protein 10(16) 
Clf = Clumping factor 
C. neoformans = Cryptococcus neoformans 
CNS = Central nervous system 
COPD = Chronic Obstructive Pulmonary Disease 
C. pneumoniae = Chlamidia pneumoniae 
D10 media = DMEM + 10% FBS + L- glutamine 
D39 = Wildtype strain of S. pneumoniae 
DMEM = Dulbecco's modified eagle's medium 
dNTPs = Deoxynucleotide- triphosphates 
DPBS = Dulbecco's phosphate buffered saline 
DPBS +I+ = Dulbecco's phosphate buffered saline containing calcium and magnesium 
DPBS "/_ = Dulbecco's phosphate buffered saline without calcium and magnesium 
DPPC = Dipalmitoylphosphatidylcholine 
DTT = Dithiothreitol 
ECL = Enzymatic chemiluminescence 
ECM = Extracellular matrix 
E. coli = Escherichia coli 
EDTA = Ethylenediaminetetraacetic acid 
ELISA = Enzyme -linked immunosorbent assay 
FACS = Fluorescence - activated cell -sorting 
FBS = Foetal bovine serum 
FBI = Fluorescent bead immunoassay 
FITC = Fluorescent isothiocyanate 
FnBP = Fibronectin binding protein 
GM -CSF = Granulocyte macrophage colony -stimulating factor 
GMO = Genetically modified organism 
GORD = Gastro- oesophogeal reflux disease 
H2O2 = Hydrogen peroxide 
H &E = Haemotoxylin and eosin 
HAP = Hospital- acquired pneumonia 
HCAP = Health- care -associated pneumonia 
H. influenzae = Haemophilus influenzae 
Hla = Alpha toxin 
Hlb = Beta toxin 
Hld = Delta toxin 
Hlg = Gamma toxin 
HRP = Horseradish peroxidase 
HT156 = Human type I 56 
Hyl = Hyaluronate lyase 
ICAM -1 = Intercellular adhesion molecule 1 
ICU = Intensive care unit 
IFN -y = Interferon gamma 
Ig = Immunoglobulin 
IIPs = Idiopathic interstitial pneumonides 
IL = Interleukin 
IPCVD = Interstitial pneumonia with collagen vascular disease 
IPD = Invasive pneumococcal disease 
IPF = Interstitial pulmonary fibrosis 
LBP = Lipopolysaccaride binding protein 
L. pneumophila = Legionella pneumophila 
LPS = lipopolysaccaride 
LRTI = Lower respiratory tract infection 
LTA = Lipoteichoic acid 
LytA = N- acetylmuramic acid L- alanine amidase 
KGF = Keratinocyte growth factor 
K. pneumoniae = Klebsiella pneumoniae 
MCP -1 = Monocyte chemotactic protein 1 
MIP = Macrophage inflammatory protein 
MMC4 = APN 
MMC6 = protein on surface of ATII cells 
M.O.I = Multiplicity of infection 
M. pneumoniae = Mycoplasma pneumoniae 
MRSA = methicillin- resistant S. aureus 
NCTC = National collection of type cultures 
NK = Natural killer 
OCT = Optimum cutting temperature compound 
OD = Optical density 
P. aeruginosa = Pseudomonas aeruginosa 
DAMP = Pathogen- associated molecular pattern 
PAP = Pulmonary alveolar proteinosis 
PBS = Phosphate buffered saline 
P. carinii = Pneumocystis carinii 
PCP = Pneumocystis carinii pneumonia 
PCR = Polymerase chain reaction 
Strep -PE = Streptavidin- phycoerythrin 
PG = Peptidoglycan 
PLN -A = Pneumolysin- deficient mutant of D39 S. pneumoniae 
Ply = Pneumolysin 
PMNs = Polymorphonuclear cells 
PRR = Pattern recognition receptor 
PsaA = Pneumococcal surface adhesin A 
PspA = Pneumococcal surface protein A 
PVDF = Polyvinylidene fluoride 
PVL = Panton -valentine leukocidin 
RBC = Red blood cell 
RDS = Respiratory distress syndrome 
xiv 
RIPA = Radioimmuno precipitation assay 
RTI40 = Rat type I 40 
RTII70 = Rat type II 70 
RT -PCR = Reverse transcriptase polymerase chain reaction 
SARS = Severe acute respiratory syndrome 
S. aureus = Staphylococcus aureus 
SDS -PAGE = Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SP = Surfactant protein 
SpA = Staphylococcal protein A 
SPF = Specific pathogen free 
S. pneumoniae = Streptococcus pneumoniae 
SV40 -T2 = Simian virus -transformed ATII cell line 
TBS = Tris -HC1 buffered saline 
TBST = TBS containing 0.05% Tween 20 
TGF -ß = Transforming growth factor beta 
TNF -a = Tumour necrosis factor alpha 
TLR = Toll -like receptor 
TSST-1 = Toxic shock syndrome toxin 1 
VAP = Ventilator- associated pneumonia 
VEGF = Vascular endothelial growth factor 
xv 
CHAPTER 1: INTRODUCTION 
1.1 : PNEUMONIA 
1.1.1 Clinical Importance of Pneumonia 
Pneumonia is an important infectious pathological lung condition, which was 
recognised as far back as ancient Greece and has been a key disease throughout 
history (Blasi et al., 2007). Even today pneumonia is still a significant cause of 
morbidity and mortality worldwide, and in `developed' countries such as the USA it is 
the sixth most common cause of death, and has a mortality rate of 13.4 per 100,000 
(Blasi et al., 2007; Franquet, 2001). 
Most cases of pneumonia can be classified into one of two categories. community - 
acquired pneumonia (CAP), can affect even young healthy people, with an incidence 
of 6/1000 between the ages of 18 -39, which rises to 34/1000 in the over -75s (Blasi et 
al., 2007). Hospital admission can be required in 20 -50% of cases, and 5 -10% need 
intensive care treatment (Blasi et al., 2007; BTS Guidelines, 2001; Franquet, 2001; 
Hoare and Lim, 2006). Mortality is higher in developing countries, the elderly and 
children (Blasi et al., 2007; Franquet, 2001; Hoare and Lim, 2006). When managed in 
the community, mortality is less than 1 %; however, this rises to 5 -12% of hospital 
admissions and is over 50% in patients admitted to the Intensive Care Unit (ICU) 
(Blasi et al., 2007; BTS Guidelines, 2001; Hoare and Lim, 2006). Nosocomial or 
Hospital- Acquired Pneumonia (HAP) occurs when the patient contracts the disease 
after admission to hospital and includes Ventilator -Associated Pneumonia (VAP) and 
Health- Care -Associated Pneumonia (HCAP) (ATS Guidelines, 2005; Franquet, 
2001). Among hospital- acquired infections, HAP is a leading cause of death, with a 
mortality rate of 20 -55% in the ICU (Franquet, 2001). 
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Pneumonia can be caused by a variety of microbiological agents, including fungi, 
viruses and bacteria. Fungal pneumonias are most significant in immunocompromised 
AIDS patients, particularly Pneumocystis carinii (Pneumocystis jirovecii) (Agarwal et 
al., 2006) pneumonia (PCP) (Franquet, 2001). Viruses, mostly influenza viruses, are 
responsible for 5 -20% of out -patient CAP, especially in children, and are often 
associated with secondary bacterial superinfection (Blasi et al., 2007). They tend to be 
uncommon in severe pneumonia, i.e. requiring admission to the ICU; however, there 
are obvious exceptions to this, such as Severe Acute Respiratory Syndrome (SARS) 
and the `avian flu' virus H5N1 (Blasi et al., 2007; Hoey, 1998; Zhang, 2003). 
Bacteria are the most common cause of pneumonia and treatment is usually based on 
antibiotics. However the increasing incidence of antibiotic resistance has resulted in a 
pressing need for additional therapies (Blasi et al., 2007). Vaccines against the most 
common causes of the disease, such as Streptococcus pneumoniae (pneumococcus), 
can be highly effective (AlonsoDeVelasco et al., 1995; Bricks and Berezin, 2006; 
Jedrzejas, 2001), but it is unlikely to be practical to vaccinate against all causative 
agents, especially given that different patient groups can be susceptible to different 
organisms. 
An estimated 5 million children under the age of 5 still die every year from 
pneumonia worldwide (Jedrzejas, 2001). It therefore remains a major human disease 
that requires urgent further study. A more thorough understanding of how each 
organism instigates and develops the disease is vital in order to develop appropriate 
treatments. 
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1.1.2 Disease and Aetiology 
Pneumonia is classified as an acute lower respiratory tract infection (LRTI), 
characterised by symptoms including shortness of breath and rapid breathing, cough 
often with production of sputum, and pleuritic chest pain combined with an increase 
in white blood cell count and fever (BTS Guidelines, 2001; Hoare and Lim, 2006). 
However identification of consolidation by shadowing in a chest radiograph is vital to 
accurate diagnosis (Franquet, 2001; Hoare and Lim, 2006). Figure 1.1 shows a chest 
radiograph from a patient with pneumonia (http: / /www.emedicine.com). 
Figure 1.1 -A chest radiograph from a patient with bacterial pneumonia. 
Arrow shows consolidation in the lower left region. 
Aetiological agents of pneumonia can differ considerably according to a variety of 
patient risk factors, as well as geographical location (Blasi et al., 2007). However, in a 
high proportion of cases the causative pathogen is never actually identified (Blasi et 
al., 2007; BTS Guidelines, 2001). By far the most common aetiological agents are 
bacteria, although this can be in conjunction with or following a viral infection (Blasi 
et al., 2007). Actual figures, even for Western Europe and North America, can vary 
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markedly, from 3 -76 %, but it is well established that the most common cause of CAP 
is S. pneumoniae (Jones et al., 2000; Lim et al., 2001; Logroscino et al., 1999; Sopena 
et al., 1999). Other common species such as Haemophilus influenzae can cause 10- 
20% of CAP cases treated in the community (BTS Guidelines, 2001; Vilar et al., 
2004), but this drops to 2 -7% in hospitalised patients (BTS Guidelines, 2001). 
Mycoplasma pneumoniae has been shown to account for up to 37% of CAP cases 
although numbers are highly variable due to cyclical epidemics, and this species tends 
to affect younger patients rather than the elderly (Blasi et al., 2007; BTS Guidelines, 
2001; Vilar et al., 2004). Another so- called `atypical' and difficult to diagnose 
intracellular pathogen, Chlamydia pneumoniae, is often coexistent with M. 
pneumoniae (Vilar et al., 2004) and is responsible for up to 20% of CAP cases, 
particularly in hospitalised patients (Blasi et al., 2007; BTS Guidelines, 2001; Vilar et 
al., 2004). Legionella pneumophila is rare in community- treated patients but is the 
causative agent for up to 17% of severe pneumonias admitted to the ICU (Blasi et al., 
2007; BTS Guidelines, 2001). Aerobic Gram -negative bacilli such as Enterobacteriae, 
Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa are rare in 
CAP, as is the Gram -positive coccus Staphylococcus aureus, however these species 
are much more prevalent in HAP infection (ATS Guidelines, 2005; Blasi et al., 2007; 
BTS Guidelines, 2001; Vilar et al., 2004). 
Thus, although the pathogen- specific aetiology of pneumonia is by no means clear cut 
on presentation by the patient, the importance of bacteria as causative agents is well 
established, particularly that of S. pneumoniae in CAP. 
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1.1.3 Pathogenesis 
Broadly speaking, there are two radiologically distinctive types of pneumonia, and 
although pathology is not necessarily indicative of causal agent, some pathogens can 
often exhibit radiological characteristics (Franquet, 2001; Vilar et al., 2004). Lobar 
pneumonia is characterised by continuous expression of disease, usually affecting 
only one lobe or segment (Vilar et al., 2004). In CAP lobar pneumonia is most 
frequently caused by S. pneumoniae (Franquet, 2001; Vilar et al., 2004), although 
other causes can be K pneumoniae, L. pneumophila, H. influenzae and occasionally 
M. pneumoniae (Franquet, 2001). In contrast, bronchopneumonia has a diffuse 
multifocal distribution involving more lobes and is associated more in HAP with S. 
aureus and H. influenzae (Franquet, 2001; Vilar et al., 2004), although it can be also 
be caused by S. pneumoniae (Vilar et al., 2004). Interstitial pneumonia involves the 
walls of the bronchi and bronchioli and tends to be caused more by viral pathogens or 
unusual bacterial pathogens such as M. pneumoniae and C. pneumoniae (Franquet, 
2001; Vilar et al., 2004). 
Despite the variety of causative agents of pneumonia, and variations in pathological 
type, the basic pathogenesis of the disease remains essentially the same. Although 
other routes of infection such as direct inhalation can be important for environmental 
pathogens like L. pneumophila (Vilar et al., 2004), colonisation often begins in the 
nasopharynx with normally asymptomatic commensal organisms such as S. 
pneumoniae (AlonsoDeVelasco et al., 1995; Catterall, 1999; Tuomanen et al., 1995) 
and S. aureus (Lindsay and Holden, 2004). Adhesion to the musosal epithelium is an 
important factor in nasal colonisation (Catterall, 1999; Tuomanen et al., 1995). 
Dissemination of bacteria from the nasopharynx to the lungs is dependent on a 
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number of factors, including bacterial virulence and host immune status. Pre -existing 
viral infection can reduce the host's immune capability (AlonsoDeVelasco et al., 
1995; Catterall, 1999; Tuomanen et al., 1995), and microaspiration of bacteria from 
the nasopharynx is thought to enable translocation to the lower respiratory tract (Ben - 
David et al., 2005). If local defence systems are unable to deal with the invasion, 
inflammation becomes established and damage to lung tissue can occur, including that 
caused by the bacteria themselves and secondarily by factors release by inflammatory 
cells. This series of events is discussed in detail in Section 1.2.2 (Host Defence of the 
Lung). Alveoli become flooded with protein -rich exudate and erythrocytes from the 
circulatory system as the air -blood barrier is damaged and made more permeable and 
an acute inflammatory response with recruitment of neutrophils is initiated (Catterall, 
1999; Tuomanen et al., 1995). Then, as consolidation is established, alveoli continue 
to fill up with blood products such as erythrocytes due to progressive leakage into the 
lungs (Tuomanen et al., 1995). As consolidation of the lungs progresses, deposition of 
fibrin reduces the influx of fluid across the air -blood barrier and allows clearance by 
recruited neutrophils (Catterall, 1999; Tuomanen et al., 1995). Finally, resolution 
occurs as leukocytes phagocytose any remaining debris and apoptotic neutrophils are 
cleared by macrophages (Catterall, 1999; Tuomanen et al., 1995). Diagram 1.2 shows 
normal (A) and pneumonic (B) human lung at the microscopic level 
(http: / /teaching.path. cam. ac.uk) 
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Figure 1.2 showing normal (A) and pneumonic (B) lung at the microscopic. 
A. Arrow illustrates clear airspaces and conserved alveolar structure 
B. Arrow shows alveoli filled with inflammatory cells and exudate 
Although the basic pathogenesis of the disease is roughly similar regardless of 
pathogen -specific aetiology, there are variations between different causative agents, 
which can affect recovery. For example, lungs tend to completely return to normal in 
S. pneumoniae infection, whereas pneumonia caused by S. aureus and K pneumoniae 
often leads to abscesses and fibrosis (Catterall, 1999; Tuomanen et al., 1995). 
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1.1.4 Summary 
Pneumonia is a consolidated lower respiratory tract infection, which is a significant 
source of mortality and morbidity throughout the world. Bacterial infection is the 
cause of most cases. S. pneumoniae is the most important aetiological agent in 
community- acquired disease, although other species like S. aureus and P. aeruginosa 
are more prevalent in pneumonia contracted in hospital. Bacterial species, pre- existing 
viral infection and the ability of the host to defend itself are important factors in 
determining risk of development of disease. Colonisation often begins in the 
nasopharynx and progresses to the alveolar regions, leading to progression of disease 
then resolution. Pneumonia still kills millions of children throughout the world every 
year, and understanding the effects and interactions of causative agents on the host 
systems is vital to successful treatment and prevention. 
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1.2: THE LUNG 
1.2.1 Structure and Function 
1.2.1.1 Overview 
The fundamental purpose of the lungs is to facilitate gas exchange between the 
external environment and the circulatory system. It does this by providing a large 
surface area open to the atmosphere, enabling haemoglobin in blood erythrocytes to 
exchange excreted CO2 for fresh 02 (Weibel, 1983). In 1962 Weibel and Gomez 
described 3 functional zones in the lung; 
1. The Conducting Zone, facilitating the distribution of gases 
2. The Respiratory Zone, dedicated to gas exchange 
3. The Intermediate or Transitory Zone, linking the conducting and respiratory 
zones and containing aspects of both (Weibel, 1973). 
Figure 1.3 shows the main features of the Conducting, Intermediate and Respiratory 
Zones of the lung. (Adapted from http://www.anatomie.uni - 
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Figure 1.3 - Features of the Conducting, Intermediate and Respiratory Zones of 
the lung. The Conducting Zone comprises the bronchi and bronchioles as far as 
the terminal bronchioles. The Intermediate Zone is made up of the respiratory 
bronchioles, alveolar ducts and alveolar sacs. The Respiratory Zone is the 
alveoli. Adapted from http://www.anatomie.uni - 
tuebingen.de /prof ect /prof I/ stoffkatalog /Kursbuch.html#Trachea9_1. 
The basic unit of gas exchange, the acinus, comprises the respiratory bronchioles, the 
alveolar ducts and the alveolar sacs, which are clusters of alveoli (- 0.25mm dia), 
where gas exchange between the air and bloodstream takes place (Burns et al., 2003; 
Sinnatamby, 1999; Weibel, 1973). 
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1.2.1.2 Respiratory Zone (Alveolar Region) 
1.2.1.2.1 Overview 
Figure 1.4 shows a stylized diagram adapted from Ware and Matthay (2000) showing 















Figure 1.4 - Features of a normal alveolus, showing airspace and capillary. Note 
the alveolar epithelium covered by surfactant layer, and alveolar macrophages in 
the airway. The basement membrane and lung interstitium separate these from 
the blood vessel, which is lined with endothelial cells. Adapted from Ware and 
Matthay (2000). 
The alveolar region, which is where exchange of gases takes place, is made up of fine 
tissue comprising a multitude of separated airspaces in order to maximise surface area 
available for gas exchange. The alveolar region is highly vascularised, and close 
contact (0.2- 0.5µm) between the capillary endothelia and alveolar epithelia, separated 
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by a thin Extracellular Matrix (ECM) enables efficient movement of CO2 and 02 
across the boundary (Burns et al., 2003; Weibel, 1973; Weibel, 1983). Because of the 
delicate nature of this alveolar airspace, it is highly susceptible to collapse. To prevent 
this it is lined with a phospholipid- protein layer known as surfactant (Weibel, 1973; 
Weibel, 1983). Underneath the surfactant layer, the alveolar epithelium is covered by 
an aqueous lining fluid, which is involved in the dissemination of surfactant 
components (Wright, 1997). 
1.2.1.2.2 Surfactant 
The primary purpose of pulmonary surfactant is to prevent alveolar collapse by 
providing a surface - active layer at the air -liquid interface, thus decreasing surface 
tension (Haagsman and van Golde, 1991; Whitsett and Weaver, 2002). However, 
some of the factors in the protein phase are also involved in protection of the lung as 
part of the innate immune system (Wright, 1997). Surfactant is made up of two 
components, 90% lipids and 10% surfactant- specific protein (Haagsman and van 
Golde, 1991), both of which are produced, degraded and recycled by lamellar bodies 
in alveolar epithelial type II (ATII) cells (Haagsman and van Golde, 1991; Whitsett 
and Weaver, 2002; Wright, 1997). Surfactant constituents are released into the 
aqueous fluid lining the epithelium (Haagsman and van Golde, 1991; Wright, 1997), 
where the surfactant layer, a biofilm, is assembled, along with the lamellar bodies 
forming tubular myelin, important for maintaining surfactant structure (Haagsman and 
van Golde, 1991; Whitsett and Weaver, 2002; Wright, 1997). Here, also, lipid and 
protein constituents are degraded and recycled by ATII cells, although degradation is 
also carried out by alveolar macrophages (Haagsman and van Golde, 1991; Kuroki 
and Voelker, 1994; Whitsett and Weaver, 2002; Wright, 1997). 
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The lipid phase of surfactant is the constituent that is primarily involved in decreasing 
surface tension, and is made up of 80 -90% phospholipids which contains a very high 
proportion of phosphatidylcholine, particularly dipalmitoylphosphatidylcholine 
(DPPC), which is the main active ingredient of the biofilm. The additional presence of 
phosphatidylglycerol is important for the formation of tubular myelin (Haagsman and 
van Golde, 1991; Wright, 1997). 
Despite the surface -tension -lowering capabilities of surfactant phospholipids, on their 
own as surfactant they perform poorly, being inflexible and slow to form lipid layers. 
The addition of surfactant- associated proteins enables efficient formation and 
modulation of surface tension (Whitsett and Weaver, 2002). In total there are 4 
currently- identified surfactant proteins (SP); SP -A, SP -B and SP -C can be considered 
fully surfactant- associated, as they are bound to the phospholipid layer. SP -D, 
although categorised as a surfactant protein, differs in being mostly free from the lipid 
layer and is not localised to lamellar bodies (Beers and Fisher, 1992; Kuroki and 
Voelker, 1994). Surfactant proteins can be further classified into two groups; the 
hydrophobic proteins (SP -B and SP -C), and the hydrophilic collectins (SP -A and SP- 
D) (Haagsman and Diemel, 2001). 
The hydrophobic surfactant proteins SP -B and SP -C are both small molecules; 8- 
15kDa and 3.5 -6 kDa respectively, produced by post- translational cleavage of larger 
precursor proteins; Pro -SP -B and Pro -SP -C (Beers and Fisher, 1992; Kuroki and 
Voelker, 1994). Together they are involved in promoting the formation of 
phospholipid layers by enhancing adsorption, assimilation and organisation of lipids 
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into the monolayer and improving stability. They are also involved in the recycling of 
surfactant components, by enhancing the uptake of phospholipid by ATII cells 
(Haagsman and Diemel, 2001; Kuroki and Voelker, 1994; Whitsett and Weaver, 
2002). SP -B, along with SP -A, is essential for the formation of tubular myelin 
(Kuroki and Voelker, 1994; Whitsett and Weaver, 2002). SP -B is produced both by 
ATII cells and bronchiolar Clara cells, and attachment of the protein to the lipid layer 
via cationic regions of the molecule enables lysis and fusion of vesicles to create 
layers of phospholipids (Kuroki and Voelker, 1994; Whitsett and Weaver, 2002). By 
this method it aids the formation of monolayers as well as organising storage within 
the lamellar bodies (Haagsman and Diemel, 2001; Whitsett and Weaver, 2002) and 
may also be how it aids the formation of tubular myelin from lamellar bodies 
(Whitsett and Weaver, 2002). In contrast, SP -C is localised specifically to ATII cells 
(Kuroki and Voelker, 1994; Whitsett and Weaver, 2002). It is highly hydrophobic and 
very abundant, making up about 4% of the surfactant components (Whitsett and 
Weaver, 2002). SP -C is palmitoylated, which enables it to incorporate within and 
between lipid layers, helping the formation of monolayers and disruption of vesicles 
allowing lipid dissemination (Whitsett and Weaver, 2002). Thus the hydrophobic 
surfactant proteins are crucial for adequate construction and homeostasis of the 
phospholipid surfactant layer. 
The hydrophilic surfactant proteins, or collectins, are large, water -soluble oligomers 
that are highly post -translationally modified and produced by both ATII and 
bronchiolar Clara cells (Haagsman and Diemel, 2001; Kuroki and Voelker, 1994). 
Although both SP -A and SP -D are involved in maintenance of surfactant, their most 
important role is local host defence and they recognise a wide variety of microbial 
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pathogens and particles as well as interacting with alveolar macrophages to aid 
clearance (Haagsman and Diemel, 2001; Kuroki and Voelker, 1994). Like the 
hydrophobic proteins, SP -A is involved in regulation of secretion and reuptake of 
surfactant phospholipid (Kuroki and Voelker, 1994) and has opsonic activity, binding 
to alveolar macrophages and stimulating phagocytosis and chemotaxis (Crouch, 
1998a; Kuroki and Voelker, 1994; Wright, 1997). SP -D, unlike other surfactant 
proteins, is not usually bound to the phospholipid layer, but is located in the aqueous 
lining fluid covering the alveolar epithelium (Kuroki and Voelker, 1994). Despite this, 
SP -D is thought to have some effect on surfactant homeostasis, although less so than 
SP -A (Kuroki and Voelker, 1994). Like SP -A, it is also an opsonin and binds to 
alveolar macrophages, but is more involved in bacterial killing, by enhancing 
aggregation of micro -organisms to improve phagocytosis and inducing 02 radicals 
(Crouch, 1998a; Haagsman and Diemel, 2001; Kuroki and Voelker, 1994). In 
addition, both SP -A and SP -D have been shown to exhibit antifungal (McCormack et 
al., 2003) and antibacterial (Wu et al., 2003) capabilities. 
The hydrophilic collectins thus provide a wide range of services within the airspace, 
including surfactant maintenance and host defence. 
In summary, surfactant is a complicated amalgamation of lipids and proteins that 
work together in protecting the alveolus from both physical collapse and attack by 
external agents. 
1.2.1.2.3 Alveolar Epithelium 
The alveolar epithelium accounts for >99% of the internal surface area of the lung, 
and consists of two main cell types, known as alveolar epithelial type I (ATI), and 
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ATII cells (Dobbs et al., 1998; Weibel, 1973). ATI cells are large, thin, elongated, 
squamous cells (Weibel, 1973), with a diameter of 50 -1001.im and a volume of 2000- 
3000µm3 (Chen et al., 2004a), exhibiting fine cytoplasmic extensions (Weibel, 1973). 
Although they constitute only 10 -15% of the total number of lung cells, they account 
for about 95% of the alveolar surface, which is about 70m2 in humans (Rishi et al., 
1995). ATI cells are thought to be important for exchange of gases (Rishi et al., 
1995). They are anchored together by tight junctions (Weibel, 1973), and this, 
combined with the short diffusion pathway between the airspaces and bloodstream, 
make ATI cells efficient conduits for 02 and CO2 exchange. There is also evidence 
that ATI cells have other functions in addition to simple gas exchange. They have 
been shown to be highly water -permeable (Dobbs et al., 1998), contain transport 
proteins and ions (Dahlin et al., 2004) and have the capability to carry out liquid 
clearance, indicating a regulatory role in lung fluid dynamics (Ridge et al., 2003). It 
has long been assumed that these highly specialised ATI cells are terminally 
differentiated; however, there is some evidence suggesting that, in a foetal system at 
least, they are able to transdifferentiate into ATII cells (McElroy and Kasper, 2004). 
In contrast to ATI cells, ATII cells are small, cuboidal cells (Weibel, 1973), with a 
diameter of 101.tm and a volume of 450- 900µm3 (Chen et al., 2004a). They are located 
in the corners of alveoli, between ATI cells, and are identified by characteristic apical 
microvilli and cytoplasmic lamellar bodies (McElroy and Kasper, 2004; Weibel, 
1973). Like ATI cells, they also account for 10 -15% of total lung cells, although they 
make up only 5% of the alveolar surface area (Rishi et al., 1995). ATII cells are 
responsible for the production, secretion and recycling of surfactant components. The 
other important role that they are thought to fulfil is during repair, by repopulating the 
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alveolar epithelium following injury (McElroy and Kasper, 2004). They do this by a 
process of proliferation and differentiation into ATI cells to cover the denuded 
basement membrane (McElroy and Kasper, 2004). This differentiation can be 
observed easily in vitro, as isolated ATII cells readily undergo transdifferentiation 
into ATI -like cells over time, losing their ATII -like characteristics, such as lamellar 
bodies and microvilli, and adopting a flattened ATI cell phenotype (Borok et al., 
1998a; Dobbs et al., 1988). ATII cells seem to regulate this repair process using sub - 
populations of proliferative daughter cells, which develop into ATI -like cells via 
intermediate cell types (Borok et al., 1998a; Reddy et al., 2004; Tyrrell et al., 2005). 
Thus ATII cells can be considered the progenitor cells of the alveolar epithelium. 
Additionally, ATII cells are involved in lung fluid regulation (McElroy and Kasper, 
2004; Wright, 1997) and may also contribute to vascularisation due to their 
production of Vascular Endothelial Growth Factor (VEGF) (McElroy and Kasper, 
2004; Raoul et al., 2004). 
As well as the two main alveolar epithelial cell types, an additional type III or alveolar 
brush cell has also been described. These cells are very unusual and are characterised 
by large microvilli, which are consistently twice the length of those found on ATII 
cells, but do not contain lamellar bodies or produce surfactant (Koslowski et al., 1998; 
Weibel, 1973). 
Alveolar epithelial cells also have a role to play in lung defence. On their cell surface 
are Pattern Recognition Receptors (PRRs), such as Toll -Like Receptors (TLRs), that 
recognise Pathogen -Associated Molecular Patterns (PAMPs) expressed by micro- 
organisms (Martin and Frevert, 2005; Paterson and Mitchell, 2006). Epithelial cells 
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produce inflammatory mediators such as cytokines and acute phase proteins as well as 
antimicrobial peptides (Delclaux and Azoulay, 2003; Martin and Frevert, 2005). ATII 
cells are particularly important due to their production of immunomodulatory 
collectins SP -A and SP -D as well as complement components and cytokines such as 
Monocyte Chemotactic Protein 1 (MCP -1), Transforming Growth Factor Beta (TGF- 
ß), Tumour Necrosis Factor Alpha (TNF -a) and a variety of Interleukins (ILs) 
(Fehrenbach, 2001; Wright, 1997). 
In summary, the alveolar epithelium is populated mainly by two highly specialised 
cell types and is responsible for the primary function of lung tissue, gas exchange. 
The main purpose of ATI cells is to carry out this process, supported by ATII cells 
that have a protective role by providing repair capabilities and the production of 
surfactant. Both cell types to contribute to lung defence against pathogens. 
1.2.1.2.4 Pulmonary Endothelium and ECM 
The pulmonary capillaries are lined with endothelial cells, 0.1 -0.2µm 'thick and 
1000µm2 (Bums et al., 2003; Weibel, 1973), keeping the distance between the airway 
and bloodstream as narrow as possible to facilitate gas exchange. The ECM, 
consisting of the basement membrane and lung interstitium, lies between the 
pulmonary endothelia and epithelia and provides scaffolding for the lung 
ultrastructure (Bums et al., 2003; Weibel, 1983). The thickness of the ECM varies 
considerably. In places it consists of only a fused basement membrane between the 
endothelial and epithelial layers, but in other places they are separated by interstitium, 
made up of fibronectin, elastic fibres and collagen (Bums et al., 2003; Weibel, 1973). 
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Thus both the capillary endothelium and ECM maintain a thin barrier between the 
airways and blood system. 
1.2.1.2.5 Alveolar Macrophages 
Alveolar macrophages (AMs) are the resident defence cells in the gas- exchanging 
regions of the lung, responsible for protection against inhaled particles and 
microorganisms. AMs are located in the external environment of the alveolar 
airspaces (Dorger and Krombach, 2002; Knapp et al., 2003; Weibel, 1973). These 
cells are mononuclear phagocytes derived from stem cells in the bone marrow, 
entering the bloodstream as monocytes and migrating to the lung where they 
differentiate (Gjomarkaj et al., 1999; Takemura and Werb, 1984). These highly motile 
cells are abundant in the airways, making up the majority of cells recovered from 
Broncho -Alveolar Lavage (BAL) fluid (Wright, 1997). AMs have housekeeping roles 
in the normal lung by clearing up dead and dying host cells, and are involved in 
surfactant degradation (Delclaux and Azoulay, 2003; Wright, 1997). AMs are also 
involved in clearing the airways of invasive materials by phagocytosis (Delclaux and 
Azoulay, 2003; Dorger and Krombach, 2002; Weibel, 1973; Wright, 1997). Although 
they are quite capable of doing this without specific stimuli (Wright, 1997), their 
phagocytic potential can be enhanced by means of PAMP recognition (Martin and 
Frevert, 2005) and opsonisation (Delclaux and Azoulay, 2003; Dorger and Krombach, 
2002; Martin and Frevert, 2005). Once the cell has engulfed the offending invader, it 
attacks it with intracellular toxic agents, such as reactive oxygen and nitrogen species 
and antimicrobial peptides ( Delclaux and Azoulay, 2003; Dorger and Krombach, 
2002). 
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As well as phagocytosing invading organisms, AMs also co- ordinate inflammation by 
releasing inflammatory mediators, including pro -inflammatory molecules like IL -1, 6 
and 8, TNF -a and Macrophage Inflammatory Proteins (MIP) 1 and 2 and anti - 
inflammatory cytokines such as IL -10 (Delclaux and Azoulay, 2003; Dorger and 
Krombach, 2002). These mediators can influence lymphocytes (Delclaux and 
Azoulay, 2003) and activate Antigen Presenting Cells (APCs) such as lung dendritic 
cells (Martin and Frevert, 2005). By releasing these and other immunomodulatory 
proteins such as complement factors, the AM is able to orchestrate both the 
inflammatory and adaptive immune responses (Delclaux and Azoulay, 2003; Dorger 
and Krombach, 2002). Thus the AM has a dual role in protection of the lung; by 
clearing unwanted materials from the alveoli, and by initiating a more extensive 
immune response should it be unable to deal with the threat. 
1.2.1.3 Summary 
There are 3 main functional regions in the lungs. The Conducting Zones transports 
gases to and from the Respiratory Zone or Alveolar Region, where exchange of 02 
and CO2 takes place. The Intermediate Zone spans both of these regions. The Alveolar 
Region comprises a delicate and complex network providing a short diffusion 
pathway to the bloodstream to enable effective gas exchange. This structure is 
maintained and protected from physical collapse by surfactant, a composite of lipids 
and proteins which decrease surface tension in the alveoli. The alveolar epithelium 
consists of two main cell types; ATI cells are elongated and thin, providing a large 
surface area through which gas exchange can occur. They are supported by ATII cells, 
which maintain the population of the alveolar epithelium and produce surfactant. AMs 
are the resident defence cells of the Alveolar Region, phagocytosing and clearing 
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inhaled agents, aided by surfactant proteins. In the event that the local airway defence 
systems become overwhelmed, the alveolar macrophages are able to co- ordinate a 
systemic inflammatory and adaptive immune response. 
1.2.2 Host Defence of the Lung 
1.2.2.1 Introduction to Host Defence 
There are essentially two different facets to host defence in the lung, which work in 
close accordance to optimise protection against insult. Innate immunity is a `natural' 
response involving a variety of host defence systems aimed at clearing infectious 
agents. The response is rapid and non -specific, covering a wide range of pathogens 
and is functional regardless of previous exposure (Boyton and Openshaw, 2002; 
Delclaux and Azoulay, 2003). In contrast, acquired immunity is an adaptive response 
to a given infectious agent that is swifter and more efficient on subsequent exposure 
to the same pathogen (Delclaux and Azoulay, 2003) but requires a prolonged 
activation period (Boyton and Openshaw, 2002; Delclaux and Azoulay, 2003; Rogan 
et al., 2006). 
1.2.2.2 Innate Immunity 
The first stage of lung host defence is in the nose, where convolutions in the passages, 
combined with nasal hairs, encourage adhesion of inhaled particles (Cohen and Gold, 
1975). In the conducting airways, physical tracheo -bronchial clearance is co- ordinated 
by the muco- ciliary ladder (Chilvers and O'Callaghan, 2000). Secreted mucus 
provides a physical and chemical barrier to invasive agents and its highly adhesive 
nature enables particles to easily stick to it (Chilvers and O'Callaghan, 2000). Ciliated 
epithelial cells beat in a co- ordinated caudal to cephalic manner throughout the 
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epithelium to transport the mucus out of the airways to the oropharynx, where it is 
swallowed (Chilvers and O'Callaghan, 2000). Reflexes such as sneezing and cough 
are also important protective mechanisms (Boyton and Openshaw, 2002; Cohen and 
Gold, 1975; Delclaux and Azoulay, 2003). 
If physical defences are evaded and foreign material reaches the Alveolar Region, 
detection of this material is crucial to efficient protection of the lung. The most 
important method of achieving this is through the use of PRRs, stimulating 
inflammatory functions and clearance (Paterson and Mitchell, 2006). These molecules 
include the TLRs, which are expressed on both innate immune cells and the 
respiratory epithelium and mediate production of inflammatory cytokines (Kadioglu 
and Andrew, 2004; Martin and Frevert, 2005; Paterson and Mitchell, 2006). In the 
case of bacterial infection, TLRs 2 and 4 are particularly important (Carpenter and 
O 'Neill, 2007; Kadioglu and Andrew, 2004; Martin and Frevert, 2005; Paterson and 
Mitchell, 2006). Soluble proteins such as pulmonary Lipopolysaccharide binding 
protein (LBP) and soluble CD14 are also involved (Martin and Frevert, 2005; 
Paterson and Mitchell, 2006). The pulmonary collectins also function as opsonins, as 
do components of the complement cascade (Boyton and Openshaw, 2002; Paterson 
and Mitchell, 2006). 
Various soluble factors and cell types then work together, to neutralise the infectious 
agents. Secreted products such as antimicrobial peptides, manufactured by immune 
and epithelial cells, work in concert with each other to destroy pathogens (Boyton and 
Openshaw, 2002; Delclaux and Azoulay, 2003; Martin and Frevert, 2005; Rogan et 
al., 2006). Components of the complement cascade, cytokines and the pulmonary 
collectins can also be directly bactericidal (Boyton and Openshaw, 2002; Delclaux 
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and Azoulay, 2003; Rogan et al., 2006). Resident AMs are the first cellular line of 
defence in alveoli, engulfing pathogens and using intracellular toxins to destroy them. 
Neutrophils, recruited by inflammatory mediators, are stimulated by opsonised 
particles, neutralising phagocytosed pathogens using intracellular toxins in a similar 
manner to the macrophage (Boyton and Openshaw, 2002; Delclaux and Azoulay, 
2003). Natural Killer (NK) cells are lymphocytes that detect infected cells and lyse 
them by forming a pore in the membrane and injecting cytotoxin into the cell (Boyton 
and Openshaw, 2002; Delclaux and Azoulay, 2003). 
Neutrophils are not usually present in high numbers in the airways and in order to 
deal with pathogen invasion they must be recruited from the bloodstream (Delclaux 
and Azoulay, 2003). Important inflammatory cytokines produced by activated 
macrophages and epithelial cells include IL -1, IL -6, neutrophil chemoattractant IL -8 
(Boyton and Openshaw, 2002; Delclaux and Azoulay, 2003; Fehrenbach, 2001; 
Martin and Frevert, 2005) and MCP -1 (Martin and Frevert, 2005). Inflammatory 
cytokines help to control inflammation in the airways by activation of immune cells 
(Delclaux and Azoulay, 2003; Martin and Frevert, 2005) and upregulating the release 
of antimicrobial factors (Boyton and Openshaw, 2002), and soluble CD14 (Delclaux 
and Azoulay, 2003; Martin and Frevert, 2005). The pulmonary collectins can also 
activate macrophages. Neutrophils themselves also produce pro -inflammatory 
mediators and anti -microbial peptides (Boyton and Openshaw, 2002; Delclaux and 
Azoulay, 2003). Anti- inflammatory cytokines like IL -10, released by macrophages 
but not neutrophils, are responsible for controlling the influx of inflammatory 
products and decrease production of pro- inflammatory cytokines (Boyton and 
Openshaw, 2002; Delclaux and Azoulay, 2003; Martin and Frevert, 2005). 
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As well as mediating a localised inflammatory response, the innate immune system 
can also stimulate the adaptive response, particularly by the presentation of foreign 
antigens to acquired immune cells. This is done by APCs, the most notable of which 
is the dendritic cell which processes antigen and presents it to T lymphocytes (Boyton 
and Openshaw, 2002; Delclaux and Azoulay, 2003). Macrophages are less efficient 
APCs but can transport antigen to dendritic cells in the lymph nodes (Martin and 
Frevert, 2005). Soluble innate immune mediators such as IL -1, IL -6 and IL-10 can 
also activate the adaptive response, including stimulation of lymphocyte proliferation 
and antibody production by B cells, as well promotion of the T helper cell immune 
response (Delclaux and Azoulay, 2003; Martin and Frevert, 2005). The acquired 
immune system can also be stimulated by the complement cascade and NK cells 
(Boyton and Openshaw, 2002; Delclaux and Azoulay, 2003; Martin and Frevert, 
2005). 
1.2.2.3 Adaptive Immunity 
The adaptive immune system relies on the recognition of specific foreign antigen to 
stimulate production of antibodies and effector T lymphocytes. In response to cues 
from the innate immune system, such as processing and presentation of foreign 
antigens and secretion of cytokines, pathogen- specific B and T lymphocytes 
proliferate (Boyton and Openshaw, 2002; Delclaux and Azoulay, 2003). They then 
release a variety of effector molecules, including cytokines by T lymphocytes and 
high affinity immunoglobulin (Ig) antibodies by B cells (Boyton and Openshaw, 
2002; Delclaux and Azoulay, 2003). As a consequence, both T and B lymphocyte 
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memory cells are generated, enabling a swifter and more efficient response on 
additional exposure to the same pathogen (Boyton and Openshaw, 2002). 
1.2.2.4 Summary 
The defensive systems in place for defending the lung against microbial attack consist 
of two main aspects. The innate system includes physical, chemical and cellular 
elements that reduce the incidence of invasive agents in the delicate alveolar region 
and clear them if they do appear. In the event that these procedures are unable to deal 
with infection, chemical mediators released by immune cells and the respiratory 
epithelium are able to recruit and regulate a more systemic inflammatory response, 
bringing in other specialised immune cells from the circulation. The innate immune 
system is also able to regulate, and be regulated by, the adaptive immune system, 
which has chemical and cellular components to organise a longer -lasting specific 
response to any particular pathogen. 
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13: INJURY AND REPAIR OF THE LUNG 
13.1 Lung Injury and Disease 
13.1.1 Acute Injury of the Lung 
Acute pulmonary damage can result from a variety of different causes, however the 
main response to injury is relatively conserved. Acute injury of the lung is 
characterised by compromise of the air -blood barrier, including damage of alveolar 
epithelium and capillary endothelium causing an influx of plasma and blood cells 
from the capillaries into the airspaces and interstitium (Matthay et al., 2003; Ware and 
Matthay, 2000). Alveolar macrophages respond to damaging stimuli such as bacteria 
by secreting cytokines, such as IL -1 and IL -8, which recruit neutrophils from the 
circulation to the airways to help combat the threat. Movement of materials across the 
air -blood barrier can go in either direction (Ware and Matthay, 2000). ATI cells are 
more vulnerable to injury than ATII cells; however, when the progenitor cells are 
damaged this can potentially affect both surfactant production and epithelial repair. 
Damage resulting in the death of these cells may strip the alveolar basement 
membrane (Matthay et al., 2003; Ware and Matthay, 2000). Figure 1.5 shows a 
stylised diagram adapted from Ware and Matthay (2000) illustrating the main features 
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Figure 1.5 - Features of acute alveolar injury (right) and inflammation 
compared to the normal alveolus (left). In the normal alveolus, note the clear 
airspace with intact epithelium and absence of neutrophils. In the injured 
alveolus there is damage to the epithelium and a denuded basement membrane. 
Alveolar macrophages are releasing inflammatory cytokines IL-1 and TNF -u 
and neutrophil chemoattractant IL -8. Neutrophils are recruited from the 
bloodstream and travel to the airways via the interstitium through the 
endothelium. Airspaces are filled with debris, red blood cells (RBC), fibrin and 
neutrophils releasing oxidants. Adapted from Ware and Matthay (2000). 
Following acute lung injury, there are two main outcomes; repair and resolution of the 
damage, or prolonged inflammation and remodelling leading to fibrosis (Wallace et 
al., 2007). If the injurious stimulus is neutralised rapidly, ATII cells can proliferate 
and differentiate into ATI cells, repopulating the alveolar epithelium and re- 
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establishing appropriate fluid dynamics (Ware and Matthay, 2000). Extraneous 
protein and apoptotic neutrophils are phagocytosed by macrophages, with some 
clearance of protein carried out by epithelial cells, bringing about the restoration of 
normal lung tissue (Ware and Matthay, 2000). However, a sustained stimulus or 
remodelling abnormalities can result in fibrosis (permanent scarring resulting from the 
inability to properly repair the alveolar epithelium). Fibrosis is characterised by the 
loss of alveolar structure, activation of fibroblasts and continued deposition of 
extracellular matrix molecules such as fibronectin and collagen (Wallace et al., 2007; 
Ware and Matthay, 2000). Figure 1.6 shows a stylised diagram adapted from Ware 
and Matthay (2000), demonstrating resolution versus fibrosis in the alveolus. 
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Figure 1.6 - Features of injury resolution (left) compared to fibrosis (right). In 
resolution, note the repopulation of the basement membrane by proliferation 
and differentiation of ATII cells and clearance from the airways of protein and 
apoptotic neutrophils by epithelial cells and macrophages. In fibrosis, note the 
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activation of fibroblasts and deposition of fibronectin and collagen, leading to a 
change in alveolar architecture. Adapted from Ware and Matthay (2000). 
Acute injury of the lung can be caused by a variety of physical, chemical and 
biological agents. These injuries to the lung can result from direct insult or occur 
indirectly as a consequence of sepsis or trauma (Ware and Matthay, 2000). Even 
techniques devised to physically aid respiration, such as ventilation, can cause 
damage; for example if high tidal volumes are used (ARDSnet, 2000; Frank et al., 
2002). A vast array of chemicals is also able to cause injury to the lungs. These 
include industrial silica, air pollutants (Chauhan and Johnston, 2003; Hastings et al., 
2002a), high levels of oxygen (Hastings et al., 2002b) and drugs such as bleomycin 
(Wilberding et al., 2001). The injurious effects of hydrochloric acid on lung tissue 
seen in patients who have aspirated gastric contents is also clinically important (Frank 
et al., 2002; Ware and Matthay, 2000). Pneumonia induced by respiratory pathogens 
is one of the most common causes of biologically- induced lung damage (Ware and 
Matthay, 2000). In addition to external factors, host defence systems themselves can 
initiate injury to the lungs, particularly in situations of chronic inflammation where 
tissue remodelling can lead to fibrosis (Wallace et al., 2007). 
1.3.1.2 Bacterial Infection of the Lungs 
Bacterial infection is a significant and common cause of lung injury. This section will 
focus on the pathogenesis of pneumonia induced by two clinically important Gram - 
positive pathogens; S. pneumoniae, which is the chief aetiological agent of CAP, and 
S. aureus, an important cause of HAP. These are the two species of bacteria used in 
this thesis. 
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In vivo studies have shown that both pneumococcal and staphylococcal pneumonias 
are characterised by an acute, mainly neutrophilic inflammatory response (Kadioglu et 
al., 2000; Labandeira -Rey et al., 2007; McElroy et al., 1999; Yoneda and Coonrod, 
1980). Alveoli are filled with plasma and erythrocytes following damage to the air - 
blood barrier (Labandeira -Rey et al., 2007; McElroy et al., 1999; Rubins et al., 1992; 
Yoneda and Coonrod, 1980), giving rise to the characteristic pneumonic 
`hepatisation' (Bergeron et al., 1998). Both bacteria induce considerable injury to lung 
tissue (Bergeron et al., 1998; Wardenburg et al., 2007). Much of this damage is 
caused by pore -forming toxins, which are virulence factors produced by the bacteria. 
S. pneumoniae also releases an oxidant, hydrogen peroxide (H2O2), which can damage 
epithelial cells (Duane et al., 1993; Feldman et al., 2002). 
1.3.1.3 Summary 
Acute injury to the lung can be caused by a variety of environmental factors, not least 
of which is bacterial pneumonia. It is characterised by compromise of the air -blood 
barrier, complete with resultant flux of moieties across it, acute inflammation and 
damage to alveolar epithelial cells in particular. Injury to pulmonary tissue can result 
in either repair and resolution or fibrosis. Much of the response to clinically important 
Gram -positive bacteria is mediated by toxins produced by the microorganisms. 
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1.3.2 Animal Models of Lung Disease 
1.3.2.1 Overview 
Animal models, particularly those using rodents, can be a useful way to study the 
mechanisms of lung disease, although they are clearly not able to fully reproduce the 
clinical situation. In pneumonia, for example, the full natural progression from 
commensal nasal colonisation to lung consolidation in humans is dependent on a 
range of factors which would be impossible to reproduce experimentally. However, it 
is feasible to examine individual aspects of disease provided that conclusions are 
reached based on the scope of the experiment conducted and not extrapolated to other 
aspects. Similarly, host responses to stimuli differ between species; for example, 
rodents do not manufacture the antimicrobial peptide and elastase inhibitor Elafin 
which is present in humans (Sallenave et al., 1998). Nevertheless, models in whole 
living mammalian systems enable detailed examination of events from initiation to 
resolution, in intact respiratory and immune systems, that is not possible with clinical 
and in vitro studies. 
13.2.2 Techniques 
When considering the use of animal models of lung injury, the first thing to bear in 
mind is the method of injury. In pneumonia models, this entails the delivery of 
infectious agents into the lungs. Previously, this has involved surgical intubation, i.e. 
tracheotomy and instillation via a cannula inserted directly into the lungs (Rhodes et 
al., 1989a; Rhodes et al., 1989b; Yoneda and Coonrod, 1980). More recently, 
researchers have employed non -surgical intubation, where a cannula is inserted down 
the trachea via the mouth (McElroy et al., 2002; Rubins et al., 1995; Tyrrell et al., 
2005). These techniques enable direct delivery of a set number of bacteria to the 
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alveolar region and are often able to model a precisely located lobar pneumonia. 
Other techniques involve inhalation of infectious material. These include intranasal 
methods (Bergeron et al., 1998; Brown et al., 2002; Dallaire et al., 2001; Garcia - 
Suarez et al., 2007; Kadioglu et al., 2000) as well as the use of nebulisers (Clement et 
al., 2008). While both of these techniques may be representative of clinical methods 
of microaspiration, they are likely to allow for less control over the numbers of 
bacteria reaching the alveoli. In this respect the use of nebulisers could be more 
reliable, as this technique would be less likely to result in loss of inoculum by 
swallowing and attachment of bacteria to the nasopharynx. Having established the 
lung injury, it is then necessary to assess the extent of the damage and inflammatory 
response. The most obvious way to do this is to examine lung tissue morphologically 
using histological techniques, including both light and electron microscopy and 
immunohistochemical methods (Rhodes et al., 1989a; Rhodes et al., 1989b; Tyrrell et 
al., 2005; Yoneda and Coonrod, 1980). However, if a more quantitative result is 
required this is usually done by collection of BAL fluid, which can then be analysed 
as being representative of events occurring in the airways. The degree of 
inflammation can be measured in a number of ways, including direct counts of 
inflammatory cells and assessment of inflammatory cytokines (Bergeron et al., 1998; 
Dallaire et al., 2001; McElroy et al., 2002). Damage to the air -blood barrier can be 
assessed by measurement of protein flux across the barrier. A simple method of doing 
this involves measurement of protein in BAL fluid (McElroy et al., 1999; McElroy et 
al., 2002; Rubins et al., 1995). Other methods include the use of radio -labelled 
albumin (Frank et al., 2005; McElroy et al., 1995; McElroy et al., 1997a). 
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As well as assessing the injury to the air -blood barrier it is also possible to quantify 
differential damage to specific cell types within the lung, using cell- specific proteins. 
It is possible to use these cell - associated proteins to measure injury to lung cells by 
analysing their presence in BAL fluid. Many researchers have used this technique to 
quantify injury to ATI cells, using the RTI40 protein (Frank et al., 2002; Frank et al., 
2005; McElroy et al., 1995; McElroy et al., 1997b; McElroy et al., 1999; McElroy et 
al., 2002). Analysis of lung tissue itself can also provide information about effects of 
disease on the host. Assessment of lung tissue using cell- specific proteins can also 
provide information about changes in cell populations during injury (Tyrrell et al., 
2005). 
1.3.2.3 Models of Pneumococcal and Staphylococcal Pneumonia 
Many researchers have used rodent models of pneumococcal and staphylococcal 
pneumonia to elucidate mechanisms of injury (Garcia- Suarez et al., 2007; McElroy et 
al., 1999; McElroy et al., 2002; Rubins et al., 1996) and host response (Bergeron et 
al., 1998; Brown et al., 2002; Coonrod and Yoneda, 1982; Kadioglu et al., 2000; 
Rubins et al., 1996), to study bacterial pathogenesis (Benton et al., 1997; Berry et al., 
1989a; Berry et al., 1992; Dallaire et al., 2001; Feldman et al., 1991; McElroy et al., 
1999; McElroy et al., 2002; Rubins et al., 1995), and to test new treatments (Ellbogen 
et al., 2003; Hegde et al., 2008; Karzai et al., 1999; Lock et al., 1992). This section 
will review in vivo research concerning lung injury and host response in 
pneumococcal and staphylococcal pneumonia. 
Although there is a large body of work studying staphylococcal pneumonia, 
particularly using mice, there are relatively few papers that address the question of 
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mechanisms of injury to lung tissue. McElroy et al's initial S. aureus- induced 
pneumonia model in the rat used a high bacterial dose for 4 hours in ventilated 
animals, and demonstrated an acute inflammatory response with significant damage to 
the air -blood barrier and targeted injury to ATI cells (McElroy et al., 1999). This was 
assessed using the cell- specific protein RTI40 in BAL fluid. Using mutant bacteria, 
this selective injury was shown to be mediated by staphylococcal a- toxin, although 
this was not thought to be a direct cytotoxic effect on the epithelial cells (McElroy et 
al., 1999). A recovering model (which the author was directly involved in) was then 
established using a lower dose of bacteria in non -ventilated rats. This showed that 
even though the bacteria were cleared from the lungs after 24 hours, they still induced 
an acute inflammatory response with compromise of the air -blood barrier. However, 
the increase in RTI40 protein in BAL fluid was not significantly different from 
controls (McElroy et al., 2002). Animals continued to recover over time and by 96 
hours post -inoculation the inflammatory response was abated and protein movement 
across the air -blood barrier was decreased. As with the previous model, this study 
used mutant bacteria to demonstrate that in vivo, the presence of fibronectin- binding 
proteins stimulates clearance of S. aureus from the lungs (McElroy et al., 2002). This 
model was used again at a 72 hour timepoint to demonstrate a decrease in ATI cells 
and an increase in ATTI cells in the lungs during repair, by assessing cell- specific 
proteins in lung tissue (Tyrrell et al., 2005). In addition an intermediate cell type co- 
expressing proteins specific to both ATI and ATII cells was demonstrated (Tyrrell et 
al., 2005). 
A morphological study using a rat model of recovering lobar pneumonia induced by 
S. pneumoniae serotype 25 examined the histological features of pathogenesis, but 
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differential damage to alveolar epithelial cells was not addressed (Yoneda and 
Coonrod, 1980). Mother rat model demonstrated targeted damage to ATI cells; 
however, this study used the related bacterium Streptococcus sanguis as 
representative of pneumococcal disease (Rhodes et al., 1989b). The same authors, 
using pneumococcal serotype 25, showed damage to ATII cells, but this model 
appeared to induce an unusual fibrotic pathology (Rhodes et al., 1989a) and it is 
questionable how relevant these latter two results are to the typical disease caused by 
S. pneumoniae. There is also an extensive body of work in mice, which establishes the 
importance of the pneumococcal toxin pneumolysin (Ply) as a virulence factor. In 
particular, the use of mutant bacteria to induce pneumococcal pneumonia has shown 
that Ply affects host survival (Berry et al., 1989a; Berry et al., 1992; Rubins et al., 
1996), bacterial growth and bacteraemia (Kadioglu et al., 2000; Rubins et al., 1995; 
Rubins et al., 1996). Animal models have also shown that Ply contributes to air -blood 
barrier damage (Rubins et al., 1995) and affects the inflammatory response (Kadioglu 
et al., 2000; Rubins et al., 1996). Studies using wildtype bacteria, usually serotypes 2 
or 3, have shown S. pneumoniae to induce an increase in BAL leukocytes, particularly 
neutrophils, up to 24 hours post -instillation (Bergeron et al., 1998; Dallaire et al., 
2001; Kadioglu et al., 2000; Rubins et al., 1996), an increase in lung TNF -a and IL -1, 
including IL-1f3, by 12 hours and MCP -1 by 24 hours (Bergeron et al., 1998; Dallaire 
et al., 2001). Damage to the air -blood barrier was detected as early as 3 hours post - 
inoculation (Rubins et al., 1995; Rubins et al., 1996). However, to date, no studies 
have looked at specific damage to individual cell types and most of this research has 
involved the use of lethal rather than recovering pneumonia models. 
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13.2.4 Summary 
Rodent models of infective lung injury are a good way of studying mechanisms of 
disease. A variety of techniques can be used to provide information about pulmonary 
injury and host response. Rat models of staphylococcal pneumonia have shown an 
acute inflammatory response and damage to the air -blood barrier, particularly ATI 
cells. In vivo models of pneumococcal pneumonia in mice have also demonstrated an 
inflammatory response and pulmonary injury; however, information about cell - 




Biomarkers can be defined as quantifiable moieties, measurement of which provides 
information about either normal or abnormal biological processes, and include the use 
of imaging techniques, and assessment of DNA and protein (Gundert-Remy et al., 
2005). Disease can induce changes in both the expression of genes and function of 
proteins. Studying the dynamics of these changes not only enables more efficient 
diagnosis and assessment of prognosis, but also can offer insights into how disease 
affects the body. Proteins in particular can be obtained by a variety of invasive and 
non -invasive techniques and used to monitor disease. For example, detection of 
microalbuminuria is a commonly -used marker of kidney damage and cardiovascular 
disease (Erdmann, 2006) and podoplanin (RTI40) has been used as a marker of the 
lymphatic endothelium, both as a prognostic indicator and to establish a lymphatic 
origin of tumours (Birner et al., 2000; Sinzelle et al., 2000). In the lung, cell- specific 
proteins have been used to quantify targeted cell injury and identify changes in cell 
populations during injury and repair. Studying differential changes in cell- specific 
proteins following infection provides information about bacterial effects on the host 
as well as regulation of specific proteins. 
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1.4.2 ATI Cell -Specific Proteins 
1.4.2.1 RTI40 
1.4.2.1.1 Overview 
RTI40 (GENE 54320, OMIM 608863) is a 40kDa protein located on the apical 
surface of ATI cells (Dobbs et al., 1988). It was first identified in the lung using a 
monoclonal antibody against rat ATI cells, and was consequently abbreviated from 
`Rat Type I cell, 40kDa' (Dobbs et al., 1988). Although at the time it was thought to 
be unique to the lung, a number of homologues in other species and tissues have been 
discovered. The protein has also been identified in murine, canine and human 
systems and detected in kidney, lymphatic and vascular endothelium, bone, testis, 
Central Nervous System (CNS), thymus, dermal fibroblasts and a variety of benign 
and malignant neoplasms. Currently identified variants are T1 protein (Rishi et al., 
1995), podoplanin (Breiteneder -Geleff et al., 1997; Breiteneder - Geleff et al., 1999; 
Kahn and Marks, 2002; Kimura and Kimura, 2005; Parr and Jiang, 2003; Sinzelle et 
al., 2000), gp36 (Zimmer et al., 1999), gp38p (Boucherot et al., 2002), gp38 (Farr et 
al., 1992a; Farr et al., 1992b), gp 40 (Zimmer et al., 1995; Zimmer et al., 1997), E11 
antigen (Wetterwald et al., 1996), RANDAM -2 (Kotani et al., 2002; Kotani et al., 
2003), PA2.26 (Gandarillas et al., 1997; Martin -Villar et al., 2005), Aggrus /gp44 
(Kato et al., 2003; Kato et al., 2005; Watanabe et al., 1988), OTS -8 (Nose et al., 1990; 
Ohizumi et al., 1998; Taniguchi et al., 2000), D2 -40 and M2A antigens (Bailey et al., 
1986; Marks et al., 1999). 
Such extensive expression of a single protein in very different cells in a variety of 
organs may be explained by the complex structure of RTI40. The size of RTI40 varies 
between species, from about 36kDa in humans up to 44kDa in the mouse (Dobbs et 
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al., 1988; Watanabe et al., 1988; Zimmer et al., 1995; Zimmer et al., 1997). The open 
reading frame (ORF) codes for a predicted protein considerably smaller than this (Farr 
et al., 1992b; Kotani et al., 2002; Ma et al., 1998; Rishi et al., 1995; Scholl et al., 
1999; Taniguchi et al., 2000; Wetterwald et al., 1996; Zimmer et al., 1997; Zimmer et 
al., 1999). However, there are multiple sites for post -translational modification, 
particularly glycosylation (Breiteneder -Geleff et al., 1997; Farr et al., 1992b; Martin - 
Villar et al., 2005; Scholl et al., 1999; Zimmer et al., 1999). These facts, combined 
with some decrease in molecular weight of the protein when treated with O- 
glycosidase (Kotani et al., 2003; Scholl et al., 1999; Toyoshima et al., 1995; Zimmer 
et al., 1995; Zimmer et al., 1997; Zimmer et al., 1999), are consistent with the idea 
that the RTI40 is indeed highly post -translationally glycosylated. This may explain 
the presence of different forms of the protein in various cells, tissues and species. 
Epitopes bound by different antibodies may be located on variable regions of 
modification, producing conflicting results from different research groups. Indeed, the 
E11 antibody (raised against a rat osteoblastic cell line) does not bind to the 18kDa 
core protein expressed from cDNA in transfected cells, whereas the RTI40 antibody 
(raised against isolated rat ATI cells) does (Williams et al., 1996). In addition, 
treatment with 0-glycanase resulted in loss of reactivity to another antibody against 
the protein in the mouse (Toyoshima et al., 1995). 
1.4.2.1.2 Function 
Although RTI40 has been shown to be a platelet aggregation factor (Toyoshima et al., 
1995; Watanabe et al., 1988; Watanabe et al., 1990), and is important for cancer 
metastasis (Sugimoto et al., 1991), as well as being a receptor for the Influenza C 
virus (Zimmer et al., 1995), its function in the normal adult lung is as yet unknown. 
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Despite its expression on ATI cells, which demonstrate high water permeability, the 
protein has been shown not to be involved in water transport or regulation of water 
channels (Ma et al., 1998), or transport of amino acids or folic acid (Boucherot et al., 
2002). However, production of RTI40- deficient mice demonstrated that the protein is 
crucial for normal lung development (Ramirez et al., 2003). In the normal foetal 
rodent lung, RTI40 levels progressively increase during gestation (Williams and 
Dobbs, 1990). RTI40- deficient mice die of respiratory failure shortly after birth, 
demonstrating poorly -developed lungs with narrow airspaces and a decreased 
inflation volume, although a few ATI cells do develop (Ramirez et al., 2003). This 
phenomenon indicates that RTI40 is involved in pattern formation, perhaps through 
regulation of cell shape or motility. Indeed it has been demonstrated in a number of 
different cell types that RTI40 is not only frequently localised to a specific surface of 
the cell (Breiteneder -Geleff et al., 1997; Dobbs et al., 1988; Zimmer et al., 1997) and 
membrane projections, but that cells transfected to express the protein actively 
demonstrated a more elongated morphology and increased membrane protrusions, as 
well as tube -forming behaviour (Gandarillas et al., 1997; Martin -Villar et al., 2005; 
Schacht et al., 2003; Scholl et al., 1999). There is also evidence of a role for RTI40 in 
cell migration. Not only has the protein been shown to be involved in regulation and 
organisation of the actin cytoskeleton (Scholl et al., 1999; Scholl et al., 2000), but a 
wound- healing assay also demonstrated increased motility in RTI40- transfected 
keratinocytes (Scholl et al., 1999). In vivo, physical wounding of both skin and bone 
in rodents has resulted in induction or upregulation of the protein, suggesting a role in 
injury /repair (Gandarillas et al., 1997; Hadjiargyrou et al., 2001). 
40 
1.4.2.1.3. ATI Cell Marker 
Despite the RTI40 protein's extensive expression by cells in different organs, much 
research has been carried out using it as a cell- specific marker. In non -respiratory 
organs, it has been used as a marker for glomerular epithelial cells (podocytes) in the 
rodent kidney (Kohda et al., 2000; Schiwek et al., 2004), human lymphatic 
endothelium (Birner et al., 2000; Cursiefen et al., 2002; Hirakawa et al., 2003; Nisato 
et al., 2003) and as a marker of differentiation from osteocyte to osteoblast in tooth 
and bone in rats (Liu et al., 1997; Schwab et al., 1999; Tenorio et al., 1993; 
Wetterwald et al., 1996). 
In the lung, RTI40 is a marker of rodent ATI cells. It has been used as a laboratory 
tool for improving the purity of isolated alveolar epithelial cells (Chen et al., 2004a; 
Dobbs et al., 1988; Roper et al., 2003); however, it is used more commonly to 
specifically identify ATI cells in various situations. This has included developmental 
ontology studies in both normal (Meneghetti et al., 1996; Williams and Dobbs, 1990; 
Williams et al., 1996) and transgenic (Cole et al., 2004) animals, and as a marker of 
differentiation from the ATII to ATI cell phenotype, where it characterises an 
intermediate transition cell type (Tyrrell et al., 2005). It has been shown both in vitro 
(Borok et al., 1998a; Gutierrez et al., 1998; Gutierrez et al., 1999; Gutierrez et al., 
2003) and developmentally in vivo (Kitterman et al., 2002; Yoshizawa et al., 2003), 
that distension causes an increase in RTI40 expression, while contraction decreases it. 
In vitro this corresponds with a decrease in ATII cell- specific proteins and a more 
ATI cell -like phenotype. Other factors, such as serum, Keratinocyte Growth Factor 
(KGF) and VEGF result in a decrease in RTI40 and inhibition or delay in the 
development of the ATI phenotype (Borok et al., 1998a; Raoul et al., 2004). 
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1.4.2.1.4 Injury Marker 
As well as being a well- established cell- specific marker in a variety of organs, RTI40 
has also been used as a marker of injury and disease. Its induction in some cancer 
cells has led to its use as a human diagnostic marker of neoplasms, including 
mesothelioma (Kimura and Kimura, 2005), lymphangioma (Sinzelle et al., 2000), 
seminoma, dysgerminoma (Bailey et al., 1986) and Kaposi's sarcoma (Gessain and 
Duprez, 2005; Schmid et al., 2003). Expression on the lymphatic endothelium has 
also enabled investigation of lymphangiogenesis and prognostic significance in 
human tumours (Renyi -Vamos et al., 2005; Schoppmann et al., 2004; Valencak et al., 
2004). In the lung it has been extensively used as a marker of ATI cell injury in a 
variety of rodent models. This was initially established using an acute rat model of 
pneumonia induced by P. aeruginosa (McElroy et al., 1995), which showed an 80- 
fold increase in RTI40 in BAL fluid, associated morphologically with extensive 
damage to ATI cells. However, this method has also been found to have a wide 
sensitivity range, with increases of about 2 -fold being associated with less extensive 
damage to the alveolar epithelium (McElroy et al., 1997b; McElroy et al., 1997a). The 
technique has been used to assess an array of clinically relevant insults, including 
mechanical and chemical challenges and bacterial infections. Assessment of RTI40 
has demonstrated injury to ATI cells in rat models of hyperoxia, high tidal ventilation 
volume following acid injury, bleomycin- induced pulmonary fibrosis and NO2- 
induced emphysema (Frank et al., 2002; Koslowski et al., 1998; McElroy et al., 
1997b; McElroy et al., 1997a). Bacterial lung infections caused by S. aureus, and 
P. aeruginosa have also shown damage to ATI cells, and have also been pivotal in 
identifying virulence factors (McElroy et al., 1995; McElroy et al., 1999; McElroy et 
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al., 2002). RTI40 has therefore been broadly used as a marker of ATI cell injury in 
vivo. 
1.4.2.1.5 Summary 
RTI40 is a protein that is widely used as a cell -specific marker in a number of organs. 
Its highly post -translationally modified structure has led to some controversy in the 
literature. In the lung, RTI40 is restricted to ATI cells and has been used as a 
biomarker both to identify ATI cells and quantify injury to them. RTI40 is essential 
for lung development, but its function in the normal adult lung is still unknown. It 
may have a role in the regulation of cell shape, migration and pattern formation. 
1.4.2.2 Aquaporin 5 
There are 11 known mammalian aquaporins (AQPs), which act as water channels, 
facilitating fluid movement by increasing the water permeability of the plasma 
membrane. They are therefore mainly found in tissues with high regulation of fluid 
(Gabazza et al., 2004; King and Agre, 1996). AQP5 is mercury- sensitive (Borok et 
al., 1998b; Krane et al., 2001), and was first identified in the salivary gland (King and 
Agre, 1996). In human and rat respiratory systems, it has been identified at the apical 
surface of sub -mucosal gland secretory cells of the nasopharynx and proximal 
airways, but is predominantly found on ATI cells (Gabazza et al., 2004; King et al., 
1997). However, in mouse lung it is more extensively expressed, including on 
tracheal and bronchial epithelium and ATII cells (Krane et al., 2001), making rat 
models perhaps more representative of human lungs. The exact mechanism of AQP5 
fluid transport is not well understood. AQP5- deficient mice demonstrated decreased 
saliva secretion and although there was a decrease in water permeability of the air- 
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blood barrier, fluid absorption from the lungs was not affected (Ma et al., 2000). In 
addition, they also showed hypersensitivity to cholinergic- stimulated 
bronchoconstriction (Krane et al., 2001). AQP5's specific location to ATI cells in rats 
and humans has led to its use as an ATI cell- specific marker in vitro, particularly to 
identify transdifferentiation of isolated ATII cells (Borok et al., 1998b; Chen et al., 
2004b). It has also been used in conjunction with RTI40 in vivo to identify changes in 
cell populations during repair in a model of S. aureus- induced pneumonia (Tyrrell et 
al., 2005). However, decreased expression of AQP5, independent of changes in cell 
population, has been demonstrated in the lung in a number of models of injury, 
including adenoviral infection (Towne et al., 2000), bacterial product instillation (Jiao 
et al., 2002), and bleomycin- induced fibrosis (Gabazza et al., 2004). It has also shown 
to be downreguated by TNF -a in cultured mouse epithelial cells (Towne et al., 2001). 
Thus, while AQP5 has important potential uses as a cell- specific marker of ATI cells, 
expression may be differentially affected by a variety of factors. 
1.4.2.3 MMC6 
MMC6 is an antigen localised to the apical surface of ATI cells in the rat lung 
(Franklin, 2006). In the adult rat, MMC6 is unique to the lung, being undetectable in 
kidney, thymus, liver, brain, stomach, bladder, muscle, placenta and gonads, small 
and large intestine and macrophages (Franklin, 2006). The antigen has been identified 
as an epitope on a membrane -associated protein (Franklin, 2006) co- localised on the 
apical surface of ATI cells along with RTI40, and is not expressed on ATII cells, 
capillary endothelium, Clara cells or bronchiolar epithelial cells (Franklin, 2006; 
McKechnie, 2008). Developmentally, MMC6 is not detectable until E20, when it is 
co- expressed with RTI40 on squamous cells. However, RTI40 was expressed as early 
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as E17, suggesting that these are not the same protein. Like RTI40, MMC6 is not 
expressed in isolated ATII cells but was detected in cultured cells by day 3 
(McKechnie, 2008). The protein has not been characterised and its function is as yet 
unknown (Franklin, 2006; McKechnie, 2008). The specific location of MMC6 
suggests its use as a possible marker of rat ATI cells. Indeed, it has been used in 
conjunction with RTI40 to assess levels of epithelial cell damage in a recovering 
model of S. aureus- induced pneumonia in rats, where the increase in BAL fluid of 
MMC6 was shown to correlate well with that of RTI40, indicating its use as a marker 
of ATI cell injury (Franklin, 2006). It was also shown to correlate with RTI40 levels 
in BAL fluid in a haemorrhagic shock model of lung injury in the rat (McKechnie, 
2008). In summary, although the identity and function of MMC6 is currently 
unknown, it has potential use as a cell -specific marker of ATI cells in rat models of 
lung injury. 
1.4.3 ATII Cell- Specific Proteins 
1.4.3.1 SP -C 
As stated in section 2.1.3.1.2 (Surfactant), SP -C is a small, hydrophobic protein, 
produced only by ATII cells, which is involved in the formation and homeostasis of 
surfactant. Like its associated hydrophobic surfactant protein, SP -B, the mature form 
of SP -C is generated by post -translational cleavage of a larger precursor protein. This 
precursor protein, known as Pro -SP -C, is about 21kDa in size and is restricted to the 
cytoplasm, where it is processed in multivesicular bodies. Mature SP -C, about 
3.5kDa, is then secreted into the airways (Beers and Fisher, 1992; Whitsett and 
Weaver, 2002). The study of SP -C has proved challenging in the past due to its highly 
hydrophobic nature; however, the production of antibodies against both Pro -SP -C and 
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SP -C have enabled progress to be made (Beers et al., 1992; Schmidt et al., 2002). 
Defects in the production of SP -C are characteristic of a number of lung diseases, 
including Acute Respiratory Distress Syndrome (ARDS) (Schmidt et al., 2002), 
Respiratory Distress Syndrome (RDS) of the newborn (Tong et al., 2006) and 
idiopathic interstitial pneumonides (IIPs) (Glasser et al., 2003). Indeed, studies on SP- 
C- deficient mice have demonstrated pulmonary pathology reminiscent of IIPs 
(Glasser et al., 2003) and SP -C is a crucial component of the synthetic surfactant used 
to treat RDS of the newborn (Beers and Fisher, 1992). Production of SP -C has been 
shown to be modulated by a variety of conditions, being increased by corticosteroids 
and hyperoxia (Beers and Fisher, 1992). It has been used as a biomarker both to 
investigate surfactant dysfunction (Russo et al., 2002; Savani et al., 2001; Vaporidi et 
al., 2005) and to determine the effects of mitogens on ATII cells (Raoul et al., 2004; 
Tong et al., 2006; Yano et al., 2000). SP -C has also been used as a marker of ATII 
cell phenotype (Gutierrez et al., 1998; Gutierrez et al., 1999; Gutierrez et al., 2003; 
Meneghetti et al., 1996; van Tuyl et al., 2005). 
1.4.3.2 RTII70 
RTII70 is an antigen located on the surface of rat ATII cells (Dobbs et al., 1998). 
Developmentally, it is expressed at E20 on ATII -like cells (McKechnie, 2008). 
RTII70 has been used as a cell- specific marker of ATII pneumocytes in a number of 
in vivo studies, including investigation of oligohydramnios and tracheal occlusion in 
rat foetuses (Kitterman et al., 2002; Yoshizawa et al., 2003), and a rat model of 
S. aureus- induced pneumonia (McElroy et al., 2002). The protein has also been used 
in conjunction with APN/MMC4 to identify intermediately differentiated alveolar 
epithelial cells during repair in a S. aureus- induced rat model of pneumonia, as well 
46 
as aiding in the description of a novel ATI cell- specific protein, MMC6 (McKechnie, 
2008; Tyrrell et al., 2005). Although RTII70 has not yet been characterised and its 
function is unknown, it is an established cell- specific marker of rat ATII cells. 
1.4.3.3 SP -D 
As discussed in section 1.1.3.1.2 (Surfactant), SP -D is a large, hydrophilic, post - 
translationally modified protein expressed by both ATII and Clara cells. It is only 
minimally involved in surfactant maintenance and its main function is to interact with 
foreign particles to enhance their removal by phagocytes. As well as being present in 
high levels in the lungs, SP -D is also found in the gastrointestinal and genitourinary 
tracts, as well as a variety of glands (Griese and Starosta, 2005; Reid, 1998). The 
protein is a 43kDa monomer, but in most cases tends to form dodecamers, made up of 
four trimeric units in a cruciform structure. The presence of carbohydrate- binding 
domains, which are able to bind to a variety of microbial moieties in a calcium - 
dependent manner, are crucial to its role in recognising PAMPs (Crouch, 1998b). SP- 
D has been shown to be important in the clearance of DNA (Palaniyar et al., 2005) as 
well as a host of microorganisms. It is able to bind to, agglutinate and enhance 
neutrophil binding to viruses such as Influenza A (Hartshorn et al., 1998; Ofek et al., 
2001; Restrepo et al., 1999), and can bind to and inhibit replication of HIV (Meschi et 
al., 2005). The protein also binds and aggregates a variety of fungi. These include 
Aspergillus fumigatus, for which it also enhances clearance by neutrophils (Madan et 
al., 1997), P. jirovecii, for which it enhances macrophage association but not 
phagocytosis (Ofek et al., 2001) and Cryptococcus neoformans (Restrepo et al., 
1999). SP -D also affects Gram -negative bacteria, particularly through its binding 
lipopolysaccharide (LPS) leading to agglutination (Ofek et al., 2001). Specifically, it 
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has been shown to bind to and aggregate E. coli, to increase phagocytosis by 
neutrophils and to enhance association with macrophages, although it does not affect 
macrophage phagocytosis (Hartshorn et al., 1998; LeVine et al., 2000; Restrepo et al., 
1999). P. aeruginosa is bound and agglutinated by SP -D, and is more readily 
phagocytosed by macrophages, although there is some controversy as to whether 
agglutination is required for this (Bufler et al., 2004; Giannoni et al., 2006; Griese and 
Starosta, 2005; Restrepo et al., 1999; Wright et al., 1999). K pneumoniae is bound, 
aggregated and phagocytosed more efficiently by neutrophils in the presence of SP -D 
(Ofek et al., 2001; Restrepo et al., 1999) and internalisation of Chlamydia spp by 
macrophages is also enhanced (Oberley et al., 2004). SP -D has been shown to bind to 
lipoteichoic acid (LTA) and peptidoglycan (PG) from Gram -positive bacteria (van de 
Wetering et al., 2001); however, there is some controversy over the actual effects. 
While there is evidence that it does indeed bind to and agglutinate pneumococcus 
(Hartshorn et al., 1998; Jounblat et al., 2004), contention remains as to whether it 
affects phagocytosis by alveolar macrophages (Kuronuma et al., 2004; Sano et al., 
2006) and neutrophils (Hartshorn et al., 1998; Jounblat et al., 2004; Restrepo et al., 
1999). Nevertheless, it is clear that SP -D influences clearance of S. pneumoniae from 
the lungs (Jounblat et al., 2005). Similarly, there is conflicting evidence about the 
aggregation properties of SP -D on S. aureus (Bufler et al., 2004; Hartshorn et al., 
1998), although it does appear to enhance uptake by neutrophils (Hartshorn et al., 
1998; Restrepo et al., 1999). 
SP -D can be used as a marker of surfactant production. It has been shown to be 
decreased in BAL fluid in cystic fibrosis (Hartl and Griese, 2006; Postle et al., 1999), 
ARDS (Hartl and Griese, 2006; Kuroki et al., 1998), interstitial pulmonary fibrosis 
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(1PF), interstitial pneumonia associated with collagen vascular disease (IPCVD) 
(Kuroki et al., 1998), gastro -oesophageal reflux disease (GORD) and RSV infection 
(Hartl and Griese, 2006). SP -D is increased in BAL fluid in pulmonary alveolar 
proteinosis (PAP) (where it has been used as a diagnostic indicator) (Kuroki et al., 
1998), sarcoidosis, asthma, and eosinophilic pneumonia ( Hartl and Griese, 2006). 
Levels in serum are increased in Chronic Obstructive Pulmonary Disease (COPD) 
(Sin et al., 2007), IPF, PAP, IPCVD (Hartl and Griese, 2006; Kuroki et al., 1998) and 
sarcoidosis ( Hartl and Griese, 2006). There is no effect on SP -D in serum in bacterial 
pneumonia (Kuroki et al., 1998). Thus, SP -D tends to be used as a marker of 
surfactant function, although it has been used as a cell- specific marker in 
differentiation during repair (Ohtsuki et al., 2007). 
1.43.4 APN/MMC4 
In 2001 an antigen was identified on the apical surface of rat ATII and Clara cells, 
during the development of a monoclonal antibody against isolated ATII cells. As well 
as being expressed in the lung, it was also found in the kidney and small intestine, but 
not the liver or on alveolar macrophages. This antigen was thought to be a novel 
protein, with the potential to be used as a marker of ATII and Clara cell injury in the 
rat, much in the same way that RTI40 is utilised to quantify ATI cell damage. It was 
designated MMC4 (Boylan et al., 2001). Purification of MMC4, however, revealed it 
to be rat aminopeptidase N (APN), a membrane -bound metallopeptidase, which is 
homologous to CD13 in the mouse (Franklin, 2006). This finding was surprising, as 
APN had already been eliminated as a candidate for MMC4 due to its presence in the 
liver and on the surface of macrophages (Boylan et al., 2001). However, further study 
showed that MMC4 was indeed expressed on a small percentage of alveolar 
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macrophages (Franklin, 2006). Although levels of the protein were increased in BAL 
fluid in a rat model of mutant (expressing the normally MRSA -specific surface 
protein Pls) S. aureus- induced pneumonia (but not using the wildtype strain) the 
APN /MMC4 protein was not considered suitable as a marker of damage to ATII and 
Clara cells due to its expression on alveolar macrophages (Franklin, 2006). However, 
the fact that the level of APN /MMC4 did not significantly increase in the wildtype 
staphylococcal pneumonia model, despite an obvious inflammatory response, 
suggests that there might still be a role for the protein as a preliminary screen to 
identify rat models that warrant further investigation into ATII and Clara cell injury. 
Furthermore, its use as a marker of ATII cells has already been established, as 
demonstrated by its contribution to the identification and investigation of an 
intermediate cell phenotype during differentiation, both in vitro and during repair in 
vivo (McKechnie, 2008; Tyrrell et al., 2005). 
1.4.4 Clara Cell -Specific Proteins 
1.4.4.1 CC10 
Clara Cell Protein (GENE ID 7356, OMIM 192020), also known as CC10, CC16 and 
Clara Cell Specific Protein (CCSP), is a 16kDa protein secreted by bronchiolar Clara 
cells. Clara cell functions include protection of the respiratory tract, production of 
surfactant proteins and repair of the epithelium following injury by proliferation and 
differentiation into ciliated cells (Boylan et al., 2001; Broeckaert et al., 2000; 
Magdaleno et al., 1997). CC10 has also been shown to be the same as alpha - 
microprotein (protein 1) in urine from patients with tubular dysfunction (Bernard et 
al., 1992; Magdaleno et al., 1997) and uteroglobulin in the uterus (Muller -Schottle et 
al., 1999). The exact function of CC10 is as yet unknown, but it is thought to play a 
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role in protection of the epithelium by immunosuppression, as it has been shown to 
have anti -inflammatory properties, inhibiting both Interferon gamma (IFN -y) and 
TNF -a, as well as being upregulated by IFN -y (Broeckaert et al., 2000; Magdaleno et 
al., 1997). As expected, CC10 is present at highest levels in the lung, but is detectable 
in both serum and urine (Halatek et al., 1998). Although CC10 has been used as a 
direct marker of Clara cells in the rat (Barth and Muller, 1999) and to measure renal 
injury in both rodents and humans (Bernard et al., 1992; Halatek et al., 1998; 
Hermans et al., 1998), its most common use as a biomarker is to assess air -blood 
barrier permeability and Clara cell damage. Its elevation in serum has been used in 
humans to demonstrate damage of the air -blood barrier in response to smoke, ozone 
and LPS- induced lung inflammation as well as in sarcoidosis (Bernard et al., 1992; 
Broeckaert et al., 2000; Hermans et al., 2001). A decrease in both BAL fluid and 
serum CC10 has been taken as evidence of damage to Clara cells in COPD, lung 
cancer and in response to tobacco smoke and crystalline silica in humans (Bernard et 
al., 1992; Broeckaert et al., 2000). In addition, it has also been described as a marker 
of leakage from the lungs into the pleural space in humans (Hermans et al., 1998). 
Thus, CC10 is a well -established marker of Clara cells, and has been used in a variety 
of settings to assess both Clara cell injury and air -blood barrier permeability. 
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1.4.5 Summary 
Biomarkers, particularly proteins, can be a valuable source of information about 
inflammation, alveolar damage and surfactant production in the lung. Cell- specific 
proteins in particular can prove useful in investigating targeted cell injury, cell 
population dynamics and differentiation. In the lung these include RTI40, AQP5 and 
MMC6 (ATI cells), SP -C and RTII70 (ATII cell only), SP -D and APN /MMC4 (ATII 




Although there is a wide range of bacteria important in human lung infection, this 
section will focus on two clinically relevant microorganisms; S. pneumoniae and S. 
aureus. 
1.5.2 Streptococcus pneumoniae 
1.5.2.1 Clinical Importance of Streptococcus pneumoniae 
S. pneumoniae is a major worldwide human pathogen, responsible for a variety of 
important diseases including pneumonia, bacteraemia, meningitis, otitis media and 
sinusitis (Bricks and Berezin, 2006; Garcia -Suarez et al., 2006; Lopez, 2006). 
However it is most important as the commonest aetiological agent of CAP. 
Pneumococcal disease is highest in the young, the elderly and the 
immunocompromised (Bricks and Berezin, 2006; Garcia -Suarez et al., 2006; Lopez, 
2006). In the developed world the incidence of invasive pneumococcal disease (IPD) 
is 10 -20 per 100,000, with an overall mortality of 7 -36 %, although socio- economic 
factors can also contribute to risk (Parsons and Dockrell, 2002). In the developing 
world pneumococcal disease kills over 1 million children under the age of 5 (Bricks 
and Berezin, 2006) and worldwide approximately 5 million die every year due to 
pneumonia, the most common cause of which is S. pneumoniae (Jedrzejas, 2001). 
S. pneumoniae is sensitive to a variety of antibiotics, particularly penicillin (Jedrzejas, 
2001; Lopez, 2006; Restrepo et al., 2005). However, the emergence of penicillin - 
resistance was documented as early as the 1970s and is continuing to increase (Fuller 
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et al., 2005), with a worrying trend toward multi -drug resistance including 
cephalosporin and macrolides (Fuller et al., 2005; Jedrzejas, 2001; Lopez, 2006; 
Pallares et al., 1995). Tolerance to vancomycin, a drug used only as a last resort, has 
already been shown (Novak et al., 1999), suggesting that development of full 
resistance is only a matter of time. 
Development of a vaccine for pneumococcal disease started as far back as 1914 and a 
hexa -valent (6 serotype) vaccine was developed after WWII but was withdrawn in 
favour of antibiotic treatment (Watson et al., 1993). Emergence of antibiotic 
resistance in the 1970s fuelled interest in alternative treatments, and a 14- valent 
vaccine, based on the 14 serotypes causing 80% of disease, was finally developed in 
1978 (AlonsoDeVelasco et al., 1995; Watson et al., 1993). A 23- valent vaccine, based 
on the most prevalent serotypes at the time, was licensed in 1983, but protection is 
low in those most susceptible to pneumococcal disease, such as children under the age 
of 2 (Bricks and Berezin, 2006; Jedrzejas, 2001; Kalin, 1998). A heptavalent 
pneumococcal conjugate vaccine, which included those serotypes responsible for 85% 
of pneumococcal disease in the USA, was more suitable for young children and was 
licensed in 2000 (Bricks and Berezin, 2006). This appears to have had a positive 
effect on pneumococcal disease (Bricks and Berezin, 2006). 
1.5.2.2 Bacterial Morphology 
S. pneumoniae (known historically as Diplococcus pneumoniae and pneumococcus) 
was simultaneously and independently identified and cultured by both Louis Pasteur 
and George Sternberg from human saliva in 1881 (Watson et al., 1993). It was 
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established as an aetiological agent of lobar pneumonia in the late 19th century 
(Watson et al., 1993). 
In taxonomic terms, S. pneumoniae is a Gram -positive bacterium, of the genus 
Streptococcus (Facklam, 2002; Hoskins et al., 2001). As a Gram -positive species, the 
surface of S. pneumoniae comprises a thick cell wall containing many layers of PGs, 
LTAs and teichoic acids (Schleifer and Kandler, 1972). Streptococcus spp are 
distinguished from S. aureus by their inability to produce catalase (an enzyme 
catalysing the breakdown of H2O2) (Wong, 1987). Furthermore, S. pneumoniae can be 
distinguished from other streptococci by its demonstration of a (incomplete) rather 
than ß (complete) haemolysis on blood agar, and its sensitivity to optochin (ethyl 
hydrocupreine) (Bowers and Jeffries, 1955; Garcia -Suarez et al., 2006). Within the 
species there are 91 known serotypes of S. pneumoniae (Henrichsen, 1995; Park et al., 
2007), although not all are pathogenic (Kahn, 1998). S. pneumoniae exhibits natural 
transformation competence i.e. exchange of genetic material between strains and 
uptake of extracellular DNA from the environment (Lorenz and Wackernagel, 1994), 
which has important implications for the development of novel clinical serotypes as 
well as antibiotic resistance (Mitchell, 2000; Watson et al., 1993). 
S. pneumoniae is roughly 1µm in diameter (AlonsoDeVelasco et al., 1995). When 
viewed on smears it tends to appear in pairs and has a tendency to grow in chains in 
liquid media (Watson et al., 1993). Figure 1.7 shows a Gram stain of S. pneumoniae 
on a sputum smear (http: / /www.bact.wisc.edu) 
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Figure 1.7- Gram stain of a sputum smear from a lobar pneumonia. 
Arrow shows S. pneumoniae. Note characteristic pairing of bacteria 
S. pneumoniae is a facultative anaerobe and a fastidious organism requiring complex 
media for growth (Hoskins et al., 2001), stemming in part from its inability to produce 
catalase (Restrepo et al., 2005). Laboratory culture of S. pneumoniae requires an 
external source of catalase, such as blood, to neutralise the H202 produced by the 
bacterium (Restrepo et al., 2005). In addition, S. pneumoniae tends to be prone to a 
characteristic autolysis when subjected to nutritional deficits such as that encountered 
during stationary phase (Mitchell et al., 1997). 
1.5.2.3 Virulence Factors 
1.5.2.3.1 Overview 
Virulence factors are moieties that increase a bacterium's pathogenicity. They can 
promote enhancement of adhesion, colonisation and invasion, modulate the host 
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immune system and also include toxins. Some of the most important virulence factors 
of S. pneumoniae will be addressed here. 
1.5.2.3.2 Intracellular Factors 
1.5.2.3.2.1 Pneumolysin 
Pneumolysin (Ply), known historically as pneumococcal haemolysin, was first 
identified by Libman in 1905 (Lorian et al., 1973). By the 1980s, the toxin had been 
purified, cloned and sequenced (Paton et al., 1986; Shumway and Klebanoff, 1971; 
Walker et al., 1987) and was being used diagnostically to identify pneumococcal 
disease (Kalin et al., 1987). 
Purification of the toxin led to an extensive body of work determining its pathological 
effects. Instillation of Ply into rat lungs induced all the relevant histological features 
of pneumonia (Feldman et al., 1991), and it has been shown to cause damage to both 
pulmonary endothelial and epithelial cells (Rubins et al., 1992; Rubins et al., 1993), 
and to inhibit ciliary beat in respiratory epithelial cells (Feldman et al., 2002; 
Jedrzejas, 2001). Ply can influence immune cells, inhibiting respiratory burst and 
bacterial killing in neutrophils and monocytes (Nandoskar et al., 1986; Paton and 
Ferrante, 1983), as well as decreasing chemotaxis and migration by neutrophils (Paton 
and Ferrante, 1983). It also stimulates the production of inflammatory cytokines TNF- 
a, IL-113 and IL -8 (AlonsoDeVelasco et al., 1995; Hirst et al., 2004) and binds to 
TLR -4 (Malley et al., 2003). The toxin also affects lymphocytes by inhibiting 
proliferation and production of both antibodies and lymphokines (Rubins and Janoff, 
1998). Immunisation with purified Ply has also conferred protection against 
subsequent insult (Lock et al., 1992; Paton et al., 1993). The development of 
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pneumolysin- deficient bacteria, and demonstration of their decreased virulence in 
pneumococcal pneumonia (Berry et al., 1989b), has led to a number of studies 
contributing to the knowledge about the extent of the toxin's importance in lung 
pathogenesis. Such studies have shown that pneumolysin enhances expansion of S. 
pneumoniae in both pneumonia and sepsis (Benton et al., 1997; Kadioglu et al., 2000; 
Rubins et al., 1995), damage to the air -blood barrier including pulmonary endothelial 
cells (Rubins et al., 1992; Rubins et al., 1995), and inflammation, including neutrophil 
influx and lymphocyte accumulation (Kadioglu et al., 2000). In pneumococcal 
pneumonia, expression of Ply is histologically associated with lung damage, apoptosis 
in leukocytes and bronchial epithelial cells, and infiltration of inflammatory cells 
(Garcia- Suarez et al., 2007). 
Further studies on the toxin, found in all clinical isolates of the pneumococcus, have 
shown it to be a 53kDa polypeptide which is stored in the bacterial cytoplasm and can 
be released on autolysis and during logarithmic growth (Jedrzejas, 2001; Rubins and 
Janoff, 1998; Spreer et al., 2007). The toxin interacts with cholesterol in the plasma 
membrane of the target cell, leading to insertion of the molecule and the formation of 
a pore (Jedrzejas, 2001). There are two main activities of Ply, cytotoxicity and 
complement activation, both of which are important for virulence (Garcia- Suarez et 
al., 2006). The cytolytic effect is most critical for bacterial growth earlier on in 
infection, and contributes to tissue damage and neutrophil recruitment (Rijneveld et 
al., 2002; Rubins et al., 1995; Rubins et al., 1996). Ply can also activate the classical 
complement pathway by binding to Fc domain of IgG (Paton et al., 1993). In vivo 
studies have shown this activity to be more important for bacterial growth during the 
later stages of infection, and that it is not involved in tissue injury or leukocyte 
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recruitment but affects killing by neutrophils. The mechanism for these effects is not 
yet known (Rubins et al., 1995; Rubins et al., 1996). Studies using mutant bacteria 
which are separately deficient in the cytotoxic and complement activating activities 
have identified an additional, independent property of the pneumolysin toxin, but its 
purpose is as yet unknown (Berry et al., 1999). In summary, Ply is an important 
virulence factor for S. pneumoniae, affecting bacterial growth, tissue injury and 
inflammation. 
1.5.2.3.2.2 Neuraminidase 
Neuraminidase is a sialidase enzyme produced by a number of human microbial 
pathogens, including S. pneumoniae, P. aeruginosa and influenza viruses. It acts by 
by cleaving terminal sialic acids from carbohydrate moieties on host cell surfaces or 
in body fluids, enhancing bacterial adhesion (Davies et al., 1999; Jedrzejas, 2001; von 
Itzstein M., 2007). In the pneumococcus it is released from the cytoplasm following 
autolysis, thus contributing to pneumococcal pathogenesis (Jedrzejas, 2001). There 
are at least 2 active forms of the enzyme, NanA and NanB (Jedrzejas, 2001; Mitchell, 
2000). The virulence of NanA has been demonstrated in vivo, and immunisation with 
the enzyme confers partial pneumococcal protection (Mitchell, 2000; Paton et al., 
1993). Although the precise contribution of neuraminidase to pathogenesis is not yet 
known, its action may damage host tissues, expose bacterial adhesion receptors on the 
surface of epithelial cells and decrease the viscosity of mucus, thus aiding bacterial 
colonisation (Jedrzejas, 2001; Mitchell et al., 1997; Mitchell, 2000). 
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1.5.2.3.2.3 Hydrogen Peroxide 
H2O2 is a strong oxidant, produced by S. pneumoniae, as a by- product of aerobic 
metabolism (Spellerberg et al., 1996). However, it has also been shown to be an 
important virulence factor in vivo (Spellerberg et al., 1996). In vitro it has been 
demonstrated to be toxic to lung epithelial cells, as well as affecting ciliary function in 
both lung and neural cells (Duane et al., 1993; Feldman et al., 2002; Hirst et al., 
2000), and demonstrates a bactericidal effect on other competing bacteria such as H. 
influenzae and S. aureus (Pericone et al., 2000; Regev -Yochay et al., 2006). 
1.5.2.3.3 Surface Factors 
1.5.233.1 Capsule and Cell Wall Components 
Variations in the pneumococcal capsule are the basis of serotype classification. 
Although both capsulated and unencapsulated forms of the bacteria are found 
naturally, the capsule is required for virulence and clinical isolates are always 
encapsulated (Catterall, 1999). The capsule is itself non -toxic, non -inflammatory, 
antiphagocytic and inhibits the alternative complement pathway (AlonsoDeVelasco et 
al., 1995; Catterall, 1999; Garcia - Suarez et al., 2006), all of which contribute to 
bacterial growth in host tissues. In contrast, cell wall polysaccharide, particularly 
LTA, is highly inflammatory, binding to TLR -2 (Carpenter and O 'Neill, 2007; 
Kadioglu and Andrew, 2004; Martin and Frevert, 2005; Paterson and Mitchell, 2006), 
thus potentially contributing to tissue damage. Inflammatory responses induced by 
pneumococcal cell wall components include activation of the alternative complement 
pathway, leading to recruitment of inflammatory cells and production of cytokines. 
The presence of phosphorylcholine in LTA also enables adhesion of the bacteria to 
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activated cells via inflammatory receptors on the plasma membrane (Catterall, 1999; 
Garcia -Suarez et al., 2006). 
1.5.23.3.2 Autolysin 
Four bacterial peptidoglycan hydrolases, or autolysins, have so far been identified in 
the pneumococcal cell wall (Moscoso et al., 2005). These enzymes are responsible for 
the autolytic phenomenon demonstrated by S. pneumoniae and by the breaking of a 
choline bond, leading to break down of the cell wall (Jedrzejas, 2001; Mitchell, 2000; 
Paton et al., 1993). There are a number of potential functions for this process, 
including roles in the separation of daughter cells and competence in genetic 
transformation (Paton et al., 1993). However, the most obvious result of autolysis is 
the release of other bacterial virulence factors, including inflammatory cell wall PGs 
and LTAs, as well as intracellular toxins such as Ply and neuraminidase (Garcia - 
Suarez et al., 2006; Jedrzejas, 2001; Mitchell, 2000). LytA (N- acetylmuramic acid L- 
alanine amidase) is the main pneumococcal autolysin (Jedrzejas, 2001) and has been 
shown in vivo to be important for virulence (Jedrzejas, 2001; Mitchell, 2000) but there 
have been some conflicting results regarding the mechanism of this (Balachandran et 
al., 2001; Berry et al., 1989a; Berry et al., 1992; Lock et al., 1992). 
1.5.2.3.3.3 Other Surface Proteins 
In addition to the capsule, cell wall and autolysin there are a number of other 
virulence factors found on the bacterial surface. Pneumococcal surface protein A 
(PspA) is expressed on all clinical pneumococci (Jedrzejas, 2001; Mitchell, 2000) and 
inhibits alternative complement activation, thus decreasing complement- mediated 
clearance and phagocytosis (Garcia- Suarez et al., 2006; Jedrzejas, 2001). 
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Hyaluronidase, or more specifically hyaluronate lyase (Hyl), is a surface- secreted 
enzyme that breaks down hyaluronan (hyaluronic acid), present in connective tissue 
and the ECM. This activity may contribute to bacterial dissemination and the enzyme 
may also be involved in altering function of the innate immune system (Jedrzejas, 
2001; Mitchell, 2000). Bacterial adhesion is critical to successful colonisation, thus 
pneumococcal adhesion -associated proteins are important factors in virulence 
(Mitchell et al., 1997). These include direct adhesins such as Choline binding protein 
A (CbpA) (Hammerschmidt et al., 2007; Jedrzejas, 2001; Mitchell, 2000) and 
adhesion -mediators like Pneumococcal surface adhesin A (PsaA) (Jedrzejas, 2001). 
1.5.2.4 Summary 
S. pneumoniae, an encapsulated, Gram -positive coccus, is an important respiratory 
pathogen. Virulence factors such as pneumolysin, adhesion molecules and the capsule 
and cell wall components all contribute to its highly efficient lifecycle and 
pathogenesis. 
1.5.3 Staphylococcus aureus 
1.5.3.1 Clinical Importance of Staphylococcus aureus 
S. aureus is an important human pathogen (Diekema et al., 2001), particularly 
relevant as a cause of infections in the bloodstream, soft tissue and the lower 
respiratory tract (Diekema et al., 2001). S. aureus is the most common cause of 
infections acquired in hospital and is particularly important as an aetiological agent of 
HAP (ATS Guidelines, 2005; Lindsay and Holden, 2004). The bacterium colonises 
nares of between 30% and 70% of the population and usually lives commensally, but 
is able to infect the body in the event of a breach in the skin or mucous membranes 
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(Lindsay and Holden, 2004). Antibiotics remain the primary treatment for 
staphylococcal infection (Lindsay and Holden, 2004; Micek, 2007). However, the 
emergence of methicillin- resistant S. aureus (MRSA) leaves relatively limited options 
for therapy of MRSA infections, which are often treated with vancomycin or linezolid 
(Lindsay and Holden, 2004; Micek, 2007). Of particular concern are strains inducing 
severe infection, such as those expressing Panton- valentine leukocidin (PVL) which 
can cause haemolytic pneumonia (Lindsay and Holden, 2004). In addition, MRSA is 
becoming a more common cause of severe CAP (Stankovic et al., 2007). Widespread 
contamination by MRSA throughout hospitals in the developed world, and growing 
evidence of strains that are now resistant to vancomycin (Lindsay and Holden, 2004; 
Micek, 2007), make S. aureus infection a substantial burden to the health services. 
1.5.3.2 Bacterial Morphology 
S. aureus is a Gram -positive, spherical (-1 µm diameter), catalase- producing 
facultative anaerobe (Brown et al., 2005). Unlike most other staphylococci, S. aureus 
synthesises coagulase (a trait that can be used in bacterial identification) (Brown et al., 
2005), and often demonstrates haemolysis when cultured on blood agar, due to 
production of a -toxin (McClatchy and Rosenblum, 1966). S. aureus, named because 
of the golden colour of colonies on agar (Kloos, 1980) is also known historically as 
Staphylococcus pyogenes and was first identified in 1880 by Alexander Ogston, who 
demonstrated its pathogenicity in pustulent abscesses (Smith, 1982). Encapsulation of 
S. aureus varies considerably between serotypes (ORiordan and Lee, 2004; von Eiff 
et al., 2007). Those accounting for 80% of clinical isolates, demonstrating a less 
pronounced capsule, are often described as microencapsulated (von Eiff et al., 2007). 
There are currently 13 identified serotypes of S. aureus (von Eiff et al., 2007). 
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1.53.3 Virulence Factors 
S. aureus expresses a number of factors affecting virulence. The polysaccharide 
capsule can play an important role in bacterial pathogenesis. Highly encapsulated 
strains (serotypes 1 and 2) are resistant to neutrophil phagocytosis by inhibiting 
binding by complement and IgG, and are more virulent than strains lacking capsule. 
However, serotypes 5 and 8, the most clinically relevant strains, express different 
primary polysaccharides and are less virulent than those in serotypes 1 and 2 
(O'Riordan and Lee, 2004), although the capsule still confers virulence (Foster, 2005). 
This suggests that other factors are more important for clinical pathogenicity. 
However, expression of capsule is heavily dependent on culture conditions 
(ORiordan and Lee, 2004), which may explain this inconsistency. 
S. aureus also expresses surface proteins, which contribute to virulence and 
pathogenesis. Protein A (SpA) has been shown to be a virulence factor in vivo (Patel 
et al., 1987), binding to Fc regions of IgG and making them unavailable for binding to 
neutrophils, thus inhibiting phagocytosis (Foster, 2005). It also demonstrates pro - 
inflammatory capabilities (Gomez et al., 2004), stimulates apoptosis of B 
lymphocytes (Foster, 2005; Goodyear and Silverman, 2004) and contributes to 
bacterial adhesion (Gomez et al., 2006; Hartleib et al., 2000). There are a number of 
other surface molecules that promote adhesion of S. aureus. Fibronectin- binding 
proteins (FnBps) expressed on the surface of the bacterium are important for 
internalisation in host epithelial cells, although in vivo they enhance bacterial 
clearance of the lung (Dziewanowska et al., 1999; McElroy et al., 2002), suggesting a 
role in immune system avoidance that may be more important for colonisation than 
during established disease. Clumping factors (Cif) or fibrinogen- binding proteins are 
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able to stimulate cell aggregation and inhibit bacterial phagocytosis (Foster, 2005; 
Higgins et al., 2006; Miajlovic et al., 2007). Collagen- binding adhesin (Cna) has also 
been shown to be a virulence factor in a variety of disease models (Elasri et al., 2002; 
Patti et al., 1994; Rhem et al., 2000). 
S aureus also secretes a number of virulence factors, including exotoxins. A -toxin or 
a- haemolysin (Hla), responsible for the haemolytic effect of S. aureus on blood agar, 
damages host cells by forming a pore in the plasma membrane (Bhakdi and Tranum- 
Jensen, 1991; Jonas et al., 1994). It also stimulates pro -inflammatory cytokine 
production (Bhakdi et al., 1989; Grimminger et al., 1997) and is an important 
virulence factor in a number of disease models, including pneumonia (Bramley et al., 
1989; McElroy et al., 1999; Patel et al., 1987). It does not cause direct damage to 
alveolar epithelial cells however (McElroy et al., 1999), suggesting mediation of 
indirect effects on lung tissue. Inoculation with Ilia has also been shown to protect 
against lethal staphylococcal pneumonia in vivo (Deleo and Otto, 2008). Other 
haemolytic toxins include f3-toxin (nib), y -toxin (Hlg) and 6 -toxin ( Bramley et al., 
1989; Dinges et al., 2000; Foster, 2005). PVL, another pore -forming toxin, is 
expressed by a small proportion of clinical isolates but is important in staphylococcal 
pneumonia (Foster, 2005; Labandeira -Rey et al., 2007; Wardenburg et al., 2007). 
Other factors associated with S. aureus virulence include `superantigens', such as 
staphylococcal enterotoxins and toxic shock syndrome toxin -1 (TSST -1), that 
stimulate T lymphocyte proliferation regardless of antigenic specificity (Dinges et al., 
2000; Foster, 2005; Proft et al., 2003). 
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1.5.3.4 Summary 
S. aureus, like S. pneumoniae, is an important Gram -positive respiratory pathogen, 
particularly in HAP. The emergence of resistant strains of MRSA and its widespread 
infection of many organs other than the lung make it especially significant as a human 
pathogen. S. aureus produces a variety of surface adhesions and exotoxins, which 
contribute to pathogenesis and help the bacterium avoid the host immune system. 
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1.6 THESIS OBJECTIVES 
Subsequent to the discussion set forth in this Chapter, the following initial hypothesis 
was generated. 
Hypothesis 1 
Pneumococcal pneumonia induces differential damage to ATI and ATII cells 
The results of this hypothesis are detailed in Chapter 3. Following on from this, two 
further hypotheses were developed. 
Hypothesis 2.1 
Pneumococcal virulence factor pneumolysin mediates differential protein 
expression 
Hypothesis 2.2 
Differential protein expression in pneumococcal pneumonia is due to host 
response to Gram -positive bacteria 
Data from experiments investigating these hypotheses are presented in Chapter 4. 
To further investigate results generated in Chapter 3 a final hypothesis was devised. 
Hypothesis 3 
Differential protein expression in pneumococcal infection is due to direct 
interaction with bacteria or bacterial products 
Results examining this theory are detailed in Chapter 5 
A discussion of results chapters 3 -5 will be presented in Chapter 6 
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CHAPTER 2 - MATERIALS AND METHODS 
2.1: REAGENTS, ANIMALS AND GMO 
2.1.1 Reagents 
All reagents were supplied by Sigma, Poole, UK unless stated otherwise. All plastics 
were supplied by Fisher Scientific, Leicester, UK unless stated otherwise. Syringes and 
needles were supplied by B. D. Biosciences, Oxford, UK. Suppliers are listed in 
Appendix 1. 
2.1.2 Animals 
All animal experiments were carried out with approval according to the Home Office 
Animals (Scientific Procedures) Act, 1986. All animals were supplied by Harlan UK Ltd, 
Oxton, UK. Rats were male Sprague Dawley Specific Pathogen Free (SPF) weighing 
300 -350g and were kept on standard chow. All anaesthetics supplied by Genusxpress Ltd, 
Aberdeen, UK unless stated otherwise. 
2.1.3 GMO 
All use of Genetically Modified Organisms (GMO) was carried out according to the 
Genetically Modified Organisms (Contained Use) Regulations (2000). 
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2.2: BACTERIA 
All plates, media and antibiotics for bacterial culture were supplied by B. D. Biosciences, 
Oxford, UK. 
2.2.1 Streptococcus pneumoniae 
2.2.1.1 Strains 
Two strains of S. pneumoniae were used in this study, a wildtype laboratory strain (D39) 
and an isogenic pneumolysin- deficient mutant (PLN -A) which was resistant to 
erythromycin (Berry et al., 1989). Both wild -type and mutant bacterial strains were a kind 
gift from Tim Mitchell, University of Glasgow. Bacterial stocks were kept at -80 0C in 
Brain/ Heart Infusion broth plus 30% glycerol Ultra. 
2.2.1.2 Bacterial culture 
For all experiments, strains were grown overnight at 37 0C from the same batch of 
glycerol stocks on Blood Agar Base (BAB) plates containing 5% sheep blood, one colony 
was then cultured overnight at 37 °C in 3ml of Brain/ Heart Infusion broth, with no 
agitation. Growth curves carried out on bacterial cultures indicated that pneumococci 
reached mid log phase after approximately 9 hours and stationary phase after 15 hours. 
Bacteria were harvested at approximately 12 -14 hours, due to practical considerations. 
This was estimated to be late log phase, where the bacteria were thought to be still viable 
and producing virulence factors. 
The identity of each S. pneumoniae strain was checked during each experiment using 
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antibiotic (erythromycin) disks. To get an initial estimate of bacterial growth within the 
culture, the optical density of the overnight cultures was assessed using a Biomate 3 
spectrophotometer (Thermo Electron, Reading, UK). To prepare instillates, overnight 
cultures were washed twice with sterile, endotoxin -free Dulbecco's Phosphate Buffered 
Saline containing calcium and magnesium ions (DPBS + / +). This was done by 
centrifuging for 3 minutes at 11,300g then resuspending the pellet in DPBS and 
repeating. The final pellet was resuspended in 0.5ml DPBS +/+ for all experiments 
(McElroy et al., 2002). To confirm the concentration of bacteria, instillates were serially 
diluted in DPBS +/+ at 10-3 and 10-5 or 10-6, plated on BAB plates and incubated 
overnight at 370C. The number of colonies was counted and the number of colony 
forming units (cfu) instilled was calculated. 
2.2.2 Staphylococcus aureus 
One wildtype laboratory strain of S. aureus (8325 -4) was used in this study (McElroy et 
al., 2002). Bacterial stocks were kept at -800C in Todd Hewitt broth plus 30% glycerol 
Ultra. 
For all experiments, S. aureus was grown overnight at 370C from glycerol stocks on 
BAB plates, then one colony was cultured overnight at 370C in 3m1 of Todd Hewitt broth 
with agitation. Preparation of bacteria for experiments was subsequently the same as for 
S. pneumoniae. 
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23: MODELS OF INFECTION 
23.1 In vivo Models of Pneumonia 
23.1.1 Pneumonia Models 
Rats were weighed immediately prior to being anaesthetised with an intraperitoneal 
injection of 1ml of a mixture of Hypnorm (0.315mg/m1 fentanyl citrate and 10 mg/ml 
fluanisone) and Hypnovel (5m1 /m1 midazolam hydrochloride) (Wolfensohn and Lloyd, 
1998). The mouth was opened with the aid of a laryngoscope and an intubation wedge, in 
the form of a modified 2ml Eppendorf tube (Jou et al., 2000), was inserted to improve 
accessibility of the trachea. A catheter (Portex Fine Bore Polythene Tubing) of 0.96mm 
external diameter, 9cm in length (Portex Ltd, Hythe, UK) was inserted into the distal 
airways. 0.5ml bacterial suspension (approximately 106, 108 or 109 cfu /0.5m1) was 
inserted into the distal airways via the catheter. 0.5ml of DPBS +/+ was instilled into the 
distal airways of control rats (McElroy et al., 2002). Animals were kept for 24 hours, 72 
hours or 3 weeks and were weighed and monitored regularly throughout recovery and 
immediately prior to harvest. 
2.3.1.2 Processing of Animal Tissue 
2.3.1.2.1 Biochemical analysis 
At the end of the experimental period, rats were terminally anaesthetised with Sagatal or 
Pentoject (45mg/kg/i.p. pentobarbital) containing heparin (500units/kg/i.p) (Leo 
Pharmaceuticals, Princes Risbourough, UK). Blood was collected from the ascending 
aorta. Pleural lavage fluid was collected by lavaging the pleural cavity with 2 x 1m1 
DPBS + / +. Lungs were examined for injury. The trachea was then cannulated using a 
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modified Monoject Aluminium Hub Blunt Needle (Harvard Apparatus, MA, USA) and 
the cannula secured with Ethicon mersilk sterile black non -absorbent suture (3s 
Healthcare, Bristol, UK). BAL fluid was collected by lavaging the lungs with 2 x 10 mis 
of DPBS + / +. The lungs were then removed and placed into DPBS +/+ (McElroy et al., 
2002). 
Blood and pleural fluid were plated out undiluted; BAL fluid was serially diluted in 
DPBS onto BAB plates, which were incubated at 37 °C overnight. Blood was then 
centrifuged at 1000g for 15 mins; serum was collected then kept at -80 °C. Pleural lavage 
and BAL fluid was centrifuged at 900g for 5 minutes (McElroy et al., 1997; McElroy et 
al., 2002). Pleural lavage and BAL fluid leukocytes were quantified by haemocytometric 
counting. Approximately 200,000 cells were added to a disposable double cytofunnel 
(Thermo Electron, Reading, UK) and cytocentrifuged at 10g for 3 mins in a Cytospin 2 
cytocentrifuge (Thermo Electron, Reading, UK). Cytospins were then fixed with 
methanol for 2 mins and stained with Diff -Quick Red, then Diff -Quick Blue (Gamidor 
Technical Serviced Ltd, Abingdon, UK), for 1 min each. Differential cell counts on 
pleural and BAL fluid cells were performed on cytocentrifuged preparations. A total of 
300 cells were counted per cytospin. Pleural lavage and BAL fluid was then aliquoted 
and stored at -80 °C (McElroy et al., 2002). 
All lung tissue was weighed and homogenised in Tris -HC1 (2.42mM)- buffered saline 
(TBS), pH 8.2, containing 154mM NaC1, with the addition of Complete Protease 
Inhibitor Cocktail (Roche Diagnostics, Loughborough, UK), to prevent degradation of 
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protein in the samples. Lungs were homogenised by using an Ultra Turrax T25 
homogeniser (IKA- Werke, Staufen, Germany) on ice at approximately 4,000 rpm for 2 x 
5 seconds each. Samples were serially diluted in DPBS and plated out on BAB plates, 
which were incubated at 37 °C overnight (McElroy et al., 2002). Lung homogenates were 
then aliquoted and stored at -80 °C. 
The number of cfu present in blood, BAL, pleural fluid and lung homogenate was then 
calculated. 
2.3.1.2.2 Morphological analysis 
Rats were anaesthetised as described above. Blood was collected and processed as 
described above, and the trachea was cannulated. Lungs were examined for injury. 
For electron microscope analysis, lungs were then inflated with 10mis of 4% 
paraformaldehyde (made up using DPBS -0, secured using Ethicon mersilk sterile black 
non -absorbent suture, then removed into 4% paraformaldehyde and left at 4 °C for at least 
24 hours. Cubes were cut from the injured region and fixed in glutaraldehyde buffer 3% 
containing sodium cacodylate (0.1M). Similar regions were processed from control lungs. 
*Tissues were then postfixed in osmium tetroxide buffer (1 %) containing sodium 
cacodylate (0.1M), then dehydrated in a series of graded alcohols and embedded in 
polyethylene capsules in fresh Araldite epoxy resin. Lung sections were cut, placed on 
200 -mesh uncoated grids then stained with uranyl acetate and lead citrate for electron 
microscopic studies *. Sections were viewed with a Philips CM12 electron microscope. 
Processing * to * was carried out by Steve Mitchell 
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For immunofluorescence and histological analysis, the lungs were inflated with 10mis of 
4% paraformaldehyde containing 4% Tissue -Tek Optimum Cutting Temperature 
compound (OCT) (Bayer, Newbury, UK), secured using Ethicon mersilk sterile black 
non -absorbent suture, then removed to 4% paraformaldehyde/ OCT. Lungs were left at 
4°C for at least 72 hours. For immunofluorescence analysis, lung tissue was processed 
for frozen thin sections. Small cubes were cut from macroscopically inflamed and control 
lungs and fixed overnight in 30% (876mM) sucrose in non -sterile Phosphate Buffered 
Saline (PBS), containing 4% OCT. tFrozen sections 3 -4ium thick were then cut on a 
Leica CM1850 cryostat onto Superfrost Plus microscope slides (VWR, Poole, UK)t and 
were subsequently frozen at -20°C. For histological analysis, pieces of tissue were 
processed for paraffin section. $ Tissue was dehydrated and embedded in paraffin wax in 
a tissue processor, then set into a tissue mould. Sections 3 -4µm thick were cut on a 
Microtome then stained with Harris haematoxylin and eosin (H &E) before mounting$. 
Processing t to t and $ to $ was carried out by Susan Harvey and Robert Morris. 
23.2 In vitro Models of Bacterial Co- culture 
2.3.2.1 Bacterial Co- culture Model 
2.3.2.1.1 Reagents and plastics 
All tissue culture media and reagents were supplied by PAA Laboratories, Yeovil, UK 
unless otherwise stated. All plastics were supplied by Fisher Scientific, Leicester, UK 
unless otherwise stated. 
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2.3.2.1.2 Cell lines 
The rat alveolar epithelial cell line, SV40 -T2, was used in the models of bacterial 
infection (Clement et al., 1991). 
2.3.2.1.3 Cell Culture 
Cells were grown at 37 °C in a 5% CO2 humidified incubator in D10 media, consisting of 
Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% Foetal Bovine 
Serum (113S) and additional amino acids (2mM 1- glutamine). The D10 media was 
supplemented with penicillin (100 U /ml) and streptomycin sulfate (100ug/m1) to control 
unwanted bacterial infection in the cultures. Cells were grown on 75cm2 plastic flasks. 
2.3.2.1.4 Bacterial Co- culture 
For each experiment, cells were grown to approximately 80% confluency and washed 
with 2 x 10mis DPBS without calcium and magnesium ions (DPBS "/_). 10mis of fresh 
D10 media, without penicillin and streptomycin sulphate, was then added along with 
0.5ml bacterial suspension or DPBS -/_ control. 
23.2.2 Cell Processing 
2.3.2.2.1 Protein Analysis 
At the end of each experimental period, cell culture media was removed, plated serially, 
aliquoted and frozen at -80 °C. The remaining cells were then washed with DPBS "/_ and 
detached from the flask using 1m1 of 0.5mg/m1 Trypsin /0.22mg/ml EDTA 
(ethylenediaminetetraacetic acid). Cells were resuspended in 10 ml of D10 media and 
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spun at 1000g for 3 mins The cell pellet was then resuspended in 1m1 RIPA 
(Radiolmmuno Precipitation Assay) buffer (1% Igepal + 12mM sodium deoxycholate in 
PBS) containing Complete Protease Inhibitor Cocktail (Roche Diagnostics) to prevent 
degradation of protein in the samples. Samples were vortexed and drawn up and down in 
a 1ml syringe in a 25 gauge needle at least 6 times. Samples were then centrifuged at 
11,300g for 15 minutes at 4 °C, the supernatant collected and mixed well before being 
aliquoted and stored at -80 °C. 
23.2.2.2 RNA Analysis 
Cells were initially treated as for protein analysis described above. After the media was 
removed and cells washed, cells were then treated for RNA isolation using TRIZOL® 
reagent (Invitrogen, Paisley, UK). In summary, cells were incubated on ice for 5 minutes 
in 1 ml TRIZOL®. Cells were then scraped from the flask using a cell scraper. 1m1 of the 
TRIZOL® solution was incubated on ice for 5 minutes with 200111 of chloroform, and 
then centrifuged at 11,300g for 15 minutes at 4 °C in order to separate the organic and 
aqueous phases. 60011I of the clear aqueous phase was then mixed with an equal amount 
of isopropanol and kept at -70 °C for at least one hour so as to precipitate out the RNA. 
After thawing, the samples were then centrifuged at 11,300g for 20 minutes at 4 °C and 
300111 of ice -cold ethanol added to the pellet to precipitate RNA from DNA. Another 
1.1,300g centrifuge for 10 minutes at 4 °C yielded an RNA pellet which was air -dried and 
resuspended in 43µ1 of sterile nuclease -free H2O (Applied Biosystems, Warrington, UK) 





Normal rat lung tissue was used as a positive control in RNA analysis of lung -specific 
proteins. Lung tissue was removed directly into an appropriate volume of TRIZOL® 
reagent, cut into small pieces and homogenised on ice using a PowerGen 125 
homogeniser (Fisher Scientific, Leicester, UK). 1m1 of tissue homogenate was then 
processed for RNA isolation as described above. 
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2.4: ANALYSIS 
2.4.1 Protein Assessment 
2.4.1.1 Biochemical Analysis 
2.4.1.1.1 Protein Assay 
Protein concentration of BAL and pleural lavage fluid, lung homogenates and cell lysates 
were determined by the Bio -Rad Bradford assay (Bio -Rad Laboratories, Hemel 
Hempstead, UK), using bovine serum albumin (BSA) solution (Pierce Warriner, Chester, 
UK) as a standard (McElroy et al., 1999; McElroy et al., 2002). Samples were analysed at 
630 nm in a 96 -well tissue culture plate using a Dynatech Laboratories MRX Microplate 
Reader, and Revelation software. 
2.4.1.1.2 Protein Analysis 
Details of antibodies used in specific protein analysis, including suppliers, are detailed in 
Table 2.1. All primary antibodies were diluted in non -sterile DMEM containing 10% 
FBS, except loading controls which were diluted in 2.5% bovine casein in TBS. 
Rockland secondary antibodies supplied by Lorne Laboratories, Twyford, UK were used 
in all Dot and Western blots. Zymed® secondary antibodies supplied by Invitrogen, 
Paisley, UK were used for Enzyme -Linked ImmunoSorbent Assay (ELISA). All 
secondary antibodies were diluted in 2.5% casein. 
The concentration of specific proteins present in samples was evaluated using a variety of 
methods, including ELISA, ELISA -based Dot blot, Western blot and multiplex bead 
array techniques. 
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Analysis of BAL fluid for membrane -associated proteins (RTI40, APN /MMC4, and 
MMC6) was carried out on the insoluble fraction, which was obtained by treating at 
500,000g for 10 minutes in a Beckman Optima ultracentrifuge. The resultant pellet was 
resuspended in TBS. Lung homogenates were centrifuged at 11,300g for 30 seconds to 
remove any large pieces of tissue and assays were carried out on the resulting 
supernatant. All other assays were carried out on untreated sample. 
2.4.1.1.2.1 Dot Blot 
Dot blots were carried out as described previously (McElroy et al., 1995; McElroy et al., 
1997). Protein from samples was immobilised on Immobilon -P polyvinylidene fluoride 
(PVDF) membrane which had been pre- treated with methanol, using a dot blot manifold 
(Whatman Schleicher & Schuell, Keene, USA) connected to a vacuum pump. The 
membrane was then blocked for 1 -2 hours in 2.5% bovine casein in TBS, to prevent non- 
specific antibody binding. The membrane was then incubated in primary antibody for 30 
minutes at room temperature or at 4 °C overnight. Primary antibody was removed by 
washing thoroughly with 0.05% polyethylene sorbitan monolaurate (Tween 20) in TBS 
(TEST) for 25 -30 minutes before incubation with goat IgG secondary antibody 
conjugated to horseradish peroxidase (HRP), diluted to 0.15µg/ml, for 30 minutes at 
room temperature. Secondary antibody was removed by washing in TBST as before and 
the blots were visualised using Enzymatic Chemiluminescence (ECL) Western Blotting 
Detection Reagents (Amersham, Little Chalfont, UK). Finally, blots were developed 




Densitometry values for the dots were measured on a Dynatech Laboratories MRX 
Microplate Reader, using Revelation software. All relevant samples were assayed on the 
same blot; therefore data are expressed as a percentage of the mean control value. 
2.4.1.1.2.2 Western Blot 
Western blots were carried out using the NuPage® Bis -Tris Electrophoresis System 
(Invitrogen, Paisley, UK) as follows. Samples of approximately equal protein, along with 
protein standard MultiMark® Multi- Colored Standard (Invitrogen, Paisley, UK) were 
loaded and run on 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS- 
PAGE) gels. On reducing gels, samples were treated with reducing agent 0.5M 
Dithiothreitol (D'1"1) and antioxidant (Invitrogen, Paisley, UK) according to the NuPage 
System protocol. Gels were run at 200v and transferred at 30v for 2 hours onto methanol - 
treated PVDF membrane, which were then blocked for 1 hour in 2.5% casein. 
Membranes were then treated as for dot blots, except that secondary antibodies were 
diluted to 0.5µg/ml. The blots were analysed using upc grabit and upc gel plate software 
as average volume of bands. All relevant samples were assayed on the same blot; 
therefore data is expressed as a percentage of the mean control value. 
[3-actin or GAPDH antibodies were used as loading controls. 
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2.4.1.1.2.3 ELISA (Enzyme- Linked ImmunoSorbent Assay) 
(Ell Antibody) 
A direct ELISA technique was used. As purified protein was not available all relevant 
samples were assayed on the same blot; therefore data is expressed as a percentage of the 
mean control value. Protein was coated onto a 96 -well, flat -bottomed, high -binding tissue 
culture plate by incubating 1O0111 of sample overnight at 4 °C. Unbound sample was then 
removed and wells were washed x 3 with TBST then blocked in 2O01A of 2.5% casein for 
2 hours at 4 °C. Blocking buffer was removed and wells rinsed with TBST then incubated 
for one hour in 10011I of Ell antibody. Primary antibody was washed off x 3 in TBST 
then wells were incubated in 100111 of secondary antibody, diluted to 0.5µg/ml, for 30 
mins at 4 °C. Secondary antibody was washed off as described previously, and then wells 
were incubated for 5 -20 mins in 1000 of SureBlue TMB Microwell Peroxidase Substrate 
(Insight Biotechnology, Wembley, UK) developing solution. Once the colour had 
developed, the reaction was stopped using 501A of 1M H2SO4 and the plate was analysed 




























































































































































































































































































































































































































































































































































































































































































2.4.1.1.2.4 Multiplex Fluorescent Bead Immunoassay (II BI) 
A Bender Medsystems FlowCytomix rat Cytokine 6plex bead array (Invitrogen, Paisley, 
UK) assessing IL-la, MCP -1, TNF -a, IFN -y, Granulocyte Macrophage Colony - 
Stimulating Factor (GM -CSF) and IL -4 was carried out 
(http://www.bendermedsystems.com/bm_products/MAN/825FF.pdf). Lysophilised 
standards were reconstituted in Assay Buffer (1% BSA in PBS) and serially diluted. 25µ1 
of sample or standard was added to a 96 -well round -bottomed tissue culture plate and 
incubated with 2511l of antibody- coated fluorescent beads and 50µ1 of biotin -conjugated 
secondary antibody for 2 hours with agitation at 500rpm. Beads were pelleted at 300g for 
5 minutes at 4 °C and unbound sample and biotin -conjugated antibody was then washed 
off with Assay Buffer. The washing procedure was repeated once more then beads were 
pelleted again and incubated with 50111 Streptavidin -Phycoerythrin (PE) for 1 hour with 
agitation. After an additional wash, beads were resuspended in Assay Buffer and 
processed on a FACSCalibur flow cytometer (B. D. Biosciences, Oxford, UK). Data was 
analysed using BenderMedSystems FlowCytomix Pro 2.1 Software (Invitrogen, Paisley, 
UK). Data was measured as picograms of protein but is expressed as a percentage of the 
mean control. 
2.4.1.1.2.5 FACS (Fluorescence- activated cell -sorting) Analysis 
(RTI40/ICAM -1 double staining) 
SV40 -T2 cells were suspended in FACS wash buffer (30µM BSA in PBS containing 
15.4mM NaN3 sodium azide) at approximately 107 cells /ml and 104,1 (about 1 million 
cells) per well was added to a round -bottomed 96 -well tissue culture plate. Cells were 
pelleted at 300g for 5 minutes at 4 °C and the supernatant removed. Cells were blocked 
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for 15 minutes at 4 °C in 20% goat serum in FACS wash. 1O0111 of El 1 (RTI40) primary 
antibody only, at 1:20 dilution, was then added and the cells were incubated for a further 
30 minutes at 4 °C. The cells were then pelleted as described previously and washed twice 
in FACS wash. 200µ1 of Alexa Fluor® 647 -conjugated goat anti -mouse IgG1 secondary 
antibody (Invitrogen, Paisley, UK), diluted in FACS wash to 20µg /ml, was added and 
cells were incubated for 30 minutes at 4 °C. Cells were pelleted and washed as above. 
Only after staining of RTI40 was complete were the cells incubated for 30 minutes at 4 °C 
in 2O0111 of 5µg /m1 Intercellular Adhesion Molecule 1 (ICAM -1) primary antibody 
[1A29] conjugated to fluorescent isothiocyanate (FITC) (Abcam, Cambridge, UK). This 
was done as both primary antibodies were isotype IgG1, so as to avoid additional binding 
of the secondary antibody to the FITC- conjugated antibody. Cells were then pelleted and 
washed, then resuspended in 10011.1 of FACS wash before fixation in 100µ1 of 8% 
formaldehyde. Unstained and secondary antibody only cells were also processed to serve 
as controls. Cells were analysed on a FACSCalibur flow cytometer. 5000 events were 
recorded per sample, including unstained, secondary only and primary antibody stained 
cells. 
2.4.1.2 Immunohistochemical Analysis 
2.4.1.2.1 Immunofluorescence Staining 
Frozen lung sections were rinsed with PBS before immersion for 15 minutes in 100µl of 
blocking buffer (2.2g fish gelatin in 20% goat serum) containing 1% Triton to 
permeablise the cell membrane. Sections were then incubated with primary antibody for 
30 minutes at room temperature, or overnight at 4 °C, and then rinsed thoroughly with 
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PBS. Tissue was then incubated in 100111 of 20µg /m1 goat Alexa Fluor®- conjugated 
secondary antibody (Invitrogen, Paisley, UK) for 30 minutes, rinsed thoroughly with PBS 
and then immersed in a 0.1% To -Pro -3 in PBS solution, before rinsing in PBS and 
mounting using Mowiol mounting medium (Merck Biosciences, Nottingham, UK). 
Stained slides were analysed using a Zeiss ISM 510 meta confocal microscope. 
2.4.1.2.2 Antibodies 
Table 2.2 below shows antibodies used for immunofluorescence staining 
Primary Dilution 
Antibody 
Secondary Antibody Dilution 
RTI40 1:50 Alexa Fluor® Goat anti -mouse IgG1 1:100 
MMC4 1:1 Alexa Fluor® Goat anti -mouse IgG2a 1:100 
MMC6 1:1 Alexa Fluor® Goat anti -mouse IgG2b 1:100 
RTII70 1:1 Alexa Fluor® Goat anti -mouse IgG3 1:100 
Pro -SP -C 1:50 Alexa Fluor® Goat anti- rabbit IgG 1:100 
23.4 RNA Assessment 
2.3.4.1 RNA Purity Assessment 
Before mRNA analysis was carried out, the purity of isolated RNA was determined. 
RNA preparations were diluted 1:100 in H2O and the OD (optical density) of RNA 
(260nm) and protein (280nm) was assessed using a spectrophotometer. Isolated RNA was 
considered to be adequately pure if the ratio of RNA:Protein was more than 1.6. From the 
OD values, it was also possible to determine the concentration of RNA. The quality of 
the RNA was also assessed, by running 611l of preparation, in loading buffer on a 2% 
agarose gel, using SYBR SafeTM DNA Gel Stain (Invitrogen, Paisley, UK). A DNA ladder 
(Promega, Southampton, UK) was run alongside to assess band sizes. Gels were analysed 
using a VersadocTM Model 4000 and Quantity One software (Bio -rad Laboratories, 
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Hertfordshire, UK). Assessment of the 28S and 18S bands served as a rough guide of the 
integrity of RNA in isolates. 
2.3.4.2 RT -PCR (Reverse Transcription Polymerase Chain Reaction) 
Analysis of RNA was carried out by RT -PCR (Reverse Transcription Polymerase Chain 
Reaction) analysis. 
2.3.4.2.1 Reverse Transcription 
All reagents for Reverse Transcription and Polymerase Chain Reaction were supplied by 
Promega, Southampton, UK unless otherwise stated. 
cDNA was synthesised from isolated RNA using the ImProm -IITM Reverse Transcription 
System. In summary, 1 µg of RNA was combined with either Oligo (dT)15 or Random 
Primers at 50ng /p1 and denatured for 5 minutes at 70 °C, then chilled on ice for 5 minutes. 
RNA/primer solution was then incubated in lx ImProm -IITM Reaction Buffer, 6mM 
MgC12, 1mM dNTPs, 0.4U Recombinant RNasin® Ribonuclease Inhibitor and 5% 
ImProm-H Reverse Transcriptase enzyme. The solution was initially annealed at 25 °C for 
4 minutes, then first strand synthesis was carried out at 42 °C for 60 minutes. Finally the 
Reverse Transcriptase enzyme was inactivated at 70 °C for 15 minutes. 
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2.3.4.2.2 PCR 
The amount of mRNA corresponding to each protein of interest was assessed using the 
GoTagTM DNA Polymerase GoTagTM system and was optimised for each specific set of 
primers, summarised in Table 2.3. 
Gene Accession 
No. 
Primer Sequences Product 
size 
BSA cDNA 
IL -la NM_017019 F tcgggaggagacgactctaa 
R gaaagctgcggatgtgaagt 
201bp No 1µl 
MCP -1 M57441 F atgcagttaatgccccactc 
R ttccttattggggtcagcac 
167bp No 1µl 
RTI40 NM_019358 F agtgttgctctgggttttgg 
R cgccttggcagttgacttat 
184 bp No 1µ1 
SP -D M81231 F gatggaggctttgaatggaa 
R cgtgcccacatctgtcatac 
271 bp Yes 2µI 
GAP -DH BC087743 F aactttggcattgtggaagg 
R acacattgggggtaggaaca 
223bp No 1111 
B -actin NM_031144 F agccatgtacgtagccatcc 
R ctctcagctgtggtggtgaa 
228 bp No 111I 
Table 23: PCR Protocols 
Table 2.3 shows mRNA accession numbers, forward and reverse primer sequences, 
product size in base pairs (bp) and specifics of optimised PCR protocols. 
The generic PCR protocol was as follows. cDNA was incubated in lx GoTagTM Reaction 
Buffer, 1.75mM MgC12, 250µM dNTPs, 1 U GoTagTM DNA Polymerase enzyme and 
250nM each of specific forward and reverse primers. PCR was carried out as follows: 
1. Denatured at 94 °C for 3 mins 
2. Denature at 94 °C for 1 min 
3. Anneal at 60 °C for 1 min 
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4. Extend at 720C for 1 min 
5. Repeat Steps 2 -4 for 35 cycles 
6. Final extension/ blunt ending at 720C for 5 mins 
13-actin and GAPDH were used as loading controls. 
Resultant PCR products were then run on a 2% agarose gel in the same way as for RNA 
purity assessment above. Densities of bands were analysed using Quantity One software 
on a VersadocTM Model 4000. As all relevant samples were assayed on the same gel, data 
are expressed as a percentage of the mean control value. 
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2.5 STATISTICAL ANALYSIS 
Data were tested for normality (Kolmogorov and Smirnov) and subsequently tested using 
parametric methods (usually 1 -way ANOVA). Non -normally distributed data were either 
transformed (reciprocal or log) and tested as normal or tested non -parametrically (usually 
Kruskal- Wallis). Where sample sizes were too small to test for normality or variances 
between groups was significantly different (Bart letts), non -parametric tests were used. 








Pneumococcal pneumonia is an important source of mortality and morbidity 
throughout the world (Section 1.1 Pneumonia). While much research has been carried 
out to determine the pathogenesis of this disease, there is a lack of data regarding 
differential injury to alveolar epithelial cells (1.3.2.3 Models of Pneumococcal and 
Staphylococcal Pneumonia). 
3.2. HYPOTHESIS 1 
Rat models of S. aureus- induced pneumonia have demonstrated specific injury to ATI 
cells in the acute phase and proliferation of ATII cells during repair, ascertained using 
cell- specific biomarker proteins (1.3.2.3 Models of Pneumococcal and Staphylococcal 
Pneumonia). Using this premise, the following hypothesis was formulated. 
Pneumococcal pneumonia induces differential damage to ATI and ATII cells 
The aims of this chapter were to set up and characterise a rat model of acute injury, 
resolution and recovery of S. pneumoniae- induced pneumonia and to then use cell - 
specific proteins to assess differential alveolar epithelial cell damage. 
3.3. METHODS 
The methodology used to set up the recovering rat model was based on that employed 
previously in our laboratory (McElroy et al., 2002; Tyrrell et al., 2005). It was 
considered that while surgical intubation to deliver the bacteria (Rhodes et al., 1989a; 
Rhodes et al., 1989b; Yoneda and Coonrod, 1980) might be appropriate for ventilated 
animals under terminal anaesthesia (McElroy et al., 1995; McElroy et al., 1999), this 
would be inappropriate in a recovering model, both for animal welfare reasons and 
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since it would require recovery from a procedure in addition to the bacterial 
inoculation. Intranasal instillation (Bergeron et al., 1998; Brown et al., 2002; Dallaire 
et al., 2001; Garcia -Suarez et al., 2007; Kadioglu et al., 2000) allows for the 
possibility of the animals swallowing some of the inoculum and may not guarantee a 
consistent quantity of bacteria delivered directly into the lungs. Thus a non -surgical 
intra- tracheal instillation procedure, delivered under light anaesthetic, was selected. 
The wildtype D39 strain of S. pneumoniae, a virulent, encapsulated, serotype 2, 
laboratory strain, NCTC 7466 (National Collection of Type Cultures, London, UK) 
(Berry et al., 1989), was used for all experiments. Doses used were 106, 107, 108 or 
109 cfu delivered in 0.5ml PBS vehicle. Control animals were instilled with PBS 
vehicle. 
A preliminary time course indicated that the following time points represented acute 
injury (24 hours), resolution (72 hours) and recovery (3 weeks) and these were 
selected for further investigation. 24 hour, 72 hour and 3 week infected animals were 
treated during different experiments along with controls for each. 
In all graphs data presented is as a result of at least 2 separate experiments. Data 
points shown are means unless stated otherwise. Error bars are lx standard deviation 
(SD). Asterisks on graphs represent significance compared to control unless otherwise 
stated. Other levels of significance between experimental groups are qualified in the 
figure legend if appropriate. In graphs comparing 24 and 72 hour time points, 24 hour 
data is the same as (or representative of) data presented in the previous 24 hour time 
point graph. In this case asterisks are not used to demonstrate significance between 24 
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hour controls and experimental groups as this data has already been presented. 
Analysis of specific proteins is presented as a percentage of the mean control value. 
3.4. RESULTS 
3.4.1 Basic Characterisation of S. pneumoniae -induced Pneumonia Model 
3.4.1.1 Aim 
The aim of this section was to set up and characterise a rat model of acute injury, 
resolution and recovery of S. pneumoniae- induced pneumonia 
3.4.1.2. Weight Loss 
Loss of body weight was used as a crude measure of animal health during the 
experiments (Figure 3.1). All animals had a starting weight of 300 -350g. Rats instilled 
with the higher doses of S. pneumoniae (108 and 109 cfu) showed an 8% decrease in 
body weight after 24 hours. The lower doses (106 and 107 cfu) were not significantly 
lower than controls. At 48 hours the rats given the higher doses still weighed 
significantly less than controls. By 72 hours the rats given the highest dose were still 
lower in weight, although this was starting to increase. Rats inoculated with 108 cfu 
were of equivalent weight to controls although values were highly variable. From 72 
hours to 3 weeks, weights of infected animals continued to increase in a similar 
manner to controls (Figure 3.1). 
3.4.1.3 Histology 
Instillation with S. pneumoniae in most cases induced a lobar pneumonia that was 
restricted to the left lobe. By 24 hours the affected areas of lung were macroscopically 
livid and red, whereas after 72 hours were more of a grey colour. Three weeks after 
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instillation lungs were barely distinguishable from normal. H &E staining was carried 
out on control and S. pneumoniae- infected lung sections to determine microscopic 
changes in lung architecture. Control sections show clear airspaces and normal lung 
architecture (Figure 3.2a) but after 24 hours there is an influx of inflammatory cells 
and red blood cells (RBCs) (Figure 3.2b). By 72 hours inflammatory cells are still 
present and the alveolar walls are thickened (Figure 3.2c) but by 21 days the lungs 
look normal again (Figure 3.2d). 
3.4.1.4 Bacterial Recovery 
The number of viable bacteria recovered from BAL fluid and lung homogenate in S. 
pneumoniae- infected rats was used as a measure of bacterial growth and clearance. 
Ninety nine percent of instilled bacteria were cleared from the lungs by 24 hours 
(Figure 3.3a). After 72 hours there was an additional 10 -fold decrease (Figure 3.3b). 
Positive blood cultures were observed in some of the infected animals after 24 hours. 
This ranged from 0% at the 106 dose to 55% at 109 cfu. Overall, these data suggest 
that the lung is able to clear most of the S. pneumoniae by 24 hours with further but 
not complete clearance by 72 hours. 
3.4.1.5 Airway Inflammation 
In order to characterise inflammation in the airways, assessment of inflammatory cells 
in BAL fluid was carried out, including total and differential leukocyte counts. 
Instillation of S. pneumoniae induced a significant, dose dependent, up to 100 -fold 
increase in the number of BAL fluid leukocytes recovered after 24 hours (Figure 
3.4a). This infiltration decreased after 72 hours (Figure 3.4b). Of BAL fluid 
leukocytes, the most abundant in controls was the macrophage, accounting for more 
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than 80% of cells. In all S. pneumoniae infected rats after 24 hours however, the ratio 
of macrophages to neutrophils significantly reversed, regardless of dosage (Figure 
3.5a) even though the absolute numbers of macrophages increased dose -dependently 
(Control: 1.16x104 ± 6.07x103; 106 cfu: 2.58x104 ± 8.24x103; 10' cfu: 6.77x104 ± 
3.2x104; 108cfu: 8.91x104 ± 5.62x104; 109 cfu: 1.52x105 ± 1.07x105). By 72 hours the 
neutrophil percentage had dropped to about 50 %, which was significantly different 
from both controls and instilled animals after 24 hours (Figure 3.5b). The number of 
macrophages in infected animals after 24 and 72 hours was similar (24 hrs: 1.52x105 
± 1.07x105; 72 hrs: 1.45x105 ± 1.05x105). 
3.4.1.6 Damage to Air -Blood Barrier 
In order to quantify injury to the air -blood barrier, analysis was carried out on protein 
in BAL fluid as a measure of protein flux across the barrier. S. pneumoniae induced a 
significant, dose -dependent, up to 5 fold increase in BAL fluid protein after 24 hours, 
the 109 cfu inoculation level containing protein concentrations significantly higher 
than lower inoculation levels (Figure 3.6a). By 72 hours the amount of protein had 
decreased significantly although it was still significantly higher than controls (Figure 
3.6b). These data suggest that S. pneumoniae causes damage to the air -blood barrier 
after 24 hours, but that this is starting to resolve by 72 hours. 
At this point it was considered that the two higher doses of bacteria provided good 
evidence of appropriate injury and inflammation whilst still demonstrating resolution 
and recovery. Thus further analysis was carried out with inoculations of 108 and 109 
cfu only. 
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3.4.1.7 Pleural Space 
In order to determine if infection had disseminated from the lungs to the pleural 
cavity, assessment was carried out on pleural lavage fluid. This included recovery of 
viable bacteria (for bacterial dissemination), total and differential leukocyte counts 
(for influx of inflammatory cells) and measurement of protein (for leakage from lungs 
to pleural space). Positive bacterial cultures of pleural lavage fluid were recorded for 
20 -25% of rats infected with 108 and 109 cfu. Although there was no significant 
difference between the total numbers of leukocytes in S. pneumoniae -infected pleural 
lavage fluid and controls either after 24 or 72 hours (Figure 3.7a + b), the bacteria did 
induce a significant increase in percentage of neutrophils, and a decrease in 
macrophages at 24 hours (Figure 3.8a). This had returned to normal by 72 hours 
(Figure 3.8b) and there was no effect on either eosinophils or mast cells at either time 
point (Figure 3.8). The presence of 10% eosinophils in both control and bacteria - 
treated animals was unexpected. This result may be explained by some kind of low - 
,grade infection. While animals were initially supplied as SPF, the animal unit in 
which they were housed for a short time prior to treatment was not, and rats may have 
acquired pathogens from their environment during this time. Figure 10a shows that 
protein levels in pleural lavage were very variable, and there was no significant 
difference between controls and S. pneumoniae -infected animals at 24 hours. 
Variability at 72 hours was high, with bacterially instilled rats showing a significantly 
higher amount of pleural lavage protein than those at 24 hours. However, control 
values at the 72 -hour time point were also noticeably lower than those at 24 hours. 
As there were no significant differences between control groups at 24 hours and 72 




3.4.1.8 Inflammatory Mediators 
In order to determine changes in inflammatory mediators in the lungs, measurements 
were made of the cytokine IL- 1 a and chemokine MCP -1. Both proteins were only 
detectable in infected BAL fluid and not in controls. Control lung homogenates 
contained 450 ± 208 pg/ml of IL -la and 100 ± 90 pg /ml of MCP -1. Due to assay 
limitations of space samples from each treatment group were randomly selected from 
2 experiments to assess. S. pneumoniae induced a significant (10 fold) increase in IL- 
1 a after 24 hours, which was not dose -dependent (Figure 3.10a). This increase was 
maintained at 72 hours (Figure 3.10b). Similarly, levels of MCP -1 also increased, by 
25 fold after 24 hours (Figure 3.11a), this increase being sustained until 72 hours 















Figure 3.1- Rat body weight 
Data expressed as a percentage of initial weight at Day O. 
Dl: Control, D39 106, 107, 108, 109 
After 24 hours weight decreased in a dose -dependent manner, significant at doses of 108 and 109 
bacteria. 
Kruskall -Wallis p < 0.0001 
Dunns post -test Control vs D39 108 * ** p < 0.001 
Control vs D39 109 * ** p <0.001 
D39 106 vs D39 108 ** p<0.01 
D39 106 vs D39 109 * ** p < 0.001 
D39 10' vs D39 109 ** p < 0.01 
D2: Control, D39 108,109 
After 48 hours differences between groups were still significant (Kruskal -Wallis p = 0.0302) 
D3: Control, D39 108, 109 
After 72 hours differences between groups were still significant (Kruskal -Wallis p < 0.0047) 
D5 -21: Control, D39 108 
By 5 -21 days the differences between groups were not significant 
Sample Numbers 
Time point PBS D39 106 D39 10' D39 108 D39 109 
Dl 26 5 6 21 18 
D2 3 - - 3 4 
D3 8 - - 6 6 
D5 -8 3 - - 7 - 
D10 -14 3 - - 8 - 
D 15 -21 5 - - 12 - 
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Figure 3.2 -H &E of rat lung 
Original magnification x 10. Scale bars are 100µm 
A. Normal airways and lung architecture 
B. S. pneumoniae 108 cfu at 24 hours 
RBCs and inflammatory cells in airways 
C. S. pneumoniae 108 cfu at 72 hours 
Inflammatory cells in airways and thickened alveolar walls 
D. S. pneumoniae 108 cfu at 21 days 
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Figure 3.3 - CFU recovered from lungs 
Data expressed as total cfu shown on a log scale 
Bars are Instillation cfu, BAL fluid cfu and Lung tissue cfu 
Samples in each treatment group are taken from at least 3 separate 
experiments 
A. 24 hour dose response 
There were no significant differences between S. pneumoniae dosage groups 
after 24 hours (red). 
D39106n= 5 ,D39107n= 3,D39108n= 10,D39109n =5 
B. 24 hours vs 72 hours (109 cfu) 
Data expressed for 24 hours is the same as that presented in Figure A (red). 
24 and 72 hour infected groups were treated during separate experiments. 
Although the trend was for less bacterial recovery at 72 hours (blue), there 
were no significant differences between 24 hours (red) and 72 hours (blue), 
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Figure 3.4 - Number of leukocytes in BAL fluid 
Data expressed as number of cells per ml of BAL fluid shown on a log scale 
Samples in each treatment group are taken from at least 3 separate 
experiments 
A. 24 hour dose response 
S. pneumoniae induced a dose -dependent increase in BAL leukocytes after 24 
hours (red), significant at all inoculation levels. 
Transformed (Log) ANOVA p < 0.0001 
Tukey post -test Control vs D39 106 * ** p < 0.001 
Control vs D39 107 * ** p < 0.001 
Control vs D39 108 * ** p < 0.001 
Control vs D39 109 * ** p < 0.001 
D39 106 vs D39 108 * ** p < 0.001 
D39 106 vs D39 109 * ** p < 0.001 
Control n = 9,D39106n =5,D39 107n =4,D39 108n= 10,D39 109n = 5 
B. 24 hours vs 72 hours (Control + 109 cfu) 
Data expressed for 24 hours is the same as that presented in Figure A (red). 
24 and 72 hour infected groups were treated during separate experiments. 
The number of BAL fluid leukoytes recovered after 72 hours (blue) was lower 
than at 24 hours (red) but higher than in Controls. Differences between groups 
were significant (Kruskall- Wallis p = 0.0002) but only at 24 hours (see A) 
There was no significant difference between 24 and 72 hours controls. 
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Figure 3.5 - Differential leukocyte count in BAL fluid 
Data expressed as percentage macrophages and neutrophils. Percentage of 
other leukocytes <1 %. 
Samples in each treatment group are taken from at least 3 separate experiments 
A. 24 hour dose response 
There was a significant difference between percentage macrophages and neutrophils in all 
groups after 24 hours (red). S. pneumoniae induced a significant increase in the ratio of 
macrophages:neutrophils compared to controls. This was not dose -dependent. There were no 
differences between S. pneumoniae -infected groups. 
ANOVA p < 0.0001 
Tukey post -test All groups: 
Neutrophils vs macrophages * ** p < 0.001 
Neutrophils: 
Controls vs all D39 groups * ** p < 0.001 
Macrophages: 
Control vs all D39 groups * ** p < 0.001 
Control n = 9, D39 106n =5,D39 107n =4,D39 108n= 10, D39 109n = 5 
B. 24 hours vs 72 hours (Control + 109 cfu) 
Data expressed for 24 hours is the same as that presented in Figure A (red). 24 and 72 
hour infected groups were treated during separate experiments. 
The ratio of macrophages : neutrophils significantly decreased at 72 hours (blue) compared to 
24 hours (red), however it was still significantly higher than controls. There was no significant 
difference between 24 and 72 hours controls. 
ANOVA p < 0.0001 
Tukey post -test Macrophages and Neutrophils 
All Controls vs D39 72 hours ** p < 0.01 
D39 24 hours vs D39 72 hours * ** p < 0.001 
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Figure 3.6 - Protein concentration in BAL fluid 
Data expressed as protein (mg) per ml BAL fluid 
Samples in each treatment group are taken from at least 3 separate experiments 
A. 24 hour dose response 
S pneumoniae induced a dose -dependent increase in BAL fluid protein after 24 hours 
(red) which was significant at all inoculation levels. 
Transformed (Log) ANOVA p < 0.0001 
Tukey post -test Control vs D39 106 * ** p < 0.001 
Control vs D39 107 * ** p< 0.001 
Control vs D39 108 * * * p< 0.001 
Control vs D39 109 * ** p< 0.001 
D39 106 vs D39 109 * ** p <0.001 
D39 107 vs D39 109 * p < 0.05 
D39 108 vs D39 109 ** p < 0.01 
Control n = 11, D39 106n = 5, D39 107n = 4, D39 108n = 10, D39 109n = 5 
B. 24 hour vs 72 hours (Control + 109 cfu) 
Data expressed for 24 hours is the same as that presented in Figure A (red). 24 and 
72 hour infected groups were treated during separate experiments. 
S. pneumoniae still induced a significant increase in BAL fluid protein after 72 hours 
(blue) compared to controls (black), although values were significantly lower that those 
at 24 hours (red). 
There was no significant difference between 24 and 72 hours controls. 
Transformed (Log) ANOVA p < 0.0001 
Tukey post -test All Controls vs D39 72 hours * ** p < 0.001 
D3924hoursysD3972hours * ** p <0.001 
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Figure 3.7 - Number of leukocytes in pleural lavage fluid shown on a log scale 
Data expressed as number of cells per ml pleural lavage fluid 
Samples in each treatment group are taken from at least 3 separate 
experiments 
A. 24 hour dose response 
There was no significant difference in the number of pleural lavage fluid leukocytes 
between control and S. pneumoniae -infected samples after 24 hours (red) 
Controln= 8,D39108n =6,D39 109n =5 
B. 24 hours vs 72 hours (Control + 109 cfu) 
Data expressed for 24 hours is the same as that presented in Figure A (red). 
24 and 72 hour infected groups were treated during separate experiments. 
There was no significant difference in the number of pleural lavage fluid leukocytes 
between 24 (red) and 72 (blue) hours. 
There was no significant difference between 24 and 72 hours controls. 
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Figure 3.8 - Differential leukocyte count in pleural lavage fluid 
Data expressed as percentage macrophages, neutrophils, mast cells and eosinophils. 
Percentage of other leukocytes <1 %. 
Samples in each treatment group are taken from at least 3 separate 
experiments 
A . 24 hour dose response 
S. pneumoniae induced a significant, dose -dependent increase in percentage neutrophils in 
pleural lavage fluid after 24 hours (red), as well as a significant decrease in the percentage 
of macrophages. There were no differences in 
proportions of eosinophils or mast cells. 
Neutrophils: 
Transformed (Log) ANOVA p = 0.0034 
Tukey post -test Control vs D39 108= ** p < 0.01 
Control vs D39 109= * p < 0.05 
Macrophages: 
Kruskall- Wallis p = 0.0068 
Dunns post -test Control vs D39 108= * p < 0.05 
Control n = 8, D39 108 n = 6, D39 109 n = 5 
B. 24 hours vs 72 hours (Control + 109 cfu) 
Data expressed for 24 hours is the same as that presented in Figure A (red). 
24 and 72 hour infected groups were treated during separate experiments. 
The percentage of neutrophils in pleural lavage decreased between 24 (red) and 72 
(blue) hours, although the latter value was still higher than controls there was no significant 
difference between groups. The percentage of macrophages increased to control levels by 
72 hours (blue) but was not significantly different from 24 hours (red). There were no 
differences between percentages of eosinophils and mast cells. 
There was no significant difference between 24 and 72 hours controls. 
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Figure 3.9 - Protein concentration in pleural lavage fluid 
Data expressed as protein (mg) per ml pleural lavage fluid 
Samples in each treatment group are taken from at least 3 separate 
experiments 
A. 24 hour dose response 
Although pleural lavage fluid protein appears to decrease with S. pneumoniae 
infection, there was no significant difference between groups after 24 hours (red). 
Control n = 10, D39 108 n = 6, D39 109n = 5 
B. 24 hours vs 72 hours (Control + 109 cfu) 
Data expressed for 24 hours is the same as that presented in Figure A (red). 
24 and 72 hour infected groups were treated during separate experiments. 
Asterisk shows significance between S. pneumoniae groups at 24 and 72 hours 
Protein in pleural lavage fluid appears to increase with S. pneumoniae infection 
after 72 hours (blue) and is significantly higher than at 24 hours (red). However, 
control values at 72 hours (blue) are also lower than those at 24 hours (red). 
Transformed (Log) ANOVA p = 0.317 
Tukey post -test D39 24 hours vs D39 72 hours * p < 0.05 
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Figure 3.10 - IL -la in lung tissue 
Data expressed per mg lung protein and presented as a percentage of control 
Samples in each treatment group are taken from 2 separate experiments 
A. 24 hour dose response 
S. pneumoniae induced a significant increase in IL -1 a in lung tissue after 24 hours 
(red), which was not dose -dependent. 
ANOVA Transformed (Log) p < 0.0001 
Tukey post -test Control vs D39 108 * ** p < 0.001 
Control vs D39 109 * ** p < 0.001 
Control n = 4, D39 108 n = 4, D39 109n = 4 
B. 24 hours vs 72 hours (Control + 109 cfu) 
Data expressed for 24 hours is the same as that presented in Figure A (red). 
24 and 72 hour infected groups were treated during separate experiments. 
S. pneumoniae continued to induce a significant increase in IL -1 a after 72 hours 
(blue) compared with controls (black). Although levels did increase, there was no 
significant difference between 24 hours (red) and 72 hours (blue). 
Kruskall- Wallis p = 0.009 
Dunns post -test Control vs D39 72 hours * p < 0.05 
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Figure 3.11- MCP -1 in lung tissue 
Data expressed per mg lung protein and presented as a percentage of control 
Samples in each treatment group are taken from 2 separate experiments 
A. 24 hour dose response 
S. pneumoniae induced a significant increase in MCP -1 in lung tissue after 24 hours 
(red), which was not dose -dependent. 
Transformed (Log) ANOVA p < 0.0001 
Tukey post -test Control vs D39 108 * * * p < 0.001 
Control vs D39 109 * ** p < 0.001 
Control n= 4, D39 108 n = 4, D39 109 n = 4 
"B. 24 hours vs 72 hours (Control + 109 cfu) 
Data expressed for 24 hours is the same as that presented in Figure A (red). 
24 and 72 hour infected groups were treated during separate experiments. 
S. pneumoniae continued to induce a significant increase in MCP -1 after 72 hours 
(blue) compared to controls (black). There was no significant difference between 
24 hours (red) and 72 hours (blue). 
Transformed (Log) ANOVA p < 0.0001 
Tukey post -test Control vs D39 72 hours * ** p < 0.001 
Control n = 4, D39 24 hours n = 4, D39 72 hours n = 4 
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3.4.1.9 Summary and Conclusions 
A recovering model of pneumococcal pneumonia was set up at the acute (24 
hours), resolving (72 hours) and recovering (21 days) phases 
Rats showed a decrease in body weight which recovered over time 
The model was characterised by progressive bacterial clearance 
The model demonstrated an acute neutrophilic response in the airways, air - 
blood barrier damage, and some evidence of inflammation in the pleural 
space, all of which started to resolve by 72 hours 
The model demonstrated an increase in pro -inflammatory IL-1 a and MCP -1 
by 24 hours which was maintained up to 72 hours 
The purpose of this section was to establish a recovering model of S. pneumoniae- 
induced pneumonia. This was characterised by histological evidence of consolidation, 
resolution and recovery from 24 hours, 72 hours and 3 weeks. Experimental animals 
demonstrated a loss of body weight suggesting a detrimental effect on health that 
improved over time. Bacteria did not actively grow in the lungs in this model. Even 
at the acute phase (24 hours) bacterial clearance was apparent, with further clearance 
at 72 hours, despite bacterial dissemination into the blood and pleural space in a few 
individuals. The pneumonia model was also characterised by an acute neutrophilic 
inflammatory response in the airways, with some evidence of neutrophilia in the 
pleural space, and stimulation of production of pro -inflammatory cytokines. By 72 
hours the inflammatory response is attenuated indicating resolution, however the 
maintenance of high levels of cytokines at this time point suggests further mediation 
of inflammation at this time point. Damage to the air -blood barrier was also apparent 
at 24 hours, with decreased protein levels in BAL fluid at 72 hours indicating the 
initiation of repair. 
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3.4.2 ATI Cell Injury 
3.4.2.1 Aim 
To assess damage to ATI cells in the S. pneumoniae- induced pneumonia model. 
3.4.2.2 Assessment of RTI40 
In order to quantify injury to ATI cells, assessment of the ATI cell- specific protein 
RTI40 was carried out in BAL fluid and lung tissue. This is a technique that has been 
widely used by the author (McElroy et al., 2002; Tyrrell et al., 2005) and others 
(McElroy et al., 1995; McElroy et al., 1997b; McElroy et al., 1997a; McElroy et al., 
1999) both as a measure of ATI cell -specific injury (analysis of BAL fluid) and as 
representative of the ATI cell population in the lung (analysis of lung tissue). The 
principle of the BAL fluid analysis is dependent on the membrane -associated nature 
of the RTI40 protein. During normal turnover in healthy lungs a basal amount of this 
protein is present in the airways. However, during lung injury, if ATI cells are 
damaged they break apart or detach from the basement membrane. As a consequence 
there is an increase in RTI40 in the airways, which can be sampled by biochemical 
analysis of BAL fluid in an ELISA -based dot blot. Assessment of the protein in lung 
tissue provides information about changes in the ATI cell population in the lung 
during injury. Due to assay limitations of space samples from each treatment group 
were randomly selected from 2 experiments to assess. 
Using the RTI40 antibody, it was demonstrated that S. pneumoniae induced a 
significant decrease in detectable RTI40 in both BAL fluid and lung tissue after 24 
hours (Figure 3.12a). This effect was unexpected and dose dependent in lung tissue. 
Having established that this model allows for resolution and recovery of animals, 
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implying that ATI cells are not completely destroyed, this result indicates that this 
method of BAL fluid RTI40 analysis is not an appropriate marker of ATI cell injury 
in this model. Furthermore these results suggest that regulation of RTI40 levels occurs 
in this model of infection. By 72 hours, levels of RTI40 in lungs were significantly 
higher than at 24 hours, although still 60% less than in controls (Figure 3.12b). To 
further investigate this phenomenon samples from the time point at 24 hours were run 
on a Western blot, which demonstrated total loss of RTI40 reactivity (Figure 3.12c). 
To determine whether the decrease in RTI40 was due to alteration of the epitope 
recognised by the monoclonal antibody, BAL fluid and lung samples from the 24 hour 
time point were assessed by direct ELISA using the El1 antibody. This antibody is 
thought to recognise another epitope not on the core protein, unlike the original RTI40 
antibody (Williams et al., 1996). This produced similar results in both BAL fluid and 
lung tissue (Figure 3.12d). 
3.4.2.3 Assessment of MMC6 
In order to further investigate damage to ATI cells, assessment of the ATI cell - 
specific MMC6 protein was carried out on BAL fluid and lung tissue. Like RTI40, 
MMC6 protein is a membrane - associated antigen and has been shown in an ELISA- 
based dot blot to reflect RTI40 levels in BAL fluid, demonstrating injury to ATI cells 
in models of staphylococcal pneumonia and haemorrhagic shock (McKechnie, 2008). 
Due to assay limitations of space samples from each treatment group were randomly 
selected from 2 experiments to assess 
In contrast to the RTI40 data, S. pneumoniae induced a significant (2 -3 fold) increase 
in MMC6 in BAL fluid after 24 hours, which was dose dependent. There were no 
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significant differences in levels in lung tissue (Figure 3.13a). However, after 72 hours 
the significant increase in BAL fluid was maintained (Figure 3.13b). 
In order to further investigate differential expression of RTI40 and MMC6 proteins 
and injury to ATI cells in this model, frozen sections of tissue were stained for both 
RTI40 and MMC6. Gross differences in protein expressed by immunofluorescence 
were assessed by eye but were not quantified. Figure 3.14a shows a control section, 
with ATI cells co- expressing both RTI40 (green) and MMC6 (red). 24 hours after 
infection with S. pneumoniae, extensive loss of reactivity to RTI40 was observed. 
Much of the epithelium is still stained with MMC6, although some slight decrease in 
expression was observed, (Figure 3.14b). By 72 hours RTI40 staining of the 
epithelium is still reduced (Figure 3.14c). Figure 3.15 shows that after 72 hours, those 
sections of the epithelium not stained with MMC6 (blue) are stained with ATII cell - 
specific marker APN /MMC4 (red). It is also worth noting that APN /MMC4 stained 
cells present in the airways are more likely to be macrophages than sloughed ATII 
cells at this time point, however additional ATII cell or macrophage markers were not 
used to confirm this. 
3.4.2.4 Assessment of Aquaporin 5 
To further investigate differential protein expression and injury in ATI cells, analysis 
of Aquaporin 5 was carried out. Aquaporin 5 is another membrane -associated protein 
expressed on the surface of ATI cells and has been used in conjunction with RTI40 as 
a marker of ATI cells (Tyrrell et al., 2005). The amount of Aquaporin 5 in BAL fluid 
was below the detection level of the Western blot so only lung tissue was assessed. 
Due to assay limitations of space samples from each treatment group were randomly 
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selected from 2 experiments to assess. Although at the highest inoculation level there 
was a slight decrease in Aquaporin 5, there was no significant difference between S. 
pneumoniae- infected lung tissue and control (Figure 3.16a). At the 108 cfu dose 
Aquaporin 5 appears to increase, although Figure 3.16b demonstrates that this is in 
fact due to a solitary outlier and should not therefore necessarily be considered 
different from control. After 72 hours, levels of Aquaporin 5 in rats inoculated with 
109 cfu were beginning to increase again, although they were not significantly 
different (Figure 3.16c). Despite the fact that assessment of BAL fluid was not 
possible, lung data for Aquaporin 5 appear to correlate with those for MMC6. 
3.4.2.5 Morphological Assessment 
Given that biochemical methods of assessing ATI cell injury were proving 
inconclusive in this model, a morphological analysis by EM was carried out on lung 
tissue at 24 hours. There was no evidence of ATI cell damage and the cells looked 
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Figure 3.12 - RTI40 in BAL fluid and lung tissue 
Samples in each treatment group are taken from 2 separate experiments 
A. 24 hour dose response (BAL/ Lung) 
Data expressed per ml BAL fluid or per mg lung protein and presented as 
percentage of control 
S. pneumoniae induced a significant decrease in RTI40 in both BAL fluid and 
lung tissue after 24 hours (red). 
BAL fluid: Transformed (Log) ANOVA p = 0.008 
Tukey post -test Control vs D39 108 * p < 0.05 
Control vs D39 109 * p < 0.05 
Control n = 4, D39 108n =7,D39 109n =5 
Lung tissue: Kruskal-Wallis p < 0.0001 
Dunns post -test Control vs D39 109 * p < 0.01 
Control n = 3, D39 108n = 7, D39 109n = 5 
B. 24 hours vs 72 hours - Lung only (Control + 109 cfu) 
Data expressed per mg lung protein as percentage of control 
Data expressed for 24 hours is representative of that presented in Figure A 
(red). 
24 and 72 hour infected groups were treated during separate experiments. 
S. pneumoniae still induced a significant decrease in RTI40 in lung tissue at 72 
hours (blue) compared to control (black), however levels were also 
significantly higher than at 24 hours (red). 
ANOVA p < 0.0001 
Tukey post -test Control vs D39 72 hours * ** p< 0.001 
D39 24 hours vs D39 72 hours * p < 0.05 
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D. E11 antigen in BALI Lung at 24 hours 
Data expressed as per ml BAL fluid or per mg lung protein as percentage 
of control 
Samples in each treatment group are taken from 2 separate experiments 
S. pneumoniae induced a significant decrease in Ell antigen in both BAL 
fluid and lung tissue after 24 hours (red). 
BAL fluid: Unpaired t test Control vs D39 108 * ** p = 0.0008 
Lung tissue: Unpaired t test Control vs D39 108 ** p = 0.0019 
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Figure 3.13 - MMC6 in BAL fluid and lung tissue 
Data expressed per ml BAL fluid or per mg lung protein and presented as 
a percentage of control 
Samples in each treatment group are taken from 2 separate experiments 
A. 24 hour dose response 
S. pneumoniae induced a significant increase in M1VIC6 in BAL fluid after 24 
hours which was dose -dependent. There was also a decrease in MMC6 in lung 
tissue but this was not significant. 
BAL fluid: Transformed (Log) ANOVA p < 0.0001 
Tukey post -test Control vs D39 108 * ** p < 0.001 
Control vs D39 109 * * * p < 0.001 
Control n = 4, D39 108 n = 7, D39 109n = 5 
B. 24 hours vs 72 hours (Control + 109 cfu) 
Data expressed for 24 hours is representative of that presented in Figure A 
(red). 
24 and 72 hour infected groups were treated during separate experiments. 
S. pneumoniae still induced a significant increase in MMC6 in BAL fluid after 
72 hours (blue) compared to controls (black). There was no difference in 
MMC6 levels between 24 hours (red) and 72 hours (blue). There was no 
difference between groups in MMC6 in lung tissue. 
BAL fluid: Kruskal- Wallis p = 0.0062 
Dunns post -test Control vs D39 72 hours * p < 0.05 





Figure 3.14 - Immunofluorescence staining of rat lung 
Original magnification x63 
Sections stained with RT140 (green) and MMC6 (red) with nuclear stain To -Pro -3 
(blue) 
A.Control 
Arrow shows both RTI40 and MMC6 co- expressed on the surface of ATI cells 
B.S. pneumoniae (109 cfu) at 24 hours 
Extensive loss of RTI40 expression. Arrow shows areas of alveolar epithelium stained with 
MMC6 only. Some small sections are still stained with both RTI40 and MMC6 
C. S. pneumoniae at (109 cfu) 72 hours 
24 and 72 hour infected groups were treated during separate experiments. 
RTI40 loss maintained but recovering. Arrow shows areas of alveolar epithelium still stained with 
only MMC6. More staining of RTI40 is apparent than at 24 hours. 
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Figure 3.15 - Immunofluorescence staining of S. pneumoniae- infected rat lung 
Original magnificgtion x 63 
Sections stained with R1140 (green), MMC6 (blue) and APN/MMC4 (red) 
Image shows infected (109 cfu) lung after 72 hours. Arrow shows that most of the epithelium 
not stained with MMC6 is stained with APN /MMC4. Note that cells expressing APN /MMC4 
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Figure 3.16 - Aquaporin 5 in lung tissue 
Data expressed per mg lung protein and presented as a percentage of 
control 
Samples in each treatment group are taken from 2 separate experiments 
A. 24 hour dose response (showing individual data points) 
S. pneumoniae did not induce a significant change in Aquaporin 5 in lung 
tissue after 24 hours (red). The increase in Aquaporin 5 at the 108 dose was 
due to one outlier. 
Controln =3,D39 108n =3,D39 109n =3. 
B. 24 hours vs 72 hours (Control + 109 cfu) 
Data expressed for 24 hours is representative of that presented in Figure A 
(red). 
24 and 72 hour infected groups were treated during separate experiments. 
S. pneumoniae did not induce a significant difference in Aquaporin 5 in lung 
tissue after 72 hours (blue) compared to controls (black), nor was there any 
difference between 24 hours (red) and 72 hours (blue). 
Control n = 3, D39 24 hours n = 3, D39 72 hours n = 3 
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Figure 3.17 - EM of S. pneumoniae- infected (108 cfu) rat lungs 
at 24 hours 
Original magnification x 3,000 
Image shows a healthy ATI cell 
Arrows indicate lung ultrastructure such as RBC, ATI 
basement membrane (BM) and capillary endothelium (CE) 
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3.4.2.4 Summary and Conclusions 
S. pneumoniae induced a pronounced decrease in RTI40 protein in BAL fluid 
and lung tissue by 24 hours, shown biochemically and by 
immunofluorescence, which was starting to normalise by 72 hours 
The decrease in RTI40 at 24 hours was shown biochemically with two 
different antibodies against the protein 
S. pneumoniae induced an increase in MMC6 in BAL fluid after both 24 and 
72 hours 
There was no significant decrease in MMC6 or Aquaporin 5 in lung tissue 
There was no morphological evidence of injury to ATI cells 
In summary, it was established that infection with S. pneumoniae induced a 
significant decrease in RTI40 in both BAL fluid and lung tissue after 24 hours. One 
possible explanation of this phenomenon is the wide -scale destruction of ATI cells. 
However, the fact that experimental animals were still alive at 24 hours and went on 
to recover fully from the infection suggests that this is not the case. Furthermore, 
levels of protein in BAL fluid were not consistent with a high degree of lung injury. 
In addition, immunofluorescence staining on infected lung tissue, which showed a 
loss of RTI40 staining without a corresponding decrease in MMC6, suggests the 
continued presence of the ATI cell population. The lack of a significant decrease in 
MMC6 and Aquaporin 5 levels in lung tissue also supports this idea. It was possible 
that the decrease in RTI40 was due to a loss of antibody reactivity against the protein. 
However, the effect was detected biochemically using two separate antibodies against 
the RTI40 protein, thought to bind to different epitopes. These data therefore suggest 
that S. pneumoniae induces a specific decrease in RTI40 protein that differs from that 
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of other ATI cell- specific proteins. The subsequent increase in RTI40 expression 
suggests that this effect may be reversible following resolution, and the full recovery 
of animals after 72 hours implies that the decrease in RTI40 expression does not 
appear to adversely affect resolution of the disease. These data also indicate that the 
method of RTI40 assessment in BAL fluid as previously used is not representative of 
damage to ATI cells in this in this model of lung injury RTI40. 
An increase of MMC6 in BAL fluid after 24 hours of infection implied that damage to 
ATI cells was taking place. However, the maintenance of this increase at 72 hours, 
despite other indications of resolution at that time point, makes this data difficult to 
interpret, and gives rise to two possibilities. Firstly, that the increase of MMC6 in 
BAL fluid at 72 hours reflects continued injury to ATI cells, and in spite of 
progressive clearance of bacteria, attenuation of inflammation and repair of the air - 
blood barrier, further damage to ATI cells is occurring, although the lack of 
morphological evidence of injury at 24 hours does not support this. The alternative is 
that S. pneumoniae induces shedding of MMC6 that is independent of ATI cell injury. 
Although MMC6 is thought to be an integral membrane protein, the lack of 
knowledge about its structure and function suggests that this could indeed be a 
possibility. 
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3.4.3 ATII /Clara Cell Injury 
3.4.3.1 Aim 
To assess damage to ATII and Clara cells in the S. pneumoniae- induced pneumonia 
model 
3.4.3.2 Rationale 
Unlike ATI cells, there is no established method of quantifying damage to ATII cells. 
This would provide valuable information about disease pathogenesis and if used in 
conjunction with ATI cell injury markers could enable investigation into targeted 
injury and differential damage to alveolar epithelial cells, perhaps with a view to 
treatment design. 
3.4.3.3 Evidence of ATII Cell Injury 
In order to determine whether there was any morphological evidence of injury to ATII 
cells in this model of S. pneumoniae- induced infection EM was carried out on S. 
pneumoniae -infected (108 cfu) lung tissue after 24 hours. Figure 3.18a shows a 
normal ATII cell, with characteristic microvilli and lamellar bodies, firmly embedded 
in the basement membrane of the lung. Figure 3.18b however, representative of a 
number of cells observed in infected tissue, shows an ATII cell that is sloughing away 
from the basement membrane. This data suggests injury to ATII cells in S. 
pneumoniae -induced pneumonia. 
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3.4.3.4 Quantification of ATII Cell Injury 
3.4.3.4.1 Rationale 
This thesis describes biochemical and morphological techniques to quantify injury to 
ATII cells. In particular it describes a novel morphological immunofluorescence 
method of ATII cell injury quantification, using monoclonal antibodies against ATII 
cell- specific proteins on lung sections. 
3.4.3.4.2 Immunofluorescence Quantification 
Control and S. pneumoniae- infected frozen lung sections were stained for 2 proteins; 
RTII70, a membrane -associated protein restricted to rat ATII cells (Dobbs et al., 
1998); and APN/MMC4, a membrane -associated protein on the surface of rat ATII 
cells, Clara cells and macrophages (Franklin, 2006). Membrane co- localisation of 
these proteins was used as the principle of ATII cell identification in this technique, 
with cell type confirmation obtained by triple staining with the addition of a 
polyclonal antibody against Pro -SP -C, an ATII cell specific cytoplasmic precursor 
protein to surfactant protein SP -C (Beers et al., 1992). Stained sections were viewed 
by confocal microscopy under x40 magnification. Four areas of approximately 1mm2 
(0.85mm2) from each section were randomly selected and scanned using a tiling 
system. All morphologically damaged cells stained with RTII70 and APN /MMC4 
were counted in each scanned tile. Damaged cells were considered to be completely 
detached from the epithelium into the airspace or cells which appeared to be in the 
process of sloughing off from the basement membrane. Figure 3.19a shows a normal 
ATII cell double stained with RTH70 (green) and APN (red). The two proteins are co- 
localised on the apical membrane of the cell. Figure 3.19b demonstrates morphology 
that was considered to be `sloughing', with the ATII cell detaching from the basement 
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membrane. Confirmation of the identity of these sloughing cells by triple staining 
with the addition of Pro -SP -C (blue), staining the cytoplasm of cells already labelled 
with RTII70 and APN is shown in Figure 3.19c. 
Figure 3.19d shows the results of this quantification, and demonstrates that at 24 
hours there were significantly more sloughing cells than controls. Between 24 and 72 
hours the numbers further decreased, but levels were not significantly different from 
those either in controls or at 24 hours. 
3.4.3.4.2 Biochemical Quantification 
To further investigate injury to ATII cells and determine if it was possible to detect 
and quantify damage to ATII cells biochemically, other ATII cell- specific proteins 
were used. Unfortunately neither blotting nor direct ELISA techniques worked using 
the RTII70 antibody. Due to assay limitations of space samples from each treatment 
group were randomly selected from 2 experiments to assess. 
3.43.4.2.1 Assessment of Pro -SP -C 
Levels of Pro -SP -C in BAL fluid were below the detection sensitivity of Western 
blotting so only lung tissue was analysed. Unfortunately, due to subsequent technical 
difficulties with the Pro -SP -C antibody on Western blots, it was only possible to 
assess samples from the 24 hours time point biochemically. S. pneumoniae induced a 
significant (16 fold) decrease in Pro -SP -C in lung tissue at the highest dosage after 24 
hours (Figure 3.20a). In order to determine whether this was representative of a 
reduction in the ATII cell population or decreased protein expression, 
immunofluoresence staining of Pro -SP -C in conjunction with 2 other ATII cell- 
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specific proteins, RTII70 and APN /MMC4 was carried out on lung tissue. Control 
lung (Figure 3.20b) showed relatively low expression of Pro -SP -C in the cytoplasm of 
RTII70 and APN /MMC4- positive ATII cells, as expected. 24 hours after instillation 
of S. pneumoniae however, staining intensity did not appear to be different to that of 
controls, nor did there appear to be an obvious decrease in the ATII cell population. 
Indeed there seemed to be an increase in the number of Pro -SP- 
C/RTII70/APN/MMC4- positive cells overall at both 24 hours (Figure 20b) and 72 
hours (Figure 20c). This is discussed on p129 -130. 
3.4.3.4.2.2 Assessment of SP -D 
SP -D is a surfactant protein secreted by both ATII and Clara cells. To determine 
whether S. pneumoniae infection affected cell function or the production of SP -D 
indicative of cell- specific damage, biochemical analysis of SP -D on BAL fluid and 
lung tissue was carried out. 
Control levels of SP -D in both BAL fluid and lung tissue were about 250- 350ng/ml, 
as assessed against a standard curve of recombinant rat SP -D, kindly provided by 
Erica Crouch, Washington University, St Louis. Infection with S. pneumoniae 
induced a significant dose -dependent increase in the protein in BAL fluid, as much as 
6 -fold more than controls at the highest inoculation level, after 24 hours. SP -D in lung 
tissue was higher in infected rats than controls, but this was not significant (Figure 
3.21a). After 72 hours, levels significantly increased even further than at 24 hours. 
SP -D in BAL fluid was 8 -fold higher than controls, although the difference between 
24 and 72 hours was not significant. The increase of SP -D in lung tissue was 
particularly pronounced, showing up to 43 -fold more than controls (Figure 3.21b). 
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Although the values were highly variable, Figure 3.21c shows that they were 
consistently higher than at 24 hours. 
3.43.4.2.3 Assessment of APN /MMC4 
In order to further investigate biochemical methods of injury assessment in ATII cells, 
ELISA -based dot blot analysis was carried out on BAL fluid and lung tissue using a 
monoclonal antibody against rat APN /MMC4 (found on ATII, Clara cells and 
macrophages). Despite the protein's expression on alveolar macrophages, previous 
work has shown that levels of APN/MMC4 in BAL fluid vary between models of 
wildtype and mutant S. aureus - induced pneumonia, despite an equivalent 
inflammatory response (Franklin, 2006). This has suggested that APN/MMC4 might 
still be used as a preliminary screen for ATII and Clara cell injury to identify rat 
models warranting further investigation. As the current model of pneumococcal 
pneumonia has established and quantified injury to ATII cells, it was decided that this 
system would be a good opportunity to test the APN/MMC4 assessment technique. 
The most pronounced damage to ATII cells was at 24 hours, so this time point was 
selected to investigate further. Figure 3.22 shows that S. pneumoniae induced a 
significant, dose -dependent increase in APN/MMC4 in BAL fluid, with no particular 




3.4.3.5 Assessment of Clara Cell Injury 
3.4.3.5.1 Assessment of CC10 
Measurement of Clara cell- specific protein CC10 in BAL fluid and serum has been 
used as a measure of air -blood barrier permeability and Clara cell damage (Section 
1.4.4.1 CC10). Assessment of CC10 in rat BAL fluid and serum was kindly carried 
out by A. Bernard, Catholic University of Louvain, using an automated latex 
immunoassay (Halatek et al., 1998). Control levels in BAL fluid were 3785 ±698ng /ml 
and 31 ±8ng/ml in serum. Figure 3.23 demonstrates that instillation of S. pneumoniae 
induced a significant 2 -fold decrease in CC10 in BAL fluid and a similar increase in 
serum. 
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A - Normal ATII cell B - Sloughing ATII cell 
Figure 3.18 - EM of S. pneumoniae (108 cfu) infected lungs at 24 hours 
A. Normal ATII cell 
Original magnification x 10,000 
Arrows show normal ATII cell with characteristic microvilli (MV) 
and lamellar bodies (LB), attached to basement membrane 
B. Sloughing ATII cell 
Original magnification x 8,000 







Figure 3.19 - Quantification of ATH cell sloughing in S. pneumoniae -infeced rat lungs (109 du) 
Samples in each treatment group are taken from 2 separate experiments 
A. Double immunofluorescence staining of normal ATII cell stained for membrane proteins RT1170 (green) and 
APN/MMC4 (red) with nuclear stain To -Pro -3 (blue). 
Original magnification x 40. 
Shows normal ATII cell co- expressing RTII70 and APN /MMC4 (yellow). 
B. Double immunofluorescence staining of sloughing ATII cell 
Stained for membrane proteins RT1170 (green) and APN (red) with nuclear stain To -Pro -3 (blue). 
Original magnification x 40. 
Shows cell coexpressing RTII70 and APN /MMC4 sloughing off from basement membrane. 
C. Triple immunofluorescence staining of sloughing ATH cell 
Stained for membrane proteins RT1170 (green), APN (red) and cytoplasmic protein Pro -SP -C (blue). 
Original magnification x63. 
Shows RTII70 and APN /MMC4- positive sloughing cell stained with Pro -SP -C. 
D. Sloughing ATII cells at 24 and 72 hours (Control + 109 cfu) 
Data expressed as number of sloughing cells 
24 and 72 hour infected groups were treated during separate experiments. 
S. pneumoniae induced a significant increase in the number of sloughing ATII cells after 24 hours (red) compared to 
controls (black). By 72 hours (blue) numbers were still elevated above controls (black) but below levels at 24 hours (red) 
and were not significantly different from either. 
Kruskal -Wallis p = 0.0139 
Dunes post -test Control vs D39 24 hours * p < 0.05 
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Figure 3.20 - Pro -SP -C in lung tissue 
A. 24 hour dose response 
S. pneumoniae induced a significant decrease in Pro -SP -C in lung tissue after 24 hours (red), which was 
roughly dose dependent. 
Kruskall- Wallis p = 0.0248 
Dorms post -test Control vs D39 109 p < 0.05 
Control n = 3, D39 108 n = 4, D39 109 n = 4 
B. Immunofluorescence of control lung tissue 
Stained for membrane proteins RTII70 (green), APN/MMC4 (red) and cytoplasmic protein Pro -SP -C (blue). 
Original magnification x 40 
Arrow shows staining of Pro -SP -C restricted to cytoplasm of RTII70 and APN /MMC4- positive ATII cells. 
C. Immunofluorescence of S. pneumoniae- infected tissue at 24 hours (109 cfu) 
Stained for membrane proteins RTIT70 (green), APN /MMC4 (red) and cytoplasmic protein Pro -SP -C (blue). 
Original magnification x 40 
Image shows Pro-SP -C restricted to RTII70 and APN /MMC4- positive cells. Staining intensity does not appear reduced. 
Arrow indicates the presence of an abundance of ATH cells. 
D. Immunofluorescence of S. pneumoniae- infected tissue at 72 hours (109 cfu) 
Stained for membrane proteins RTI 70 (green), APN /MMC4 (red) and cytoplasmic protein Pro -SP -C (blue). 
Original magnification x 4 
Image shows Pro -SP -C restricted to RTII70 and APN/MMC4- positive cells. Staining intensity does not appear reduced. 
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Figure 21- SP -D in BAL fluid and lung tissue 
Data expressed per ml BAL fluid or per mg lung protein as a percentage of control 
Samples in each treatment group are taken from 2 separate experiments 
A. 24 hour dose response 
S. pneumoniae induced a significant increase in SP -D in BAL fluid after 24 hours (red) which was dose -dependent. 
There was no significant increase in lung tissue. 
BAL fluid: ANOVA p = 0.001 
Tukey post -test Control vs D39108 * p < 0.05 
Control vs D39 109 ** p < 0.01 
Control n = 4, D39 108 n = 5, D39 109n = 5 
B. 24 hours vs 72 hours (Control + 109 cfu) 
Data expressed for 24 hours is representative of that presented in Figure A (red). 
24 and 72 hour infected groups were treated during separate experiments. 
S. pneumoniae still induced a significant increase in SP -D in BAL fluid after 72 hours (blue) compared to controls 
(black). There was also a particularly large increase in lung tissue after 72 hours (blue), however there was no 
significant difference between 24 hours (red) and 72 hours (blue) in BAL fluid or lung tissue 
BAL fluid: ANOVA p = 0.0028 
Tukey post -test Control vs D39 72 hours ** p < 0.01 
Control n = 4, D39 24 hours n = 4, D39 72 hours = 4 
Lung tissue: Kruskal -Wallis p = 0.0062 
Dunns post -test Control vs D39 72 hours * p < 0.05 
Control n = 3, D39 24 hours n = 4, D39 72 hours n = 4 
C. Individual values 24 vs 72 hours (lung tissue only) 
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Figure 3.22 - APN/MMC4 in BAL fluid and lung tissue at 24 hours 
Data expressed per ml BAL fluid or per mg lung protein and presented as 
a percentage of control 
Samples in each treatment group are taken from 2 separate experiments 
S. pneumoniae induced a significant increase in APN /MMC4 in BAL fluid 
after 24 hours which was dose -dependent. There was no difference in 
APN /MMC4 levels in lung tissue. 
BAL: ANOVA p = 0.0037 
Tukey post -test Control vs D39 108 * p < 0.05 
Control vs D39 109 ** p < 0.01 
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Figure 3.23 - CC10 in BAL fluid and serum at 24 hours 
Data expressed per ml BAL fluid or serum and presented as a percentage 
of control 
Samples in each treatment group are taken from 2 separate experiments 
S. pneumoniae induced a significant decrease in CC10 in BAL fluid and an 
increase in serum which was not dose -dependent. 
BAL fluid: ANOVA p = 0.0026 
Tukey post -test Control vs D39 108 ** p < 0.01 
Control vs D39 109 * p < 0.05 
Serum: ANOVA p = 0.0012 
Tukey post -test Control vs D39 108 
Control vs D39 109= 




p < 0.01 
p < 0.01 
3.43.6 Summary and Conclusions 
S. pneumoniae induces injury to ATII cells 
A novel method of immunofluorescence quantification of ATII cell injury was 
developed that demonstrated damage to ATII cells 24 hours after infection 
with S. pneumoniae which was resolving after 72 hours 
S. pneumoniae induced a decrease in Pro -SP -C in lung tissue by Western blot 
after 24 hours but this was not supported by immunofluorescence data 
S. pneumoniae induced an increase in SP -D in BAL fluid after 24 hours which 
was maintained at 72 hours, and an increase in lung tissue after 72 hours 
S. pneumoniae induced an increase in APN/MMC4 in BAL fluid after 24 
hours 
S. pneumoniae induced an increase in CC10 in serum but a decrease in BAL 
fluid 
The purpose of this section was to assess injury to ATII and Clara cells in the model 
of pneumococcal pneumonia. Having established the nature of this damage in the case 
of ATII cells as sloughing of cells away from the basement membrane into the 
airways, this was quantified using a novel method. Injury was detected at 24 hours 
and was shown to be resolving by 72 hours, suggesting that ATII cell damage was not 
adversely affecting the repair process. A biochemically demonstrated decrease in 
ATII cell- specific protein Pro -SP -C was observed. Although this was initially thought 
to be representative of a decrease in the ATII cell population following cell- specific 
injury, immunofluoresence data did not support this, suggesting that there was no 
evidence of decreased ATII cells or Pro -SP -C staining intensity at 24 or 72 hours. 
This implies that the biochemical decrease may be due to artefact of the blotting 
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process, the bacteria perhaps affecting the protein's ability to be degraded by SDS. 
Overall the data suggests that Pro -SP -C did not appear to be a good biochemical 
marker of the ATII cell population in this injury model, although the 
immunofluorescence data indicates that damage to the cells did not affect their 
proliferative capabilities. Surfactant- associated protein SP -D secretion, as measured in 
BAL fluid, was stimulated by infection with S. pneumoniae after 24 hours, although 
production, as measured in lung tissue, was more greatly increased after 72 hours. 
This implies the release of stored SP -D early on during infection, but in order to 
maintain this during the resolution phase, an increase in protein production is 
initiated. Furthermore, this data suggests that injury to ATII cells either does not 
adversely affect collectin production or that this is compensated for by Clara cells. 
Investigation of APN /MMC4 demonstrated an increase in the protein in BAL fluid 24 
hours after S. pneumoniae infection. While this result may be due to the increase in 
macrophages number during infection, it may also correspond to ATII cell injury at 
this time point. These data suggest that further investigation is required but 
APN /MMC4 may still be a candidate for preliminary screening of ATII /Clara cell 
damage in rat models of injury. Infection with S. pneumoniae induced a significant 
increase in levels of Clara cell- specific protein CC10 in serum and a corresponding 
decrease in BAL fluid. This data is consistent with damage to the air -blood barrier as 
CC10 from the airways leaks across into the bloodstream. Extensive injury or 
functional inhibition of Clara cells, would result in a decrease in CC10 in both BAL 
fluid and serum, due to loss of cells or a failure to produce the protein. This is not 
consistent with the data observed in this model. 
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3.4.4 Overall Conclusions 
The initial purpose of this chapter was to set up a series of acute, resolving and 
recovering models of pneumococcal pneumonia and investigate differential damage to 
ATI and ATII cells. These models showed acute inflammation and damage to the air - 
blood barrier that resolved over time leading to full recovery. Assessment of ATI cell 
injury demonstrated unexpected differential expression of ATI cell- specific proteins 
RTI40, MMC6 and Aquaporin 5 but no visible morphological evidence of specific 
cell damage. This included for the first time evidence of regulation of RTI40 protein 
expression. Injury to ATII cells was identified and quantified using a novel 
immunofluorescence method. Biochemical techniques of quantification were also 
evaluated, including the use of APN/MMC4 as a screen for ATII and Clara cell 
injury. Damage to ATII cell in this model did not appear to functionally inhibit the 
repair process. Infection with S. pneumoniae stimulated differential expression in 
surfactant- associated proteins SP -D and Pro -SP -C, with the identification of increased 




In Chapter 3 it was established that pneumococcal pneumonia induced visible ATII 
cell injury and differential expression of injury- associated cell- specific proteins in 
both ATI and ATII cells. In particular, the pronounced decrease in ATI expression of 
RTI40 compared to Aquaporin 5 and MMC6 (Section 3.4.2 ATI Cell Injury) was 
intriguing. Furthermore, a significant increase in surfactant protein SP -D in both BAL 
and lung tissue was observed, which differed markedly from expression of Pro -SP -C 
(Section 3.4.3 ATII Cell Injury). 
Bacteria can interact with host tissue in a huge variety of ways, some of which are 
mediated by species- specific virulence factors and some involve pathways that are 
common to other pathogens. Further investigation of the effects of these factors on the 
observations presented in Chapter 3 might provide valuable information about the 
mechanism underlying these results. It was therefore postulated that these effects 
might be mediated by the pneumococcal virulence factor pneumolysin, or be due to an 
effect common to Gram -positive bacteria. Comparison of the initial model of S. 
pneumoniae- induced lung injury with other models, induced by pneumolysin deficient 





Pneumolysin is an important virulence factor of S. pneumoniae and is responsible for 
a variety of pathological effects in the lung (Section 1.5.2.3.1 Pneumolysin). Thus it 
may modulate differential protein expression in pneumococcal pneumonia. 
4.2.2 Hypothesis 2.1 
Pneumococcal virulence factor pneumolysin mediates differential protein 
expression 
The aim of this section was to establish a model of pneumolysin- deficient 
pneumococcal pneumonia and to compare cell specific protein expression with the 
wildtype model. 
4.23 Methods 
The pneumolysin- deficient pneumonia model was set up as for the wildtype 
established in Chapter 3 (see Chapter 2 - Materials and Methods). An isogenic mutant 
of D39, PLN -A was used, which is deficient in both cytotoxic and complement - 
inducing functions of pneumolysin and is resistant to erythromycin (Berry et al., 
1989). In all experiments the identity of PLN -A was confirmed using erythromycin 
discs. Production of pneumolysin was tested in both wildtype and mutant bacteria by 
reduced Western blot using a mouse monoclonal antibody ([9.1/2/3/6]) against the 
recombinant protein (Abeam, Cambridge, UK), diluted 1:1000 and a Zymed ® goat 
anti -mouse IgG2b HRP secondary antibody (Invitrogen, Paisley, UK) diluted 1:2000. 
Bacterial cultures were harvested at late logarithmic /stationary phase, centrifuged to 
pellet bacteria and supernatant was collected. The bacterial pellet was then lysed 
138 
using RIPA buffer. See Chapter 2 (Materials and Methods) for detailed protocols. 
Samples of S. aureus strain 8325 -4 were used as negative controls. For the in vivo 
study the 24 -hour time point was selected for investigation, as this was when acute 
injury was detected and significant differences in expression of proteins specific to 
ATI and ATII cells was apparent in the wildtype infection (Chapter 3). Instillation 
doses of PLN -A at 106 (5.82x106 ± 2.91x106) and 108 (2.02x108 ± 7.03x107) cfu were 
comparable to those of the wildtype D39 (5.27x106 ± 1.34x106 and 1.8x108 ± 
1.61x108). Wildtype and pneumolysin- deficient bacteria were instilled during the 
same experiments. For technical reasons, due to problems with the antibodies, it was 
not possible to assess levels of Aquaporin 5 and Pro -SP -C in samples. The 
APN/MMC4 protein was used as a preliminary screen to determine if there was any 
potential mediation of ATII /Clara cell injury by pneumolysin. As in Chapter 3, all 
graphs show data generated as a result of at least 2 separate experiments. Graphs 
show means with SD error bars. Asterisks illustrate significant differences between 
experimental data and controls unless stated otherwise. Analyses of specific proteins 
are presented as a percentage of the mean control value. As with Chapter 3, assay 
limitations of space necessitated the random selection of samples from 2 separate 
experiments for specific protein analysis. 
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4.2.4 Results 
4.2.4.1 Basic Comparison of S. pneumoniae Wildtype and Pneumolysin- Deficient 
Models 
Figure 4.2.1 shows a Western blot confirming that the wildtype D39 produced 
pneumolysin but the mutant PLN -A does not. Both D39 and PLN -A caused a loss of 
body weight after 24 hours, and although rats infected with the mutant strain were 
heavier, there was no significant difference (Figure 4.2.2). Similarly, the number of 
bacteria recovered from the lungs did not differ between wildtype and pneumolysin- 
deficient strains (Figure 4.2.3) and there were also no particular variations in terms of 
dissemination into the bloodstream or pleural space. Both strains stimulated similar 
increases in BAL fluid leukocytes (Figure 4.2.4), proportion of neutrophils (Figure 
4.2.5) and protein (Figure 4.1.6). As with the D39 strain, PLN -A showed no 
difference in total pleural lavage fluid leukocytes (Figure 4.2.7a) or protein (Figure 
4.2.7c) compared with controls. However, the significant increase in the percentage of 
neutrophils compared to controls observed when using D39 was not seen with the 
pneumolysin mutant, although there was no significant difference between the strains 
(Figure 4.2.7b), suggesting attenuation of this effect in the mutant. Both D39 and 
PLN -A induced significant increases in pro- inflammatory cytokines IL -1 a (Figure 
4.2.8) and MCP -1 (Figure 4.2.9) in lung tissue. The pneumolysin- deficient strain 
generated lower levels of cytokines than the wildtype, although this was only 
significant with MCP -1. 
140 
4.2.4.2 Differential Protein Expression 
Both PLN -A and D39 induced significant decreases in expression of RTI40 in both 
BAL fluid and lung tissue (Figure 4.2.10), as well as similar increases in MMC6 in 
BAL fluid (Figure 4.2.11). Lower values for the pneumolysin- deficient bacteria for 
MMC6 were not significant from wildtype. Expression of SP -D in BAL fluid was also 
increased with both PLN -A and D39, however the pneumolysin- deficient strain was 
again lower than the wildtype and the increase was not significant (Figure 4.2.12). 
PLN -A and D39 both induced a significant increase in levels of APN/MMC4 in BAL 
fluid, and although the pneumolysin- deficient strain was again lower than the 
wildtype there were no significant differences (Figure 4.2.13). 
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Figure 4.2.1- Pneumolysin expression in S. pneumoniae D39 and PLN -A 
Western blot showing expression of pneumolysin in bacterial 
supernatants and lysates. Negative control is S. aureus 8325 -4. 
















Figure 4.2.2 - Rat body weight after 24 hours 
Data expressed as a percentage of initial weight at Day 0 over time 
Data expressed for D39 (red) is the same as that presented in Chapter 3 at 106 
and 108 cfu 
Although body weight decreased in all S. pneumoniae- infected groups, there 
was no significant difference between PLN -A (green) and controls after 24 
hours. There were also no significant differences between equivalent 
inoculation of D39 (red) and PLN -A (green). 
Control n = 26, D39 106n =5,D39 108 n= 21, PLN -A 106n= 6,PLN -A 108 
n =6 
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Figure 4.2.3 - CFU recovered from lungs after 24 hours 
Data expressed as total cfu shown on a log scale 
Bars are Instillation cfu, BAL fluid and Lung tissue 
Samples in each treatment group are taken from at least 2 separate 
experiments 
Data expressed for D39 (red) is the same as that presented in Chapter 3 at 106 
and 108 cfu. 
There were no differences in cfu recovered from BAL fluid and lungs between 
PLN -A (green) and D39 (red) at any instillation level. 
D39 106 n = 5, D39 108 n = 10, PLN -A 106n= 4,PLN -A 108n =6 
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Figure 4.2.4 - Number of leukocytes in BAL fluid after 24 hours shown on 
a log scale 
Data expressed as number of cells per ml of BAL fluid 
Samples in each treatment group are taken from at least 2 separate 
experiments 
Data expressed for D39 (red) is the same as that presented in Chapter 3 at 106 
and 108 cfu. 
Both D39 (red) and PLN -A (green) induced a significant increase in BAL 
fluid leukocytes compared to controls, but there were no differences between 
strains at any instillation level, or between instillation levels for each strain. 
Transformed (Log) ANOVA p < 0.0001 
Tukey post -test Control vs PLN -A 106 * ** p < 0.001 
Control vs PLN -A 108 * * * p < 0.001 
(Control vs D39 106 * * * p < 0.001) 
(Control vs D39 108 * ** p < 0.001) 
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Figure 4.2.5 - Differential leukocyte count in BAL fluid after 24 hours 
Data expressed as percentage macrophages and neutrophils. Percentage 
of other leukocytes <1% 
Samples in each treatment group are taken from at least 2 separate 
experiments 
Data expressed for D39 (red) is the same as that presented in Chapter 3 at 106 
and 108 cfu. 
Both PLN -A (green) and D39 (red) at the higher instillation level induced a 
significant increase in the ratio of neutrophils:macrophages compared to controls, 
but there was no difference between the two strains. 
Kruskal- Wallis p < 0.0001 
Dunns post -test Control vs PLN -A 108 macrophages 
Control vs PLN -A 108 neutrophils 
(Control vs D39 108 macrophages 
(Control vs D39 108 neutrophils 
p < 0.05 
p < 0.05 
p < 0.001) 
p < 0.001) 
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Figure 4.2.6 - Protein concentration in BAL fluid after 24 hours 
Data expressed as protein (mg) per ml BAL fluid 
Samples in each treatment group are taken from at least 2 separate 
experiments 
Data expressed for D39 (red) is the same as that presented in Chapter 3 at 106 
and 108 cfu. 
Both PLN -A (green) and D39 (red) induced a significant increase in BAL 
fluid protein after 24 hours at all inoculation levels. There were no differences 
between the two strains. 
Transformed (Log) ANOVA p < 0.0001 
Tukey post -test Control vs PLN -A 106 * ** p < 0.001 
Control vs PLN -A 108 * * * p < 0.001 
(Control vs D39 106 * ** p < 0.001) 
(Control vs D39 108 * ** p < 0.001) 
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Figure 4.2.7 - Pleural Lavage Fluid after 24 hours 
Samples in each treatment group are taken from at least 2 separate experiments 
A. Number of leukocytes shown on a log scale 
Data expressed as log number of cells per ml pleural lavage fluid 
Data expressed for D39 (red) is the same as that presented in Chapter 3 at 106 and 108 cfu. 
There were no differences in the number of pleural lavage fluid leukocytes between PLN -A 
(green), D39 (red) and controls. 
Control n = 8, D39 108 n = 6, PLN-A 108n =6 
B. Differential leukocyte count 
Data expressed as percentage macrophages, neutrophils, mast cells and eosinophils. Percentage of 
other leukocytes <1 %. 
Data expressed for D39 (red) is the same as that presented in Chapter 3 at 106 and 108 cfu. 
Unlike D39 (red), PLN -A (green) did not induce a significant increase in percentage neutrophils or 
decrease in the percentage of macrophages in pleural lavage fluid. 
Neutrophils: 
Transformed ANOVA (Log) p = 0.0123 
Tukey post test (Control vs D39 108 ** p < 0.01) 
Macrophages: 
Transformed (Log) ANOVA p = 0.003 
Tukey post test (Control vs D39 108 ** p < 0.01) 
There were no significant differences between PLN -A (green) and control (black) or D39 (red). 
There were no differences in proportions of eosinophils or mast cells. 
C. Protein concentration 
Data expressed as protein (mg) per ml pleural lavage fluid 
Data expressed for D39 (red) is the same as that presented in Chapter 3 at 106 and 108 cfu. 
Although pleural lavage fluid protein appeared to increase with PLN -A (green) infection above control 
(black) and D39 (red) levels, there were no significant differences between groups. 
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Figure 4.2.8 - I1,-1a in lung tissue after 24 hours 
Data expressed per mg lung protein and presented as a percentage of control 
Samples in each treatment group are taken from at least 2 separate 
experiments 
Data expressed for D39 (red) is the same as that presented in Chapter 3 at 108 
cfu. 
Both PLN -A (green) and D39 (red) induced a significant increase in IL -la in 
lung tissue. Although values for PLN -A (green) were lower than D39 (red), 
there was no significant difference between strains. 
Transformed (Log) ANOVA p < 0.0001 
Tukey post -test Control vs PLN -A 108 * ** p < 0.0001 
(Control vs D39 108 * ** p < 0.0001) 
Control n = 4, D39 108n = 4, PLN -A 108 n = 4 
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Figure 4.2.9 - MCP -1 in lung tissue after 24 hours 
Data expressed per mg lung protein and presented as a percentage of control 
Samples in each treatment group are taken from at least 2 separate 
experiments 
Data expressed for D39 (red) is the same as that presented in Chapter 3 at 108 
cfu. 
Both PLN -A (green) and D39 (red) induced a significant increase in MCP -1 in 
lung tissue. Levels with PLN -A (green) were also significantly lower than 
those for D39. 
Transformed (Log) ANOVA p < 0.0001 
Tukey post -test Control vs PLN -A 108 * ** p < 0.0001 
D39 108 vs PLN -A 108 * p < 0.05 
(Control vs D39 108 * ** p < 0.0001) 
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Figure 4.2.10 - RTI40 in BAL and lung tissue after 24 hours 
Data expressed per ml BAL fluid or per mg lung protein and presented as a 
percentage of control 
Samples in each treatment group are taken from at least 2 separate 
experiments 
Data expressed for D39 (red) is representative of that presented in Chapter 3 at 
108 cfu. 
Both PLN -A (green) and D39 (red) induced a decrease in RTI40 in both BAL 
fluid and lung tissue, with no differences between the two strains. 
BAL: 
ANOVAp =0.02 
Tukey post -test Control vs PLN -A 108 * p < 0.05 
(Control vs D39 108 * p < 0.05) 
Control n = 4, D39 108n = 3, PLN -A 108n = 4 
Lung tissue 
ANOVA p < 0.0001 
Tukey post -test Control vs PLN -A 108 * ** p < 0.0001 
(Control vs D39 108 * ** p < 0.0001) 
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Figure 4.2.11 - MMC6 in BAL and lung tissue after 24 hours 
Data expressed per ml BAL fluid or per mg lung protein and presented as a 
percentage of control 
Samples in each treatment group are taken from at least 2 separate 
experiments 
Data expressed for D39 (red) is representative of that presented in Chapter 3 at 
108 cfu. 
Both PLN -A (green) and D39 (red) induced an increase in MMC6 in BAL 
fluid with a slight decrease in lung tissue. Values for PLN -A (green) in BAL 
fluid were lower than D39 (red), but this difference was not significant. 
Control n = 4, D39 108n = 4, PLN-A 108n = 4 
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Figure 4.2.12 - SP -D in BAL fluid and lung tissue after 24 hours 
Data expressed per ml BAL fluid or per mg lung protein and expressed as a 
percentage of control 
Samples in each treatment group are taken from at least 2 separate 
experiments 
Data expressed for D3 9 (red) is representative of that presented in Chapter 3 at 
108 cfu. 
Both PLN -A (green) and D39 (red) induced an increase in SP -D in BAL fluid, 
however unlike D39 (red), this difference was not significantly different from 
controls (black) for PLN -A (green) (Kruskall- Wallis p = 0.006). Both strains 
induced a similar, non -significant decrease in SP -D in lung tissue. 
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Figure 4.2.13 - APN /MMC4 in BAL fluid and lung tissue after 24 hours 
Data expressed per ml BAL fluid or per mg lung protein and presented as a 
percentage of control 
Samples in each treatment group are taken from at least 2 separate 
experiments 
Data expressed for D39 (red) is representative of that presented in Chapter 3 at 
108 cfu. 
Both PLN -A (green) and D39 (red) induced a significant increase in 
APN /MMC4 in BAL fluid, and although PLN -A (green) was lower than D39 
(red), there was no significant difference between them. 
BAL: 
ANOVA p = 0.002 
Tukey post -test Control vs PLN -A 108 * p < 0.05 
(Control vs D39 108 ** p < 0.05) 
Control n = 5, D39 108 n = 6, PLN -A 108 n = 4 
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43 S. aureus 
43.1 Introduction 
S. aureus is a Gram positive bacterium and a clinically important lung pathogen. A 
recovering model of S. aureus- induced pneumonia had already been established in the 
laboratory (McElroy et al., 2002; Tyrrell et al., 2005). The differential cell - specific 
protein expression identified in pneumococcal pneumonia may have been due to an 
effect common to Gram -positive bacteria. 
43.2 Hypothesis 2.2 
Differential protein expression in pneumococcal pneumonia is due to host 
response to Gram -positive bacteria 
The aim of this chapter was to compare cell- specific protein expression in the model 
of pneumococcal pneumonia with that of caused by S. aureus. 
433 Methods 
The model of staphylococcal pneumonia used in this chapter was equivalent to that 
already established by the author (McElroy et al., 2002), using the wildtype laboratory 
strain 8325 -4 (derived from NCTC 8325 -4) (Novick, 1967) at 108 cfu (1.97x108 ± 
3.50x106), enabling comparison with the streptococcal model at the same dose 
(1.87x108 ± 1.54x108). As for section 4.2 (Pneumolysin), the 24 -hour time point was 
selected. Infected animals were treated during different experiments along with 
controls for each. For technical reasons due to problems with the antibodies it was not 
possible to assess levels of Pro -SP -C in these samples. This set of experiments also 
provided the opportunity to further investigate the use of APN /MMC4 as a 
preliminary indicator of ATII /Clara cell injury by comparing two different models of 
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bacterial infection. As in Chapter 3, all graphs show data generated as a result of at 
least 2 separate experiments. Graphs show means with SD error bars unless stated 
otherwise. Asterisks illustrate significant differences between experimental data and 
controls unless stated otherwise. Analyses of specific proteins are presented as a 
percentage of the mean control value. As with Chapter 3, assay limitations of space 
necessitated the random selection of samples from 2 separate experiments for specific 
protein analysis. 
4.3.4 Results 
4.3.4.1 Basic Comparison of S. aureus and S. pneumoniae Models 
Both S. aureus and S. pneumoniae induced a similar loss of body weight (Figure 
4.3.1). The number of bacteria recovered from the lungs was comparable in both 
models, although it is worthy of note that with S. pneumoniae there were more cfu in 
BAL fluid than lung tissue but more in lung tissue than BAL fluid in the 
staphylococcal model (Figure 4.3.2), perhaps suggesting different mechanisms of 
virulence between the two species. It is also of interest that in contrast to 
pneumococcal infection, no evidence of dissemination into the bloodstream was 
observed in any S. aureus- infected animals. Both strains induced similar significant 
increases in BAL fluid leukocytes (Figure 4.3.3) and proportions of neutrophils 
(Figure 4.3.4). The increase in BAL fluid protein induced by S. aureus was 
significantly higher than that induced by S. pneumoniae (Figure 4.3.5). S. aureus 
infection also induced higher levels of pro- inflammatory cytokines, significant for IL- 
1 a (Figure 4.3.6) but not MCP -1 (Figure 4.3.7) compared to the pneumococcal model. 
Also of note is the fact that S. aureus- infected lung tissue contained a large amount 
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(887 ±224pg /m1) of IFN -y, a pro- inflammatory cytokine that was barely detectable in 
either control or S. pneumoniae- infected tissue. 
4.3.4.2 Differential Protein Expression 
Expression of the ATI cell- specific protein RTI40 was significantly different between 
S. aureus and S. pneumoniae- induced lung infections. The decrease in both BAL fluid 
and lung tissue observed in the pneumococcal model was not seen in the 
staphylococcal one (Figure 4.3.8). Other ATI cell- specific proteins MMC6 (Figure 
4.3.9) and Aquaporin 5 (Figure 4.3.10) showed similar decreases in lung tissue and 
increases in BAL fluid (MMC6 only). As with the streptococcal model, S. aureus 
induced a similar increase in ATII /Clara cell- specific protein SP -D in both BAL fluid 
and to a lesser extent lung tissue (Figure 4.3.11). Finally, the increase in APN/MMC4 
in BAL fluid from S. pneumoniae- infected lungs was not observed in the 
staphylococcal model (Figure 4.3.12). Both infections demonstrate similar 
percentages (4.3.4.1 Basic Comparison of S. aureus model with S. pneumoniae) and 
numbers (S. pneumoniae 8.9x104 ± 4.8x103 vs S.aureus 9.4x104 ± 3.2 x 103) of 
macrophages in BAL fluid, and while it is possible that this result could be due to 
differential effects of the pathogens on protein expression on the macrophages, it 
could also be that these data suggest that in the model of pneumococcal pneumonia 
levels of APN /MMC4 are representative of injury to ATII/Clara cells. 
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Figure 4.3.1 - Rat body weight after 24 hours 
Data expressed as a percentage of initial weight at Day O 
Data expressed for D39 S. pneumoniae (red) is the same as that presented in 
Chapter 3 at 108 cfu. 
S. pneumoniae and S. aureus infected animals were treated during different 
experiments. 
After 24 hours weight significantly decreased in both 8325 -4 S. aureus (yellow) 
and D39 S. pneumoniae- infected rats. More weight was lost in the D39 S. 
pneumoniae (red) model but the difference was not significant. 
ANOVA p < 0.0001 
Tukey post -test Control vs 8325 -4 108 cfu * ** p < 0.001 
(Control vs D39 108 cfu * * * p < 0.001) 








Figure 4.3.2 - CFU recovered from lungs after 24 hours 
Data expressed as total cfu shown on a log scale 
Bars are Instillation cfu, BAL fluid and Lung tissue 
Samples in each treatment group are taken from at least 2 separate 
experiments 
Asterisk represents significant difference between D39 and 8325 -4 
Data expressed for D39 S. pneumoniae (red) is the same as that presented in 
Chapter 3 at 108 cfu. 
S. pneumoniae and S. aureus infected animals were treated during different 
experiments. 
There was no difference in total numbers of bacteria recovered from lung tissue 
between the 8325 -4 S. aureus (yellow) and D39 S. pneumoniae (red) models. Cfu 
in BAL fluid was noticeably lower with S. aureus (yellow), but this was not 
significant. Similarly, cfu in lung tissue was higher in S. aureus (yellow), which 
was significant. 
Mann -Whitney D39 vs 8325 -4 * p = 0.0336 
D39 108n = 10, 8325 -4 108n = 4 
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Figure 4.3.3 - Number of leukocytes in BAL fluid after 24 hours 
Data expressed as number of cells per ml of BAL fluid shown on a log scale 
Samples in each treatment group are taken from at least 2 separate 
experiments 
Data expressed for D39 S. pneumoniae (red) is the same as that presented in 
Chapter 3 at 108 cfu. 
S. pneumoniae and S. aureus infected animals were treated during different 
experiments. 
Both 8325 -4 S. aureus (yellow) and D39 S. pneumoniae (red) induced a 
significant increase in BAL leukocytes after 24 hours, but there was no difference 
between the two strains. 
Transformed (Log) ANOVA p < 0.0001 
Tukey post test Control vs 8325 -4 108 
(Control vs D39 108 
Control n = 17, D39 108n = 10, 8325 -4 108n = 4 
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p < 0.001 









Control D39 8325-4 
Treatment 
Figure 4.3.4 - Differential leukocyte count in BAL fluid after 24 hours 
Data expressed as percentage macrophages and neutrophils. Percentage of 
other leukocytes <1% 
Samples in each treatment group are taken from at least 2 separate 
experiments 
Data expressed for D39 S. pneumoniae (red) is the same as that presented in 
Chapter 3 at 108 cfu (red). 
S. pneumoniae and S. aureus infected animals were treated during different 
experiments. 
Both 8325 -4 S. aureus (yellow) and D39 S. pneumoniae (red) induced a 
significant increase in the ratio of macrophages:neutrophils compared to controls 
but there was no difference between the two strains. 
ANOVA p < 0.0001 
Tukey post test Control vs 8325 -4 108*** p < 0.001 
(Control vs D39 108 * ** p < 0.001) 
Control n = 17, D39 108n = 10, 8325 -4 108n = 4 
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Figure 4.3.5 - Protein concentration in BAL fluid after 24 hours 
Data expressed as protein (mg) per ml BAL fluid 
Samples in each treatment group are taken from at least 2 separate 
experiments 
Data expressed for D39 S. pneumoniae (red) is the same as that presented in 
Chapter 3 at 108 cfu (red). 
S. pneumoniae and S. aureus infected animals were treated during different 
experiments. 
Both 8325 -4 S. aureus (yellow) and D39 S. pneumoniae (red) induced a 
significant increase in BAL fluid protein after 24 hours. Values for 8325 -4 S. 
aureus (yellow) were significantly higher than D39 S. pneumoniae (red). 
Transformed (Log) ANOVA p <0.001 
Tukey post -test Control vs 8325 -4 108 * ** p < 0.001 
D39 108 vs 8325 -4 108 ** p < 0.01 
(Control vs D39 108 * * * p < 0.001) 
Control n = 18, D39 108 n = 10, 8325 -4 108n = 4 
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Figure 4.3.6 - IL -la in lung tissue after 24 hours 
Data expressed per mg lung protein and presented as a percentage of control 
Samples in each treatment group are taken from at least 2 separate experiments 
Data expressed for D39 S. pneumoniae (red) is the same as that presented in 
Chapter 3 at 108 cfu (red). 
S. pneumoniae and S. aureus infected animals were treated during different 
experiments. 
Both 8325 -4 S. aureus (yellow) and D39 S. pneumoniae (red) induced a 
significant increase in IL-la in lung tissue after 24 hours (red). Levels IL-la in 
8325 -4 S. aureus- infected tissue (yellow) were also significantly higher than those 
using D39 S. pneumonaie (red). 
Transformed (Log) ANOVA p < 0.0001 
Tukey post -test Control vs 8325 -4 108 * ** p < 0.0001 
D39 108 vs 8325 -4 108 * ** p < 0.0001 
(Control vs D39 108 * ** p <0.0001) 

















Figure 4.3.7 - MCP -1 in lung tissue after 24 hours 
Data expressed per mg lung protein and expressed as a percentage of control 
Samples in each treatment group are taken from at least 2 separate experiments 
Data expressed D39 for S. pneumoniae (red) is the same as that presented in 
Chapter 3 at 108 cfu (red). 
S. pneumoniae and S. aureus infected animals were treated during different 
experiments. 
Both 8325 -4 S. aureus (yellow) and D39 S. pneumoniae (red) induced a 
significant increase of MCP -1 in lung tissue after 24 hours. Levels with 8325 -4 S. 
aureus (yellow) were higher than D39 S. pneumoniae (red) but this difference was 
not significant. 
Transformed (Log) ANOVA p < 0.0001 
Tukey post -test Control vs 8325 -4 108 * ** p < 0.0001 
(Control vs D39 108 * ** p < 0.0001) 





















Figure 4.3.8 - RTI40 in BAL and lung tissue after 24 hours 
Data expressed per ml BAL fluid or per mg lung protein and expressed as 
percentage of control 
Samples in each treatment group are taken from at least 2 separate experiments 
Asterisks above BAL fluid bars represent a significant difference between D39 S. 
pneumoniae and 8325-4 S. aureus 
Asterisks above lung tissue bars represent a significant difference between bacterial 
infection and control 
Data expressed for D39 S. pneumoniae (red) is representative of that presented in Chapter 
3 at 108 cfu (red). 
S. pneumoniae and S. aureus infected animals were treated during different 
experiments. 
There was no difference in RTI40 levels in BAL fluid between 8325 -4 S. aureus -infected 
(yellow) lungs and controls, compared to the lower levels in D39 
S pneumoniae infection (red). There was also a significant difference between D39 S. 
pneumoniae and 8325 -4 S. aureus. Levels of RTI40 in lung tissue were similarly 
significantly reduced in both models (ANOVA p < 0.0002) 
BAL Fluid: 
Kruskal- Wallis p = 0.009 
Dunns post -test D39 108 vs 8325 -4 108 
Lung tissue: 
ANOVA p = 0.0002 
Tukey post -test Control vs 8325 -4 108 





Control n= 4, D39 108n = 4, 8325-4 108n = 4 
Figure 4.3.9 - MMC6 in BAL and lung tissue after 42 hours 
Data expressed per ml BAL fluid or per mg lung protein and expressed as a 
percentage of control 
Samples in each treatment group are taken from at least 2 separate experiments 
Data expressed for D39 S. pneumoniae (red) is representative of that presented in 
Chapter 3 at 108 cfu (red). 
S. pneumoniae and S. aureus infected animals were treated during different 
experiments. 
Both 8325 -4 S. aureus (yellow) and D39 S. pneumoniae (red) induced a similar 
increase in MMC6 in BAL fluid, although this was only significant in the 
streptococcal model (Kruskal- Wallis p = 0.0261; Dunns - Control vs D39 108 *p < 
0.05). Both bacteria also induced a similar non -significant decrease in MMC6 in lung 
tissue. 
Control n = 4, D39 108n = 4, 8325- 4108n =4 
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Figure 4.3.10 - Aquaporin 5 in lung tissue after 24 hours 
Data expressed per mg lung protein and expressed as a percentage of control 
Samples in each treatment group are taken from at least 2 separate experiments 
Data expressed for D39 S. pneumoniae (red) is representative of that presented in 
Chapter 3 at 108 cfu (red). 
S. pneumoniae and S. aureus infected animals were treated during different 
experiments. 
Both 8325 -4 S. aureus (yellow) and D39 S. pneumoniae (red) induced a similar non- 
significant decrease in Aquaporin 5 in lung tissue. 















Figure 4.3.11- SP -D in BAL fluid and lung tissue after 24 hours 
Data expressed per ml BAL fluid or per mg lung protein and presented as 
percentage of control 
Samples in each treatment group are taken from at least 2 separate experiments 
Data expressed for D3 9 S. pneumoniae (red) is representative of that presented in 
Chapter 3 at 108 cfu (red). 
S. pneumoniae and S. aureus infected animals were treated during different 
experiments. 
Both 8325 -4 S. aureus (yellow) and D39 S. pneumoniae (red) induced a similar 
significant increase in SP -D in BAL fluid, and a non -significant increase in lung 
tissue. There were no differences between the two bacteria. 
BAL: 
ANOVA p = 0.0043 
Tukey post -test Control vs 8325 -4 108* p < 0.05 
Control vs D39 108 ** p < 0.01 















Figure 43.12- APN /MMC4 in BAL fluid and lung tissue after 24 hours 
Data expressed per ml BAL fluid or per mg lung protein and presented as 
percentage of control 
Samples in each treatment group are taken from at least 2 separate experiments 
Data expressed for D3 9 S. pneumoniae (red) is representative of that presented in 
Chapter 3 at 108 cfu (red). 
S. pneumoniae and S. aureus infected animals were treated during different 
experiments. 
8325 -4 S. aureus (yellow) did not induce an increase in APN /MMC4 in BAL fluid, 
unlike S. pneumoniae (ANOVA p = 0.0162; Tukey - Control vs D39 108 * p < 0.05). 
There were no differences between bacteria or controls in lung tissue. 
Control n = 4, D39 108n = 7, 8325 -4 108n = 4 
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4.4 Summary and Conclusions 
Pneumolysin- deficient bacteria induced an equivalent lung infection to 
wildtype 
Pneumolysin- deficient bacteria induced an attenuated neutrophilia in the 
pleural space compared to wildtype 
Pneumolysin- deficient bacteria stimulated an attenuated response of pro - 
inflammatory cytokines compared to wildtype 
Pneumolysin- deficient bacteria induced an equivalent decrease in RTI40 and 
MMC6 expression compared to wildtype 
Pneumolysin- deficient bacteria demonstrated attenuated SP -D secretion 
compared to wildtype 
Pneumolysin- deficient bacteria induced an equivalent increase in APN/MMC4 
in BAL fluid compared to wildtype 
S. aureus induced a similar inflammatory response to S. pneumoniae but 
demonstrated a more pronounced increase in inflammatory cytokines and air - 
blood barrier damage 
S. aureus did not induce a decrease in RTI40, but expression of MMC6, 
Aquaporin 5 and SP -D was equivalent to S. pneumoniae 
S. aureus did not induce an increase in APN/MMC4 in BAL fluid 
The purpose of this series of experiments was to attempt to investigate the 
mechanism(s) by which pneumococcal pneumonia induces differential expression of 
alveolar epithelial cell -specific proteins. This was done by comparing the model of S. 
pneumoniae- induced pneumonia with rat models of lung infection induced by a 
pneumolysin- deficient mutant pneumococcus and S. aureus, another Gram -positive 
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bacterium. Section 4.2 (Pneumolysin) illustrated that in these rat models pneumolysin 
was not required for infection, inflammation or damage to the air -blood barrier, 
although attenuation of some aspects of inflammation, particularly production of pro - 
inflammatory cytokines, was observed. S. aureus stimulated a comparable lung 
infection to that induced by S. pneumoniae however there was greater damage to the 
air -blood barrier and stimulation of pro- inflammatory cytokines. Changes in 
expression of the RTI40 protein were not mediated by pneumolysin, but decreased 
expression of the protein was not observed in the staphylococcal infection, despite the 
increased levels of air -blood barrier damage with S. aureus and variations in pro - 
inflammatory cytokine production in both pneumolysin- deficient and staphylococcal 
models. This not only suggests that the decrease in RTI40 may be unique to the 
pneumococcus, but also that the effect is not likely to be mediated by the pro - 
inflammatory cytokines assessed here. An attenuated increase in SP -D secretion was 
observed in pneumolysin- deficient bacteria, whereas levels were similar in infection 
with both wildtype Gram -positive bacteria, again suggesting that this is not related to 
the degree of air -blood barrier damage or levels of the pro -inflammatory molecules 
studied. The difference in expression of APN/MMC4 protein in BAL fluid between 
the two Gram -positive models, despite an equivalent macrophage presence in the 
airways, suggests that this biochemical technique may be of some use as a preliminary 
screen of ATII and Clara cell injury in the streptococcal model, although it is 
acknowledged that this may also be due to differential effects on macrophages. This 




Chapters 3 and 4 established that pneumococcal pneumonia induces differential 
expression of ATI cell- specific proteins that is not due to a generic response to Gram - 
positive bacteria or mediated by pneumolysin. Increased production of ATII and Clara 
cell protein SP -D occurs in both Streptococcal and Staphylococcal pneumonia and is 
attenuated by pneumolysin. However, the mechanism behind these changes in protein 
expression is as yet unknown, and this suggested the idea that S. pneumoniae might be 
directly influencing expression of the proteins. 
5.2 HYPOTHESIS 3 
Differential protein expression in pneumococcal infection is due to direct 
interaction with bacteria or bacterial products 
The main aim of this chapter was to set up an in vitro model of bacterial co- culture 
with cells expressing RTI40 and SP -D and to determine whether or not infection with 
S. pneumoniae induces protein regulation. 
5.3 METHODS 
In order to establish an in vitro model to test protein responses to S. pneumoniae, it 
was necessary to acquire rat cells that were able to express both RTI40 and SP -D. 
While isolated ATII cells do progressively demonstrate ATI characteristics such as 
expression of RTI40, (Chapter 1.4.2.1 RTI40), the logistics and validity of processing 
primary ATII cells at different stages of culture, combined with the technically 
challenging nature of the isolation procedure were prohibitive to their use in these 
studies. The rat alveolar epithelial cell line SV40 -T2, was initially created to study 
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proliferation in ATII cells and indeed they maintain their characteristic lamellar 
bodies (Clement et al., 1991). However, SV40 -T2 cells have also been shown to 
express RTI40 (McElroy et al., 2002; Rishi et al., 1995). This suggested that these 
cells might be of use in investigating bacterial effects on both RTI40 and SP -D. IL -1 a 
and MCP -1 were used in this in vitro model as a measure of the inflammatory 
response stimulated by the bacteria. For the co- culture experiments only the wildtype 
D39 S. pneumoniae was used. Experiments were carried out in T75 flasks containing 
approximately 106 cells that were infected with 107 (2.59x107 ± 3.37x106) cfu of 
bacteria (M.O.I. 10). Preliminary time course experiments indicated that by 8 hours 
post -infection the plasma membrane of cells was compromised, so a 4 hour time point 
when cells were still viable was selected for study. As with Western blots, mRNA 
analysis was carried out with all samples run on the same gel, which were also 
assessed using a loading control, and analysed by densitometry (Chapter 2 Materials 
and Methods). As in Chapters 3 and 4, all graphs show data generated as a result of at 
least 2 separate experiments Graphs show means with SD error bars. Asterisks 
illustrate differences between experimental data and controls unless stated otherwise. 
Analyses of specific proteins are presented as a percentage of the mean control value. 
As with Chapters 3 and 4, assay limitations of space necessitated the random selection 
of samples from 2 separate experiments for specific protein analysis. 
5.4 RESULTS 
5.4.1 Characterisation of SV40 -T2 Cells 
Pro -inflammatory IL -1a and MCP -1 proteins (Figure 5.1a) were reproducibly 
expressed in SV40 -T2 cell lysates. However in cell culture medium protein levels of 
MCP -1 were variable and IL -1 a was not detectable. Expression of IL -1 a (Figure 5.1b) 
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and MCP -1 (Figure 5.1c) mRNA was also detected in cells. The presence of RTI40 
protein was demonstrated by Western blot (Figure 5.2a) and flow cytometry (Figure 
5.2b), and mRNA was demonstrated by RT -PCR (Figure 5.2b). Similarly, SP -D 
protein was detected in cell lysates (Figure 5.3a), but was not found in culture 
medium at any point. SP -D mRNA was also detectable in cells (Figure 5.3b). These 
data show that SV40 -T2 cells express all the molecules of interest. 
5.4.2 Characterisation of In Vitro Bacterial Co- Culture System 
The number of viable bacteria recovered from cell culture media had significantly 
decreased by 4 hours (Figure 5.4). As IL -1 a was not detected in control media, in 
order to quantify in some way the changes in expression following bacterial infection, 
the control mean was allocated 100 and data was presented as a percentage of this as 
was done previously (Figure 5.5b). The levels of pro -inflammatory cytokines IL -la 
mRNA (Figure 5.5c) and protein in both cells (Figure 5.5a) and cell culture medium 
(Figure 5.5b) increased following infection with D39. While levels of MCP -1 protein 
in cells increased significantly (Figure 5.6a), protein in culture media showed a 
pronounced decrease (Figure 5.6b), with no difference shown in mRNA (Figure 5.6c). 
5.43 Differential Protein Expression 
Assessment of RTI40 by FACS analysis (Figure 5.7a) showed a shift of 99% of 
events in the lower left quadrant (secondary antibody alone), to 89.67% in the upper 
right (primary antibodies) in control samples. S. pneumoniae- infected cells differed 
slightly in showing more auto -fluorescence (probably due to damaged cells) with 
95.7% in the lower left quadrant (secondary antibody alone), shifting to 96.12% in the 
upper right (primary antibodies). While this small change alone is unlikely to be 
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indicative of a reduction in RTI40 expression, the proportion of mean fluorescence 
intensity of ICAM:RTI40 was higher in controls (1:5) than infected samples (1:3). 
This may be indicative of a reduction in RTI40 expression, however it may also be 
due to differences in cell population due to cell damage as biochemical analysis of 
lysed cells showed no difference (Figure 5.7b). Expression of mRNA showed a 
significant increase after 4 hours (Figure 5.7c). In contrast, neither SP -D protein 
(Figure 5.8a) nor mRNA (Figure 5.8b) changed after incubation with D39. The in 
vitro results are summarised in Figure 5.9. 
5.4.4 Distribution of RTI40 Expression In Vivo 
As well as using in vitro bacterial co- culture to determine direct bacterial effects on 
expression of RTI40, this question could also be further investigated by going back to 
the in vivo situation where it was first observed. This was done by examining the 
distribution of RTI40 staining on different areas of infected lung tissue. Instillation of 
S. pneumoniae usually instigated a lobar pneumonia, so inflamed lung tissue was 
separated from unaffected tissue and immunofluorescence staining of RTI40 was 
compared between the two. Figure 5.10 shows that after 72 hours non -inflamed areas 
of infected lungs (C) demonstrated a similar loss of RTI40 protein expression to that 
of inflamed areas (B), despite lung architecture being microscopically comparable to 
control lungs (A). 
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Figure 5.1- Expression of IL-la and MCP -1 in control SV40 -T2 cells 
A. IL-la and MCP -1 protein in cell lysates and media 
Data expressed as pg /mg of protein 
Samples taken from at least 2 separate experiments 
Both EL-la and MCP -1 were expressed in cell lysates, although 
IL -la was undetectable in media and MCP -1 very variable 
n =4 
B. RT -PCR data showing IL-la mRNA in cells 
Images representative of at least 2 separate experiments 
Image shows a band at 201bp in SV40 -T2 cells 
Positive control is rat lung tissue 
C. RT -PCR data showing MCP -1 mRNA in cells 
Images representative of at least 2 separate experimant 
Image shows a band at 167óp in SV40 -T2 cells 
Positive control is rat lung tissue 
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Figure 5.2 - Expression of RTI40 in control SV40 -T2 cells 
Images representative of at least 2 separate experimants 
A. Western blot showing RTI40 protein in cell lysates 
Blot shows a band at 40kDa in SV40 -T2 cell lysates. 
Positive control was rat lung tissue. 
B. FACS data showing RTI40 protein on cell surface 
Graph shows unstained cells (purple), overlaid with 
secondary antibody only (green) and RTI40 antibody (pink) 
Graph shows a fluorescence shift with RTI40 stained cells only 
C. RT -PCR data showing RTI40 mRNA in cells 
Image shows a band at -184óp in SV40 -T2 cell lysates. 


















Figure 5.3 - Expression of SP -D in control SV40 -T2 cells 
Images representative of at least 2 separate experimant 
A. Western blot showing SP -D protein in cell lysates 
Blot shows a band at 42 lcDa in SV40 -T2 cell lysates 
Positive control is rat lung tissue 
B. RT -PCR data showing SP -D mRNA in cells 
Image shows a band at 271bp in SV40 -T2 cells 



















Figure 5.4 - CFU recovered from S. pneumoniae- infected cell culture media 
Data expressed as cfu/ml of cell culture media shown on a log scale 
Samples in each treatment group are taken from at least 2 separate 
experiments 
Numbers of S. pneumoniae show a significant decrease in cell culture media 
between 0 and 4 hours 
Transformed (Log) Unpaired t -test p = 0.0023 
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Figure 5.5 - IL -la expression after 4 hours 
Samples in each treatment group are taken from at least 2 separate experiments 
Data presented as a percentage of control 
A. Expression of IL -la protein in cell lysates 
Data expressed per mg of protein 
S. pneumoniae induced an increase in IL-1a protein after 4 hours which was not quite significant 
(Transformed (Log) Unpaired t -test p = 0.06) 
Control n = 4, D39 4 hrs n = 4 
B. Expression of IL-la protein in cell culture media 
Data expressed per mg of protein 
S. pneumoniae induced a significant increase in IL -1a protein in cell culture media after 4 hours 
Transformed (Log) Unpaired t -test * ** p = 0.0002 
Control n = 3, D39 4 hours n = 5 
C. Expression of IL -la mRNA in cell layer 
S. pneumoniae induced an increase in 1L-1a. tnRNA in the cell layer after 4 hours 
Unpaired t -test * p = 0.0174 































Figure 5.6 - MCP -1 expression after 4 hours 
Data expressed as percentage of control 
Samples in each treatment group are taken from at least 2 separate experiments 
A. Expression of MCP -1 protein in cell lysates 
Data expressed per mg of protein 
S. pneumoniae induced a significant increase in MCP -1 protein in cell lysates after 4 hours 
Transformed (Log) Unpaired t -test ** p = 0.003 
Control n = 4, D39 n = 4 
B. Expression of MCP -1 protein in cell culture media 
Data expressed per mg of protein 
S. pneumoniae induced a significant decrease in MCP -1 protein in cell culture media after 4 hours 
Unpaired t -test ** p = 0.002 
A. Expression of MCP -1 mRNA in cell layer 
S. pneumoniae induced no change in MCP -1 mRNA in the cell layer 


















Figure 5.7 - RTI40 expression after 4 hours 
A. FACS data showing RTI40 and ICAM -1 protein on cell surface 
Figure representative of 2 separate experiments shows cells stained with secondary antibody only 
(upper graph) and RTI40 /ICAM -1 (lower graph). 
Graphs show consistent expression of both RTI40 and ICAM -1 in both control and D39 -infected cells 
Control n = 3, S. pneumoniae 4 hours n = 3. S. pneumoniae 8 hours n = 3 
B. Expression of RTI40 protein in cell lysates 
Data expressed per mg of protein and presented as a percentage of control 
S pneumoniae did not induce any change in expression of RTI40 protein in cell lysates after 
4 hours 
Control n = 5, D39 n = 3 
C. Expression of RTI40 mRNA in cell layer 
Data expressed as percentage of control 
S pneumoniae induced a significant increase in RTI40 mRNA in the cell layer after 4 hours 
Unpaired t -test * * p = 0.003 
















Figure 5.8 - SP -D expression after 4 hours 
Data presented as a percentage of control 
Samples in each treatment group are taken from at least 2 separate 
experiments 
A. Expression of SP -D protein in cell lysates 
Data expressed per mg of protein 
S. pneumoniae induced no change in SP -D protein in cell lysates after 4 hours 
Control n = 4, D39 n = 3 
B. Expression of SP -D mRNA in cell layer 
S. pneumoniae induced no change in SP -D mRNA in the cell layer after 4 
hours 
Control n = 3, D39 4 hours n = 4 
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Figure 5.9 - In vitro summary table 
Table summarises expression of protein and mRNA with and without S. 
pneumoniae 
Gene Control S. pneumoniae 
Protein mRNA Protein mRNA 
IL -la +ve 











MCP -1 +ve 











































Figure 5.10 - Immunofluorescence staining of rat lung at 72 hours 
Sections stained with RTI40 ( ) and MMC6 (red) with nuclear stain 
To -Pro -3 (blue) 
A. Control 
Arrow shows both RTI40 and MMC6 co- expressed on the surface of ATI cells 
B. ,S pneumoniae - Inflamed area of lungs 
Arrow shows areas of inflamed alveolar epithelium stained with MMC6 only. 
C. S pneumoniae - Non -inflamed area of lungs 
Arrow shows areas of non -inflamed alveolar epithelium stained with MMC6 only 
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5.5 Summary and Conclusions 
SV40 -T2 cells express IL -la, MCP -1, RTI40 and SP -D protein and mRNA in 
vitro 
Co- cultured S. pneumoniae did not actively grow in cell culture medium in 
vitro 
S. pneumoniae induced an overall increase in production of IL -la and MCP -1 
in vitro 
S. pneumoniae did not change RTI40 protein expression but mRNA was 
increased in vitro 
S. pneumoniae did not affect expression of SP -D protein or mRNA in vitro 
In vivo the decrease in RTI40 protein in S. pneumoniae infection was not 
limited to areas of inflammation 
The purpose of this chapter was to determine if the changes in cell- specific proteins in 
pneumococcal pneumonia was due to a direct effect of bacteria or bacterial products. 
An in vitro system of bacterial co- culture was set up using a rat alveolar epithelial cell 
line SV40 -T2 that was shown to express RTI40 and SP -D as well as pro - 
inflammatory molecules IL -1 a and MCP -1. S. pneumoniae (which did not actively 
grow in media, representing the situation in vivo) induced an overall increase in 
cytokine production, but initiated active secretion of IL -1 a, while either inhibiting 
secretion of, or cleaving, MCP -1. However, these data do suggest that incubation of 
SV40 -T2 cells with S. pneumoniae results in an inflammatory response by the cells. 
RTI40 showed no change in protein expression biochemically, although there is some 
evidence of a reduction by FACS analysis, although levels of mRNA were shown to 
increase, suggesting that while the decrease in protein observed in vivo was not 
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reproduced, the bacteria did demonstrate a direct effect in vitro. Expression of SP -D 
did not change at all after infection with S. pneumoniae. These data suggest that 
changes in the protein expression observed in pneumococcal pneumonia require 
additional stimuli than just bacteria and protein. However this should be considered 
within the confines of the in vitro system. Limitations of both co- culture incubation 
time due to monolayer damage, and peculiarities of cell line protein expression such 
as the lack of SP -D secretion will likely have affected the results obtained. Returning 
to the in vivo observation, immunofluorescence analysis of infected lungs showed that 
the decrease in RTI40 protein expression was not restricted to areas showing the most 
response to bacterial infection, supporting the in vitro data in concluding that RTI40 
protein modulation is not a result of direct interaction between protein and bacteria. 
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CHAPTER 6: DISCUSSION 
6.1 SUMMARY OF RESULTS 
Experiments presented in Chapters 3 -5 of this thesis have demonstrated the following 
novel findings. 
Pneumococcal pneumonia: A recovering rat model of pneumococcal pneumonia 
showed differential expression of ATI and ATII cell- specific proteins. A pronounced 
decrease in RTI40 expression on ATI cells was observed compared to MMC6 and 
Aquaporin 5, in the absence of visible damage to ATI cells. Synthesis and secretion of 
SP -D by ATII cells and /or Clara cells was increased in contrast to expression of Pro - 
SP-C. 
Pneumolysin- deficient pneumococcal pneumonia: Pneumolysin- deficient 
pneumococcal pneumonia induced a similar lung infection to the wildtype organism 
although inflammation was attenuated in some aspects. Pneumolysin did not mediate 
the decrease in RTI40 or increase in SP -D. 
Staphylococcal pneumonia: S. aureus- induced lung infection showed similar levels 
of lung inflammation to S. pneumoniae, but demonstrated an increase in pro - 
inflammatory cytokine response and injury to the air -blood barrier. SP -D was 
increased, but in contrast to S. pneumoniae there was no decrease in RTI40. 
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Injury to ATII cells: Targeted injury of ATII cells was identified in the 
pneumococcal model and novel methods of quantification using cell- specific proteins 
were investigated. An immunofluorescence technique was shown to be effective, but 
biochemical Pro -SP -C expression was not found to be a reliable marker of ATII cells. 
Measurement of APN /MMC4 in BAL fluid was shown to be representative of ATII 
cell injury in the pneumococcal model. This injury was not apparent in staphylococcal 
infection and was not mediated by pneumolysin. 
Mechanism of protein regulation: An in vitro model of S. pneumoniae infection of 
alveolar epithelial cells showed that expression of RTI40 and SP -D protein was not 
directly mediated by bacteria, or bacterial products. This was further supported in vivo 
for RTI40 by the absence of expression in non -inflamed areas of infected lung. 
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6.2 DISCUSSION 
The purpose of this thesis was to test the following hypotheses: 
1. Pneumococcal pneumonia induces differential damage to ATI and ATII cells 
2.1 Pneumococcal virulence factor pneumolysin mediates differential protein 
expression 
2.2 Differential protein expression in pneumococcal pneumonia is due to host 
response to Gram -positive bacteria 
3. Differential protein expression in pneumococcal infection is due to direct 
interaction with bacteria or bacterial products 
Detection of an increase in RTI40 protein in BAL fluid is a well- established technique 
for identifying targeted damage to rat ATI cells (Franklin, 2006; McElroy et al., 
1995). In this thesis a pronounced decrease in RTI40 in both BAL fluid and lung 
tissue was detected in a model of pneumococcal pneumonia. This is the first time that 
such regulation of RTI40 expression has been identified independent of 
morphological ATI cell injury. Even in a highly injurious, ventilated model of 
P. aeruginosa -induced lung infection, levels of RTI40 showed a huge (80 -fold) 
increase in BAL fluid as opposed to a decrease (McElroy et al., 1995). The only 
previous studies that demonstrated a decrease in RTI40 were in lung tissue. In a 
model of staphylococcal pneumonia this was interpreted as a measure of shift to a 
more ATII cell phenotype during lung repair (Tyrrell et al., 2005). A rat model of 
bleomycin- induced lung fibrosis also showed a decrease in RTI40 expression in lung 
tissue, associated with an increase in BAL fluid indicating ATI cell injury (Koslowski 
et al., 1998). Although morphological evidence of ATI cell injury was not identified 
in the pneumococcal model, the contrast in expression between RTI40 and other ATI 
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cell- specific proteins, MMC6 and Aquaporin 5, suggests that S. pneumoniae is 
affecting ATI cells in some way. Nevertheless, these results do indicate that the 
established interpretation of RTI40 in BAL fluid as a marker of ATI cell damage does 
not apply in this model. This result highlights the importance of using an array of 
ATI -cell specific proteins in this type of analysis, particularly when the function and 
regulatory mediators of the protein are unknown. The fact that the decrease is not 
observed in another model of Gram -positive bacterial lung infection, mediated by 
pneumolysin or occurring as a result of direct bacterial effects, while inconclusive, is 
consistent with the idea that it is induced by a specific host response to pneumococcal 
infection. However, the increased expression of pro- inflammatory cytokines 
stimulated by S. aureus compared to S. pneumoniae, and a similar induction of SP -D 
secretion combined with an absence of effect on RTI40, indicates a process that is 
likely to be complex. A host of inflammatory and anti -microbial molecules produced 
and regulated in response to the pneumococcus, or interactions between them, could 
be responsible for these results. Similarly, the mechanism by which the protein is 
decreased has yet to be established. Despite the fact that the function of RTI40 in the 
adult lung is unknown, its extensive expression on normal lung epithelium suggests 
an important role. Indeed, expression of the protein is vital to normal lung 
development (Ramirez et al., 2003). The indication that the decrease in RTI40 
expression is reversible, as demonstrated by an increase in protein after 72 hours, 
combined with the full resolution of disease over time suggests that decrease in 
protein expression does not appear to adversely affect disease progression, and may 
imply a lack of protein detection rather than active down regulation. The 
demonstration of decreased RTI40 using two different antibodies that are thought to 
bind to different epitopes (Williams et al., 1996) suggests that if this is the case, the 
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conformational change induced in RTI40 must be considerable. There is a possibility 
that the post -translational modification of RTI40 could be involved in this, however 
given that the same effect was observed using antibodies that are thought to bind to 
both the core protein and post -translational modification, this is likely to be a complex 
procedure. 
Like RTI40, expression of MMC6 in the pneumococcal model has been difficult to 
interpret. Maintenance of an increase in MMC6 in BAL fluid by 72 hours may be 
explained by three possible theories: continued damage to ATI cells in the resolution 
phase; protein shedding into the airway stimulated by bacterial infection; or some 
combination of the two. As mentioned earlier, an absence of visible damage to 
epithelial cells does not necessarily preclude injurious effect. In a severe model of 
P. aeruginosa - induced pneumonia, it was noted that an increase in ATI cell- specific 
protein in BAL fluid was detected 2 hours post -infection, before evidence of 
morphological damage (McElroy et al., 1995). While this might explain the MMC6 
data at 24 hours, it does not rationalise further injury during resolution. To this end, it 
is worthy of note that of all parameters measured, the only other proteins that 
demonstrated an up regulation of expression at both 24 and 72 hours are those 
involved in innate immunity, namely pro- inflammatory IL-1a and MCP -1, and the 
surfactant collectin SP -D. So little is known about the functión of MMC6 that it is 
tempting to speculate the protein might therefore have some role to play in the innate 
immune system. CD14, an important PRR for the pneumococcus (Paterson and 
Mitchell, 2006) and other bacterial pathogens (Martin and Frevert, 2005), exists in 
two forms, soluble and membrane -bound, the soluble form being shed from the cell 
membrane (Martin and Frevert, 2005). Although MMC6 is restricted to ATI cells and 
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there is no evidence of protein shedding in the normal lung, it is possible that under 
certain pathological conditions this is activated, perhaps as some form of specific 
defence for the alveolar epithelium's most vulnerable cells. The increase in MMC6 in 
BAL fluid in both S. pneumoniae and S. aureus- induced lung infections suggests that 
this could be stimulated by factors in common to Gram -positive bacteria such as PG, 
LTA and teichoic acids. 
The identification of differential protein expression in this model of pneumonia has 
demonstrated the flaws of relying on one assessment parameter when using cell - 
specific proteins to quantify injury, and suggests that an array of markers be used to 
provide more reliable results. 
SP -D is an important molecule in the innate immune system of the lung, and aids lung 
clearance by binding to a variety of different microbial pathogens (Giannoni et al., 
2006; Griese and Starosta, 2005; Hartshorn et al., 1998; Restrepo et al., 1999), 
including the pneumococcus (Hartshorn et al., 1998; Jounblat et al., 2004; Jounblat et 
al., 2005). Although it has been used as a marker of surfactant production in a number 
of human diseases (Hartl and Griese, 2006; Kuroki et al., 1998; Postle et al., 1999), 
and the effects of specific lung pathogens in SP -D- deficient mice has been 
investigated (Giannoni et al., 2006; Jounblat et al., 2005; LeVine et al., 2000) few 
studies have been carried out on protein expression responses in vivo. A study of lung 
infection in pigs showed an increase in SP -D immunoreactivity in bronchopneumonia 
induced by S. aureus and Gram -negative Actinobacillus pleuropneumoniae 
(Soerensen et al., 2005). This thesis has presented for the first time a quantified 
increase in secretion and production of SP -D in response to two Gram -positive lung 
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pathogens, S. aureus and S. pneumoniae. This supports the pig data, and suggests 
stimulation of SP -D in response to a wide range of bacterial pathogens. Modulation of 
SP -D was not shown to be as a result of direct stimulation by S. pneumoniae or 
associated products, as demonstrated by in vitro data. This implies that while direct 
interaction between SP -D and pathogen does occur, regulation of protein expression is 
modulated in an indirect manner, perhaps by some interaction with host defence 
mechanisms. Unlike RTI40 however, the similar increase of SP -D expression induced 
by both Gram -positive species suggests that this could be initiated by pro - 
inflammatory molecules, such as IL -la and MCP -1, which are both up regulated in 
the lung in response to S. aureus and S. pneumoniae. 
This thesis has presented, for the first time, evidence of targeted injury to ATII cells 
in a clinically relevant model of pneumococcal pneumonia. There is evidence of S. 
pneumoniae adhesion to alveolar epithelial cells, particularly ATII cells (Cundell and 
Tuomanen, 1994). Adhesions and adhesion -mediators are important virulence factors 
for the pneumococcus (Jedrzejas, 2001; Mitchell et al., 1997) and adhesion has been 
shown to facilitate internalisation of other Gram -positive bacteria into host cells 
(Dziewanowska et al., 1999; McElroy et al., 2002). Thus preferential attraction of S. 
pneumoniae to ATII cells may facilitate cell damage, perhaps by stimulation of 
internalisation. This thesis has also demonstrated a variety of methods to quantify this 
damage, of which there were previously no well -established techniques. The use of 
cell- specific proteins has been fundamental to this. Difficulties in biochemical 
analysis of membrane -associated molecules, such as RTII70, suggested the value of 
employing an immunofluorescence -based quantification technique, which was able to 
quantify ATII cell- specific injury in this model. Biochemical investigation of ATII 
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cytoplasmic Pro -SP -C proved inconsistent with immunofluorescence data while an 
increase in SP -D expression indicated that injury to ATII cells did not adversely affect 
global production of surfactant protein. Assessment of APN/MMC4 demonstrated 
that, despite the protein's expression on the surface of macrophages, increased levels 
in BAL fluid during the acute phase of disease was likely to be representative of 
damage to ATII cells. Clearly, this expression by macrophages would mean that this 
would not be a definitive technique by which ATII and Clara cell injury could be 
quantified; however it might prove useful as a quick and easy preliminary screen to 
filter out models of lung infection worthy of further investigation using the 
immunofluorescence method, which is considerably more time consuming. 
In the presented model of pneumococcal infection bacteria did not actively grow 
either in vivo or in vitro. Despite this there is evidence of injury to both lungs and 
cultured cells. This is representative of recovering pneumonia where bacteria are 
cleared from the lungs rather than being disseminated and resulting in a more 
systemic infection. Other groups have used rat models of pneumococcal infection. 
After 18 hours Boe et al showed recovery of approximately 1 x 105 cfu of bacteria 
from lung tissue, in contrast to the 1 x 104 recovered here after 24 hours (Boe et al., 
2001). This may have been due to the difference in time point assessed, as their study 
showed a progressive decrease in viable bacteria between 6 and 18 hours, however 
over the course of 8 days S. pneumoniae- infected animals showed low mortality as 
did the model presented here, an it is possible that assessment of an earlier time point 
might have shown an increase in bacterial numbers followed by clearing by 24 hours. 
An additional control to confirm instillation dose by harvest of freshly infected lungs 
could also have been done, as could additional tests to confirm the identity of the 
195 
bacteria such as Gram -stain and optochin sensitivity. This could also apply to stocks 
of S. aureus by carrying out catalase tests. A lack of bacterial growth in vitro 
however, was surprising. This may have been due in part to the previous culture of 
epithelial cells in media supplemented with antibiotics at a bacteria -static level. This 
was carried out due to persistant infections of cultures. Despite the fact that cells were 
washing thoroughly and cultured in antibiotic -free media during bacterial infection, it 
is possible that this may have affected pneumococcal growth in vitro. However, 
preliminary studies comparing bacterial growth with cells cultured in antibiotic versus 
antibiotic -free media suggested that this did not have an effect. Other alternative 
explanations may be that bacteria were harvested at an earlier growth phase might 
have been better able to grow in media, although the presence of viable bacteria in 
culture and injury to epithelial cells suggests that pneumococci were still able to 
function. 
Pneumolysin is an important virulence factor of S. pneumoniae and pneumonia 
induced by pneumolysin- deficient bacteria has been shown to demonstrate decreased 
bacterial growth, damage to the air -blood barrier and inflammation (Berry et al., 
1989; Kadioglu et al., 2000; Rubins et al., 1995). The pneumonia model presented in 
this thesis, however, showed no difference in bacterial recovery, inflammation or 
damage to the air -blood barrier compared to the wildtype, although some attenuation 
in expression of innate immune mediating proteins was observed. While it was 
demonstrated that the wildtype bacteria did indeed express the protein and the 
deficient mutant did not, this was established under laboratory conditions and was not 
tested in lung tissue in vivo. This, combined with the unexpectedly similar results 
from the two pneumonia models suggests two possible explanations. It is possible that 
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the mutant strain reverted to wildtype in vivo; however, this is unlikely since these 
strains have been used in a number of other in vivo studies demonstrating phenotypic 
differences (Benton et al., 1997; Berry et al., 1989; Kadioglu et al., 2000; Rubins et 
al., 1995). A more plausible explanation might be that the wildtype strain was not 
producing significant amounts of pneumolysin in vivo. Previous studies illustrating 
the importance of pneumolysin as a virulence factor have been in non -recovering 
mouse models (Benton et al., 1997; Berry et al., 1989; Kadioglu et al., 2000; Rubins 
et al., 1995). This suggests that the recovering nature of the pneumonia studied in this 
thesis is fundamental to the differences observed. Pneumolysin is an intracellular 
toxin, released only on autolysis during stationary phase (Jedrzejas, 2001; Rubins and 
Janoff, 1998); however, in this model most of the bacteria were cleared from the lungs 
by 24 hours, suggesting a lack of growth in the respiratory tract. If bacteria were 
unable to reach stationary phase they would be unable to release the toxin, although 
clearly some basal levels of autolysis will have occurred. The complicated cascade by 
which inflammatory molecules such as IL -la, MCP -1 and SP -D are stimulated may 
have been slightly influenced by this small amount of pneumolysin release in a way 
that other measures of inflammation and tissue injury were not, perhaps by the 
interaction of pneumolysin with TLR -4 (Kadioglu and Andrew, 2004; Paterson and 
Mitchell, 2006). These results suggest that pneumolysin may be less important as a 
virulence factor in recovering pneumonia, perhaps due to the inability of the bacteria 
to release pneumolysin in any significant quantities. 
Figure 6.1 shows a schematic of mechanisms by which pneumococcal pneumonia 
might mediate alveolar epithelial cell injury and protein expression. 
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Figure 6.1 Possible mechanisms of S. pneumoniae mediation of alveolar epithelial 
cell injury and protein expression. S. pneumoniae stimulates sloughing of ATII 
cells by preferential attachment and internalisation. A combination of host 
response factors specific to the pneumococcus induces conformational change in 
RTI40 protein on the surface of ATI cells. Generic responses initiated by Gram - 
positive bacteria stimulate shedding of MMC6 protein from the surface of ATI 
cells, contributing to host defence. Similar host response factors induce an 
increase in production and secretion of SP -D by ATII and /or Clara cells. Basic 
alveolar structure adapted from Ware and Matthay (2000). 
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This thesis has included comparisons of animals receiving different treatments on 
different days (S. pneumoniae 24hrs vs 72 hrs, S. pneumoniae vs S. aureus). This was 
done due to practical reasons outwith the author's control. Although this method may 
not have been as scientific as setting up experiments with all treatment groups 
represented, there are a number of experimental systems whereby this method is used 
by necessity e.g. clinical studies with patients or experiments using treatment of 
genetically modified animals. While this is not the case in this study, and the 
limitations of this kind of comparison are acknowledged, there is no statistical reason 
why it should invalidate the evaluation. 
In summary, this thesis presents novel research demonstrating differential alveolar 
epithelial injury and protein expression in pneumococcal pneumonia, along with 
novel techniques of assessment. Potential mechanisms were investigated and provided 
insight into disease pathogenesis, as well as highlighting the limitations of using cell - 
specific proteins as markers of lung epithelial cell injury. 
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6.3 FUTURE WORK 
The mechanisms by which S. pneumoniae induces the effects presented in this thesis 
warrant further investigation. Determination of whether targeted attachment of 
bacteria to ATII cells is the means by which cell sloughing occurs would provide 
more information about this phenomenon, and the novel methods of ATII cell damage 
quantification could be applied to other models of lung injury. In addition, study of 
what exactly is happening to the cells during sloughing i.e. are they undergoing 
necrosis or apoptosis, would provide information about bacterial effects in 
pneumococcal pneumonia. 
Assessment of mRNA levels in vivo could help to establish whether the decrease in 
RTI40 is in fact due to a change in protein configuration. Analysis of RTI40 protein 
structure could also provide insight. An investigation of host response factors found to 
be specific to pneumococcal infection could offer potential targets for further study to 
determine the regulatory stimulus for RTI40 decrease. Anti- microbial peptides, anti - 
inflammatory cytokines and complement components may warrant particular 
attention, as they are important factors in bacterial infection. Once identified, these 
factors could then be tested in the in vitro model presented here. Further examination 
to elicit the function of RTI40 in the normal adult lung would provide insights into 
mechanisms behind regulation, as well as potentially affording a means of testing the 
functionality of the protein in the event of extensive conformational change. 
200 
The identification and sequencing of MMC6 is crucial to interpreting the function of 
the protein in normal and infected lung. Studies using purified protein might establish 
if it has a role to play as a PRR or other innate immune function. Investigation of the 
potential shedding phenomenon could be further examined by looking at other Gram - 
positive models of lung infection at the resolving phase. 
Despite the flaws in using cell- specific proteins as markers of injury in the lung, when 
properly supported these still provide valuable insights into disease pathogenesis. An 
important progression from this is the use of human marker proteins to assess clinical 
conditions. Although there is one currently identified human ATI -cell specific marker, 
HTI56 (Newman et al., 1999), techniques to analyse other proteins such as RTI40 and 
MMC6 are currently unavailable. Human antibodies against RTI40 do exist 
(Breiteneder - Geleff et al., 1999; Marks et al., 1999; Martin -Villar et al., 2005; Roy et 
al., 2005; Zimmer et al., 1999); however, variability in detection in different tissues, 
most likely due to difficulties of protein post -translational modification, mean that 
there is as yet no reliable marker of RTI40 in human lung alveolar epithelium. An 
antibody recognising such a protein would therefore be useful in human disease, 
although a previous attempt by the author to generate this proved unsuccessful. If 
accomplished this could contribute to purification of human epithelial cell isolation. 
In addition it could enable assessment of BAL fluid from CAP patients with a view to 
assessing ATI cell injury in a clinical situation or perhaps as an aid to aetiological 
diagnosis. 
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Further investigation of Gram -positive- stimulated host factors could also prove useful 
to find out more about regulation of SP -D production. Furthermore, the questions 
raised in this thesis regarding the role of pneumolysin in recovering pneumonia could 
be easily addressed by determining whether the toxin is actually produced in vivo, and 
by assessing the importance of TLR -4 in the stimulation of inflammation in this 
model of pneumococcal pneumonia. 
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APPENDIX 1: SUPPLIERS 
REAGENTS/ EQUIPMENT 
Reagents /equipment Supplier 




Biomate 3 spectrophotometer Thermo Electron 
Bio -Rad Bio -Rad Laboratories 
BSA Pierce Warriner 
Complete Protease Inhibitor Cocktail Roche Diagnostics 
Cytofunnel (double) Thermo Electron 
Cytospin 2 cytocentrifuge Thermo Electron 
Diff -Quick Gamidor Technical Services Ltd 
DNA ladder Promega 
Dot blot manifold Whatman Schleicher and Schuell 
DPBS PAA Laboratories 
DTT Invitrogen 
ECL Western Blotting Detection Reagents Amersham 
Eppendorf Fisher Scientific 
Ethicon mersilk black non -absorbent suture 3s Healthcare 
FACSCalibur flow cytometer B. D. Biosciences 
FlowCytomix rat Cytokine 6plex bead array and 
analysis software (Bender Medsystems) 
Invitrogen 
Goat anti -mouse IgG HRP secondary antibody 
(Rockland) 
Lorne Laboratories Ltd 
Goat anti -mouse IgG HRP secondary antibody 
(Zymed ®) 
Invitrogen 
Goat anti -rabbit IgG HRP secondary antibody 
(Rockland) 
Lorne Laboratories Ltd 
Goat anti -rabbit IgG HRP secondary antibody 
(Zymed ®) 
Invitrogen 
H2O (sterile, nuclease -free) Applied Biosystems 
Heparin Leo Pharmaceuticals 
ICAM1 antibody [1A29] (FITC) Abcam 
Mouse anti -rabbit GAP -DH monoclonal antibody 
[6C51 
Abcam 
Mouse anti -rat ICAM -1 monoclonal antibody [1A29] 
conjugated to FITC 
Abcam 
Mowiol Merck Biosciences 
MultiMark® Multi- Colored Standard Invitrogen 
Monoject Aluminium Hub Blunt Needle Harvard 
Nuclease -free water Applied Biosystems 
NuPage Bis -Tris Electrophoresis System Invitrogen 
OCT Bayer 
PCR primers MWG Biotech 
Portex Fine Bore Tubin ' Portex 
PowerGen 125 homogeniser Fisher Scientific 
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Rabbit anti -rat Aquaporin 5 polyclonal antibody Chemicon 
Rabbit anti -human f3-actin polyclonal antibody Abcam 
Superfrost Plus slides VWR 
SYBR SafeTM DNA Gel Stain Invitrogen 
TMB Microwell Peroxidase Substrate 
TRIZOL® Invitrogen 
Ultra Turrax IKA -Werke 
VersadocTM Model 4000 and Quantity One software Bio -rad 
LIST OF SUPPLIER ADDRESSES 
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